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SUMMARY
The investigation o f the role of cholesteryl ester transfer protein (CETP) in lipid 
metabolism was divided into five main areas. These included the developm ent of a reliable 
and reproducible assay for CETP activity, the development of polyclonal and monoclonal 
antibodies to CETP, studying the effect of various, drugs on plasma CETP activity in several 
animal species, looking at the control of CETP secretion by d ifferen t cell lines and analysing 
the relationship between restriction fragm ent length polymorphisms (RFLPs) of the CETP 
gene and various plasma lipid parameters in a population of 56 individuals.
An assay was developed which measured an activity displaying the correct char­
acteristics for CETP. The assay measured the accumulation of labelled lipid in an acceptor 
lipoprotein particle after transfer from a radiolabelled donor lipoprotein particle and 
separation of the donor and acceptor particles by heparin manganese precipitation. The 
separation of the lipoproteins by precipitation was validated using an independent lipoprotein 
separation method, ultracentrifugation. The assay could be adapted to measure low amounts 
of CETP activity by extending the length of incubation time.
Human and rabbit CETP were partially purified using previously published methods. 
This preparation was further purified by binding the CETP to Intralipid. For the production 
of monoclonal antibodies mice were immunised with both partially purified  and further 
purified  CETP. A fter fusion of mouse spleen cells with NS1 cells a clone was identified 
which produced antibodies which were positive in an ELISA using partially purified  human 
CETP as an antigen and which could inhibit human CETP activity. This clone requires 
fu rther development. Work on monoclonal antibodies to rabbit CETP was discontinued. An 
attem pt to raise polyclonal antibodies to a synthetic peptide from  the CETP sequence failed 
to produce antibodies which would recognise the native protein.
Plasma CETP activity was measured in rats in the middle of the light cycle and the 
m iddle of the dark cycle. This did not produce any evidence for a diurnal variation of 
plasma CETP activity in rats. Increased plasma CETP activity was dem onstrated in fa t-fed  
and genetically hyperlipidaemic Froxfield rabbits. The effect o f drugs which affect lipid 
metabolism was studied in rabbits, marmosets and humans. No consistent effects of these 
drugs on plasma CETP activity were demonstrated.
Human monocyte derived macrophages, J774 cells, HepG2 cells and CaCo-2 cells were 
found to secrete very small and irreproducible amounts of CETP into the medium. Due to 
the difficulty of measuring such low levels of CETP activity an attem pt was made to measure 
CETP messenger RNA levels in these cells. Due to technical d ifficulties quantitative 
measurement of messenger RNA was not achieved and it was not possible to assess how 
various effectors might control CETP secretion.
An StuI restriction fragm ent length polymorphism (RFLP) o f  the CETP gene was 
discovered. The relationship of this polymorphism, the TaqI polymorphism o f the CETP 
gene and two apo AI polymorphisms to plasma total cholesterol, HDL cholesterol, CETP 
activity and LCAT activity was investigated in a population o f 56 unrelated individuals
11
selected on the basis of their HDL levels. It was found that individuals expressing the rare 
TaqI B2 allele were more likely to have high plasma HDL and low plasma CETP activity. 
This suggests that CETP may have an influence on plasma HDL levels.
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CHAPTER I
INTRODUCTION
1 Discovery
Plasma lipoprotein cholesteryl esters (CE) were originally thought to be nonex- 
changeable. This concept was based on experiments from  the 1960s. Roheim  et al [Roheim, 
P.S. et al (1963)] demonstrated in the rat that there was no equilibration o f cholesteryl 
esters between 1 4C-cholesterol labelled chylomicrons and plasma in vitro; nor was there 
exchange of cholesteryl esters between high (d>1.063g/ml) and low (d<1.063g/m l) density 
lipoproteins, labelled biosynthetically, in vitro. Goodman [Goodman, D.S. (1964)] injected 
1 4C-m evalonate into two male volunteers to label their cholesterol moieties. He found 
that there were differences in the rate of appearance of radioactive cholesteryl ester in 
the plasma lipoproteins and that although labelled cholesterol did equilibrate between 
the lipoproteins, cholesteryl esters showed markedly different specific activities in the 
d ifferen t lipoprotein fractions. Also the fractional turnover of cholesteryl ester differed 
between high density lipoprotein (HDL) and low density lipoprotein (LDL), being higher 
in the form er and lower in the latter. The conclusion from these in vitro and in vivo 
experiments was that the pools of cholesteryl ester in d ifferent lipoprotein fractions 
were distinct and nonexchangeable.
Later evidence began to emerge which contradicted these early experiments. 
Transfer of CE and triglycerides (TG) between human lipoproteins in vitro was described 
by Nichols and Smith [Nichols, A.V. & Smith, L. (1965)]. A fter incubation of human 
serum for 36 hours at 38°C the isolated lipoprotein fractions were all found to have an 
increased cholesteryl ester content. It was proposed that this was due to synthesis of 
cholesteryl ester in HDL by lecithin cholesterol acyl transferase (LCAT) and subsequent 
transfer to other lipoprotein fractions [Rehnburg, C.S. & Nichols, A.V. (1964)]. HDL 
was also found to have increased triglycerides and it was suggested that these probably 
derived from the LDL fraction which showed a decrease in triglyceride.
In 1971 Quarfordt et al [Quarfordt, S.H., Boston, S. & H ilderm an, H. (1971)] 
m easured triglyceride mass transfer between very low density lipoprotein (V LD L)/LD L 
and VLDL/HDL donor/acceptor pairs at plasma concentrations in the absence of serum. 
No transfer was observed at 4X ; and at 37X1 only transfer between HDL and VLDL 
was observed. Transfer was not affected by pH or ionic strength but was accelerated as
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donor or acceptor concentration increased. The authors offered no mechanism for this 
transfer but it now seems likely that this was due to contaminating CETP (cholesteryl 
ester transfer protein) in the HDL fraction.
Evidence that the transfer reaction is important in man came from  Nestel et al 
[Nestel, P.J., Reardon, M. & Billington, T. (1979)]. Following injection of labelled HDL 
into humans, VLDL cholesteryl esters were rapidly labelled, the apparent flux rate from 
HDL being similar to the rate of total cholesterol esterification in plasma. Barter and 
Lally [Barter, P.J. & Lally, J.I. (1978)] demonstrated that human plasma contained transfer 
activity whereas that from  rats did not, regardless of the origin of the lipoprotein 
substrates. This difference between the species explained the contradictory results 
obtained by earlier investigators. Barter and Lally also calculated [Barter, P.J. & Lally, 
J.I. (1979)] that the rate of transfer was of the same order as the rate o f cholesterol 
esterification in plasma and they argued that this dispelled the idea of discrete non­
exchangeable pools of cholesteryl ester since CE could be transferred as quickly as they 
could be formed. If cholesteryl esters were nonexchangeable then it m ight be expected 
that the different specific activities for lipoproteins detected by Goodman [Goodman, 
D.S. (1964)] would have persisted for longer than the 48 hours observed since the half 
life of LDL and HDL is three or more days. Goodman assumed that since CE equilibration 
was not as rapid as that of the free sterol then no exchange was taking place. At the 
time the experiments were carried out it was not generally accepted that plasma CE are 
LCAT derived and that HDL was the primary substrate for LCAT. On the contrary it 
was thought that each lipoprotein could be synthesised independently from  the others. 
Glomset reported in 1968 [Glomset, J.A. (1968)] that the initial rate of cholesterol 
esterification was similar to the turnover rate of CE. This idea is not consistent with 
lipoproteins having different turnover rates unless CE can be transferred.
An active factor which could stimulate the exchange of cholesteryl ester and 
triglyceride between VLDL and LDL was first identified in rabbit plasma [Zilversmit, 
D.B., Hughes, L.B. & Balmer, J. (1975)]. Since the total mass of cholesteryl esters in 
each lipoprotein did not change during this process it appeared that an exchange activity 
was being measured. The factor increased transfer in a concentration dependent m anner 
and was found in the d>1.125g/ml fraction of plasma from both normal and hyper- 
cholesterolaemic rabbits. No transfer occurred at all without addition of this factor. The 
HDL fraction had a small stimulatory activity but the d> 1.063 or d>1.21 g /m l fractions 
caused greatest transfer. It transpired that the catalyst was a high m olecular weight 
plasma protein with isoelectric point 5.2. Transfer rates were the same in the presence 
and absence of an LCAT inhibitor (p-hydroxymercuribenzoate) and the factor was stable 
(1 hour at 56cC) under conditions where LCAT activity was destroyed. Therefore the 
active factor was unlikely to be LCAT.
2 Purification
The first satisfactory purification of a protein catalysing the exchange of cholesteryl 
esters was carried out by Pattnaik et al [Pattnaik, N.M. et al (1978)]. A glycoprotein,
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distinct from any of the known apolipoproteins was purified 3500 fold with apparent 
molecular weight 80000. At the same time Fielding’s group [Chajek, T. & Fielding, C.J. 
(1978)] isolated a human serum CETP, with molecular weight 35000, from  the HDL 
fraction and showed it to be immunologically unreactive to antibodies to the major HDL 
apolipoproteins Al, A ll and E. Antibodies were raised to this protein and could remove 
transfer activity from  HDL and d>1.21g/ml plasma. Since the purification procedure 
used was similar to that for apolipoprotein D (apoD), the authors suggested that the 
transfer protein and apoD may be identical. A triglyceride transfer protein was also 
isolated from  rabbit plasma [Rajaram, O.V., White, G.H. & Barter, P.J. (a)( 1980)]. Several 
groups followed suit most employing the basic steps o f hydrophobic and ion exchange 
chromatography with variations thereafter. In general molecular weights of 58-66K and 
pis of 5.0 - 5.2 were quoted [Morton, R.E. & Zilversmit, D.B. (1982), Albers, J.J. et al
(1984), Bastiras, S. & Calvert, G.D. (1986)] though one group [Ihm, J. et al (1980)] 
reported a much greater molecular weight of 150K. The protein appeared to catalyse 
both the exchange and mass transfer of lipid; investigators finding one or both activities 
in their studies. Sometimes purified activity appeared to run as a doublet of about 58 
and 63K [Ihm, J. et al (a)(1982), Morton, R.E. & Zilversm it, D.B. (1982), Albers, J.J. 
et al (1984), Bastiras, S. & Calvert, G.D. (1986)] but each band showed equivalent transfer 
activity. These bands were thought to be the same protein in d ifferen t forms or gly­
cosylated to d ifferent extents.
The transfer protein was initially identified by im m unoreactivity as apoD [Fielding. 
P.E. & Fielding, C. (1980), Chajek, T. & Fielding, C.J. (1978)]. This idea was disputed 
[Morton, R.E. & Zilversmit, D.B. (a)(1981)] when apo D and CETP were separated by 
gel filtration and electrophoresis and was finally dispelled when the apoD and CETP 
genes were cloned [Drayna, D. et al 1986, Drayna, D. et al (1987)].
Later investigators purified to homogeneity transfer proteins which appeared to 
have the same molecular weights and properties. In 1987 Hesler et al [Hesler, C.B., 
Swenson, T.L. & Tall, A.R. (1987)] purified the transfer protein 55000 fold using its 
affin ity  to bind a lipid emulsion. This preparation had a molecular weight of 74K. The 
protein had a high hydrophobicity, calculated to be greater than any other plasma 
apolipoprotein. Antibodies to this protein completely removed activity from  partially 
purified fractions. It was proposed that the doublet observed with polyacrylamide gel 
electrophoresis (PAGE) represented isoforms of the protein. The N term inal amino acid 
composition was different from the protein purified by Ihm et al [Ihm, J. et al (1982)] 
and was also d ifferen t from apoD. This protein could be easily degraded by the presence 
o f lipid peroxides and degradation did lead to the production o f lower molecular weight 
forms but only in the presence of lipid peroxide containing emulsions. The lower molecular 
weight forms seen could be related to the protein by degradation. Jarnagin et al [Jarnagin, 
A.S., K ohr, W. & Fielding, C. (1987)] also isolated a 74 kDa protein, purified 100000 
fold, which had an isoelectric point of 5.2. They found that the previous doublet [Ihm, 
J. et al (1982)] was due to contamination and bands could be separated by isoelectric 
focussing. The 74K protein was in fact the one responsible for transfer activity.
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The molecular weight of rabbit CETP was determined by radiation inactivation, 
a technique not requiring purified enzyme and not influenced by shape. It was found 
to be 70000 +/- 3000 and suggested that the protein was a monomer [Ierides, M. et al
(1985)]. The human cholesteryl ester transfer protein cDNA was cloned and sequenced 
in 1987 [Drayna, D. et al (1987)]. From the deduced amino acid sequence the calculated 
translated molecular weight was 53K. The high molecular weight detected previously 
may be accounted for by glycosylation and four potential asparagine linked glycosylation 
sites do occur in the molecule. Discrepancies in molecular weights between groups may 
also be accounted for by degradation effects or impurities.
Evidence that these preparations catalysed both cholesteryl ester and triglyceride 
exchange raised the question as to whether these activities proceeded under the influence 
of one protein, either on a single non-specific site or on d ifferen t sites, or several 
proteins in a complex. A single transfer protein activity is suggested by several lines of 
evidence. Firstly the species distribution of cholesteryl ester and triglyceride transfer 
activities reflect similar expression of these activities. It was found that cholesteryl ester 
and triglyceride transfer activities co-purified through all purification stages. Secondly 
the two enzyme activities also show identical inactivation profiles by denaturation either 
by heat or by proteolytic enzymes [Morton R.E. & Zilversmit D.B., (b) (1981)]. Thirdly 
the kinetics of the interaction with substrates were similar for both the triglyceride and 
the cholesteryl ester transfer activities [Rajaram, O.V. & Barter, P.J. (1980)]. Finally 
variation of LDL and HDL concentration produces similar effects on both cholesteryl 
ester and triglyceride transfer activity. However triglyceride transfer was inhibited by 
m ercurial compounds e.g. parachloromercuriphenylsulfonate whereas cholesteryl ester 
transfer was not [Morton, R.E. & Zilversmit, D.B. (1982)]. It has been concluded from 
this evidence that cholesteryl ester and triglyceride transfer are carried out by the same 
protein [Morton, R.E. & Zilversmit, D.B. (1982), Albers, J.J. et al (1984)] and that 
differential inhibition by mercurial compounds could be explained by these transfer 
activities being carried out at d ifferent sites on the same molecule. Monoclonal antibodies 
to the purified 74K CETP caused parallel and complete inhibition o f cholesteryl ester 
and triglyceride transfer activities but only partial inhibition o f phosphatidyl choline 
(PC) transfer in vitro [Hesler, C.B. et al (1988), Abbey, M. & Calvert, G.D. (1989)]. Thus 
the 74K protein accounts for all TG and CE transfer activity in hum an plasma.
3 Other Transfer Proteins
An intracellular CE and TG transfer protein has been identified in bovine liver. 
It has an apparent molecular weight of 200K and isoelectric point between 5.2 and 5.6. 
This may be similar or identical to the plasma transfer protein. However, this protein 
showed a preference fo r transferring TG over CE [Wetterau, J.R. & Zilversm it, D.B. 
(1984)]. A similar activity has been isolated from rat liver [Wetterau, J.R. & Zilversmit, 
D.B. (1986)] and appears to be associated with the microsomal fraction. Similar activities
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were identified in intestinal mucosa but not in brain, heart, kidney or plasma. This 
protein is possibly involved in the incorporation of CE and TG into precursors for 
lipoprotein synthesis by the liver and intestine.
Although both CE and TG transfer activities in plasma could be accounted for by 
one protein, PC transfer seemed to be carried out by at least two. Albers et al [Albers, 
J.J. et al (1984)] separated PC transfer activities on heparin Sepharose columns. The 
unbound fraction was temperature resistant and eluted with tem perature resistant CE 
and TG transfer activities. This fraction was called LTP-I. The second activity bound 
to heparin sepharose, was temperature sensitive and facilitated transfer o f PC but not 
CE or TG. This activity was designated LTP-II. It seems that LTP-I is identical to CETP. 
A PC transfer protein could also be separated from a C E /T G  exchange protein by ion 
exchange chrom atography [Tall, A.R., Abreu, E. & Shuman, J. (1983)]. The protein, 
which catalyses phospholipid (PL) transfer only was later purified [Tollefson, J.H., 
Ravnik, S. & Albers, J.J. (1988)]. It catalyses exchange and net mass transfer of PL, 
does not transfer CE or TG, is not recognised by antibodies to LTP-I and has an 
isoelectric point of 5.0. The molecular weight for this activity has been reported as 70K 
[Tollefson, J.H. et al (1988)], 41K [Tall, A.R. et al (1983)] and 65K [Albers, J.J. et al 
(1984)]. LT P-II enhances transfer of CE from HDL3 to VLDL when incubated with 
LTP-I. Two roles are proposed for net mass transfer of PC [Albers, J.J. et al (1984)]. 
F irst to remove free surface coat materials after lipolysis of TG rich lipoproteins and 
secondly to provide substrate for the LCAT reaction. Consideration of these phenomena 
(Table 1.1) suggests that the transfer activity in the rat may be explained by the animal 
expressing LTP-II but not LTP-I.
4 Localisation of CETP on Lipoproteins
CETP is thought to be located in the HDL and d>1.215g/ml fractions of plasma 
[Groener, J.E.M ., Van Rozon, A.J. & Erkelens, D.W. (1984)]. Activity eluted with HDL 
when plasma was passed down a gel filtration column but eluted in the position for free 
CETP when d>1.215g/ml fraction was used [Pattnaik, N.M. & Zilversmit, D.B. (1979), 
R ajaram , O.V. & Barter, P.J. (1980)]. Groener et al [Groener, J.E.M. et al (1984)] located 
CETP mainly on HDL3 and Cheung et al [Cheung, M.C. et al (1986)] reported CETP 
to reside mainly on HDL particles containing apo Al and no apo AIL The activity could 
be separated from  these particles by ultracentrifugation. CETP activity separated from 
the HDL fraction during centrifugation is found mainly in the d>1.215g/ml fraction. 
About 80% of HDL-CETP complexes are disrupted by single step ultracentrifugation.
CETP was found to form a complex with HDL but not LDL or VLDL after passage 
through a gel filtration column [Pattnaik, N.M. & Zilversmit, D.B. (1979)]. This interaction 
was thought to be electrostatic possibly due to interactions with the phosphate head 
groups o f the phospholipids. Morton [Morton, R.E. (1985)] looked at its interaction with 
Sepharose bound lipoproteins (LP). HDL form ed ' stable complexes with CETP but 
V LD L/LD L-C ETP complexes were more labile. CETP bound to all lipoproteins showing 
high affin ity  saturation binding under equilibrium conditions. The Kds were about 25nM.
TABLE 1. PROPERTIES OF CHOLESTERYL ESTER TRANSFER PROTEIN AND 
PHOSPHATIDYL CHOLINE TRANSFER PROTEIN
PROPERTY CETP
(LTP-I)
PC TRANSFER 
PROTEIN 
(LTP-II)
Molecular Weight: 70000,41000,65000
apparent 74000 -
calculated 56000 -
Isoelectric point 5.2 5.0
C E /T G  exchange + -
PC exchange + +
Heparin Sepharose 
Binding
- +
Tem perature
Resistance
+
Precipitation by 
anti LTP-I
+ -
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CETP binding and transfer increased in parallel w ith increasing CETP concentration. 
Inhibiting CETP caused decreased CETP binding to lipoproteins. It is possible that 
inhibition disrupts CETP-LP complexes. It was concluded that CETP avidly binds 
V L D L/LD L and HDL via a reversible saturable mechanism and that binding of CETP 
to lipoproteins is an integral part of the transfer reaction. Binding studies showed that 
VLDL,LDL and HDL have approximately the same affin ity  for CETP but markedly 
d iffe ren t binding capacities at saturating levels for CETP. The authors estimated that 
the m inimum  binding capacity of lipoproteins for CETP exceeds the plasma concentration 
o f CETP by at least 10 fold. HDL alone has a binding capacity greater than the plasma 
CETP concentration and could therefore essentially bind all CETP dissociated from LDL 
and VLDL during gel filtration. Thus it appears that lipoproteins in physiological 
concentrations are not saturated with CETP. Changes in HDL and LD L/V LDL pool size 
may be accompanied by shifts in CETP distribution which may explain in part the 
abnorm al CETP activity found in patients with abnormal lipoprotein profiles. CETP and 
LCAT can associate with HDL2 and HDL3; [Nishida, H.I., Kato, H. & Nishida, T. (1988)] 
and apoAI decreases their association.
The transfer protein may exist in a complex along with other proteins involved in 
cholesterol transport. Although purified CETP elutes at about 6 8 K on gel filtration, if 
whole plasma is chromatographed the transfer protein elutes with particles of much 
larger size (160-320K). This suggests that the CETP may exist in a complex [Tollefson, 
J.H. & Albers, J.J. (1986)]. Large molecular weight complexes have been isolated by gel 
filtration chromatography [Ihm, J. et al (1980)] and by immunoadsorption chromatography 
[Chajek, T. & Fielding, C.J. (1978), Fielding, P.E. & Fielding, C.J. (1980)]. LCAT, 
transfer activity and apoAI could be isolated as a complex. When plasma was briefly 
incubated w ith 3 H-cholesterol loaded fibroblasts labelled CE first appears in an apoAI 
containing species (named LpAI pre (33) which also contains apoD, LCAT and CETP 
[Francome et al (1989)].
Busch et al [Busch, S.J. et al (1987)] reported that the transfer protein existed as 
a high molecular weight fraction, greater than 150K, and low molecular weight fractions 
of 18K when the transfer activity was purified by im m unoaffinity chromatography and 
then gel filtered on an HPLC system. Cholesteryl ester and triglyceride transfer specific 
activities were higher in the lower molecular weight fraction. They identified a low 
molecular weight proteolipid consisting of a catalytic domain (3K) and a heparin binding 
dom ain which could be differentiated from each other by antibody binding. This work 
has not been confirmed by other groups.
Hesler et al [Hesler, C.B. et al (1989)] looked for an active domain fragm ent of 
CETP by protease digestion or expression of CETP cDNA restriction fragments in 
Escherichia coli. Protease treatment of CETP with trypsin or chymotrypsin did not result 
in loss of catalytic activity although the protein was degraded. Incubation with 
Staphylococcus aureus V8  proteinase resulted in partial loss of activity. Despite substantial 
proteolysis by three different proteases the monoclonal antibody to the 75K purified 
transfer protein, TP2, was still able to inhibit transfer activity. Thus the active structure
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contains an intact epitope for this antibody. Gel filtration of the products of proteolysis 
showed that they eluted in the same place as the whole protein indicating that after 
degradation the polypeptide fragments remain associated and retain the native molecular 
weight of CETP. These complexes were very stable and resistant to dissociation with 
urea, dithiothreitol or delipidating agents. CETP has a distinct and highly stable tertiary 
structure required for activity. The fragments which were expressed in E. coli were 
catalytically inactive though they did still contain an epitope for a monoclonal antibody 
which can inhibit CETP activity; and they still have similar emulsion binding properties 
to the whole protein. Therefore there is no evidence for an independently active subunit 
of CETP contrary to other reports [Busch, S.J. et al (1987)].
5 Mechanism
Investigations were carried out into the substrate specificity of CETP using 
reconstituted HDL and liposomes as donors [Morton, R.E. (1986)]. The relative transfer 
rate of d ifferen t cholesteryl esters was cholesteryl oleate > cholesteryl linoleate > 
cholesteryl arachidonate > cholesteryl palmitate. Transfer with cholesteryl oleate was 
about 154% that of cholesteryl palmitate. All m ajor species of ester were transferred 
and the relative rates are due to differences in the acyl chain. This reflects substrate 
specificity rather than availability of the substrates in the lipoprotein particle for transfer. 
D ifferences in substrate specificity would lead to a d ifferen t equilibration of cholesteryl 
esters between lipoproteins and may result in altered metabolism of lipoproteins. Since 
the composition of CE in the outer layer affects the flu id ity  of the lipoprotein particle, 
reactions such as VLDL to LDL conversions and lipoprotein remodelling may be affected.
Equimolar back transport of TG has been dem onstrated in incubations of 14C-CE 
labelled HDL and 3 H -T G  labelled LDL or VLDL with plasma thus demonstrating a 
coupled exchange of HDL cholesteryl ester for lower density lipoprotein triglyceride 
[Chajek, T. & Fielding, C.J. (1978)]. Jarnagin et al [Jarnagin, A.S. et al (1987)] found 
that the CE transfer rate was greater than that for TGs between each of the major 
lipoprotein classes using purified CETP. They suggested that CETP has a preference for 
CE and equimolar transport is the result of the combined activity o f d ifferen t transfer 
activities in plasma. M orton and Zilversmit [Morton, R.E. & Zilversm it, D.B. (1983)] 
looked at CE,TG and PC transfer. Looking at initial transfer rates (i.e. less than 10 - 
13% transfer), absolute transfer rates were affected by the donor and acceptor LP 
concentration and acceptor LP composition /, whereas the ratio of CE:TG transfer was 
not. This was also found to be the case using unilamellar vesicles as substrates. No 
correlation was found between the amount of PL transferred and the amount of CE/TG  
transferred. The authors concluded that TG and CE compete for transfer and that the 
extent of transfer depends on the relative concentrations of these lipids in the donor 
particle. PL transfer is independent. These data were from  exchange reactions not net 
transfer, and experiments were carried out using pure CETP i.e. in the absence of LCAT. 
Using liposome acceptors it was found that inhibition of TG transfer with para chlo- 
rom ercuriphenylsulphonate (pCMPS) also suppresses CE transfer from  LDL. It seems
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that net transfer of CE and TG is coupled such that one lipid is transferred in one 
direction and the other in the opposite direction. Exchange versus net transfer (heter­
oexchange) may be dependent on core composition of donors and acceptors. Human 
LDL and HDL have nearly identical CE to TG  ratios whereas the ratios in LDL and 
HDL d iffe r  greatly in rat. Transfer to the TG  rich VLDL particles found in liver 
perfusate was similar to transfer to plasma VLDL (which is more cholesteryl ester rich). 
This implies that in normal rabbit plasma the lipid composition of acceptor lipoproteins 
is not rate lim iting for transfer [de Parscau, L. & Fielding, P.E. (1984)].
Several studies were carried out to investigate the mechanism of the transfer 
reaction. Rates of exchange depended on both LDL and HDL concentration [Ihm, J. et 
al (b) (1982)]. If the ratio of LDL:HDL concentrations exceeded 9:1 then flux rates were 
independent of LDL at constant HDL concentration. Exchange was inhibited at high 
HDL concentrations when LDL concentration was constant, which the authors argued 
dem onstrated preferential HDL/HDL exchange but may have been due to the presence 
o f inhibitor. Analysis of the dependence of initial exchange on LDL concentration at 
two constant HDL concentrations suggested a productive collision i.e. ternary complex, 
mechanism. At low HDL concentrations this complex is form ed by a random sequence 
route. A t high HDL concentration the mechanism may be ordered sequential since CETP 
and HDL will already exist as a complex. These studies looked at exchange only. They 
suggest that the free energy of the complex would be reduced if CETP entered the 
complex already bound to a lipoprotein. The reaction would be second rather than third 
order. Sammett and Tall [Sammett, D. & Tall, A.R. (1985)] showed that increased CETP 
activity is associated with an increased binding of CETP to VLDL remnants and HDL, 
which is consistent with Ihm’s model.
Barter et al fitted transfer data to a mathematical model [Barter, P.J. et al (1982)]. 
The model assumed that the transfer protein interacts with the lipoprotein particles and 
may bind. If there are equal concentrations o f cholesteryl ester in each lipoprotein 
fraction then the probability of picking up cholesteryl ester in HDL:VLDL:LDL is 
28.0:4.65:1. This predicts that at physiological lipoprotein concentrations the proportion 
o f transfer protein bound to HDL is more than double that unbound. For VLDL the 
prediction is that one tenth is bound. These predictions however apply to a closed system 
not to a dynamic one as would be present in vivo.
Swenson et al [Swenson, T.L., Brocia, R.W. & Tall, A.R. (1988)] studied the 
mechanism of the CETP reaction using binding to unilamellar vesicles and then gel 
filtration  chromatography. They looked at transfer of radioactive C E /TG  and PC to 
CETP and then isolated the complexes. The isolated CETP labelled lipid complex can 
donate to LDL. Parachloromercuriphenylsulfonate, which inhibits CE and TG transfer 
decreases the binding of radiolabelled CE and TG to CETP. These experiments show 
binding sites for CE and TG on CETP which can equilibrate reddily with lipoprotein 
lipids. This suggests that CETP can act as a carrier between lipoproteins. These findings 
fu lfil two criteria of a carrier mediated mechanism. One is the isolation of a carrier 
bound with lipid and second is the ability of the carrier complex to donate bound lipid
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to a lipoprotein. Apo-A I, apoHDL and albumin do not demonstrate these properties. 
Scatchard analyses of these data demonstrate a single CE and TG binding site. Bound 
phospholipid appears to play a role since extensive delipidation of CETP leads to inactivity 
which can be retrieved by the addition of PC by PC/cholate dialysis. PL may form part 
of the hydrophobic lipid binding site.
6 Lipid Transfer Inhibitor Protein
Species differences in transfer activity were observed and led to the initial confusion 
as to whether plasma lipoprotein CE were exchangeable. Early investigators, studying 
the rat, were led to believe that there was no equilibration of cholesteryl ester between 
lipoproteins. It was only in later studies when humans and rabbits were investigated that 
the transfer of triglyceride and cholesteryl ester was seen.
R at serum showed much less (or negligible) transfer activity than hum an serum 
regardless ofthe species origin of the lipoprotein substrates [Barter, P.J. & Lally, J.I. 
(1978)]. R abbit serum was much more effective than human. Guinea pig serum showed 
activity interm ediate between that of human and rat [Barter, P.J. & Lally, J.I. (1979)]. 
A comprehensive study of cholesteryl ester transfer activity in lipoprotein free plasma 
of 16 species was carried out [Ha, Y-C. & Barter, P.J. (1982)]. It was found that transfer 
activities could be divided into high, intermediate and low activity groups. Rabbits were 
high, humans intermediate and rats low.
It is now thought that the reason for this species variation is the presence of an 
inhibitor of CETP expressed to varying extents in the plasma of d ifferen t species. It 
was found that rat and pig lipoprotein depleted plasmas (LPDPs) inhibited rabbit transfer 
activity [Zilversmit, D.B. et al (1975)]. An inhibitor o f CETP could be separated from 
CETP by phenyl Sepharose chromatography. It was characterised as a protein of molecular 
weight 35000 and isoelectric point 4 or less. CETP activity was inhibited between all 
pairs o f low, very low and high density lipoproteins [Morton, R.E. & Zilversm it, D.B. 
(b) (1981)]. Further work on inhibition showed that apoAI also inhibited CETP activity 
(though triglyceride transfer was inhibited more than cholesteryl ester transfer). Inhibition 
was independent o f CETP concentration but was decreased by higher lipoprotein con­
centrations. Inhibition was not observed between liposomes. All these points taken together 
indicated that the inhibitor interacts with substrates rather than with the transfer protein 
[Son, Y-C. & Zilversmit, D.B. (1984)]. The inhibitor may work by interfering with the 
interaction between CETP and its substrates.
A CETP inhibitor which could also inhibit LCAT and LTP-II was reported. 
Chrom atography of LPDS over phenyl Sepharose resulted in enhanced transfer activity 
for hum an serum and unmasking of activity in rat and pig plasma [Tollefson, J.H., Liu, 
A. & Albers, J.J. (1988)]. Using pig plasma, an inhibitory activity could be eluted from 
this column with ethanol. Two to three times more inhibitory activity could be eluted 
than was required to inhibit the pig transfer activity obtained from the initial phenyl
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Sepharose eluate. This inhibitory component was found to be part of HDL. ApoHDL 
still inhibited CETP and whole HDL added to a transfer assay caused inhibition. Only 
the HDL(AI with A ll) fraction inhibited and not the HDL(AI without A ll) fraction.
L ipid transfer inhibitor protein (LTIP) was isolated and characterised in 1989 
[Nishide, T., Tollefson, J.H. & Albers, J.J. (1989)]. It has an apparent molecular weight 
of 28000 and an approximate isoelectric point o f 4.6. A particular subclass of HDL with 
a particle size smaller than that of whole HDL and which only contained a small amount 
of apoAI was a rich source of LTIP. About 85% of the inhibitory activity was found in 
this HDL fraction. LTIP inhibited cholesteryl ester, triglyceride and phosphatidyl choline 
transfer of CETP (LTP-I) and to a lesser extent PC transfer by the PC transfer protein, 
LTP-II. Antibodies developed to LTIP could unmask CETP activity when human, rat 
or pig plasma were passed down an im m unoaffinity column. Increases in activity were 
17%, 125% and 200% respectively. LTIP was found to be distinct from  apoAI and it is 
possible that the inhibitory activity previously shown by apoAI is due to contaminating 
LTIP.
7 Source of CETP
Liver, which is the source of LCAT, was tested to see whether it was also a source 
of CETP. Two groups [Abbey, M. et al (1984), de Parscau, L. & Fielding, P.E. (1984)] 
detected CETP in rabbit liver perfusate alongside LCAT secretion. The first group 
measured activity after concentration of the perfusate and separation by hydrophobic 
chrom atography and the second measured a linear increase of activity using reperfusion. 
Parscau and Fielding found that the accumulation of CETP and LCAT in the perfusate 
could be blocked by colchicine which inhibits secretion at the post Golgi stage and may 
involve disruption o f microtubules. This indicates that these proteins are liver secretory 
products. Both exchange and mass transfer activity were demonstrated for the secreted 
transfer protein, exchange being about twice that of mass transfer. T ransfer was more 
rapid to VLDL than to LDL i.e. the half-m axim al rate of transfer to VLDL was higher 
than that to LDL.
CETP was also shown to be secreted in culture by human monocyte derived 
macrophages and two murine m acrophage-like cell lines, J774 and P338D [Tollefson, 
J.H. et al (1985)]. The transfer protein secreted had similar properties to those already 
described i.e. molecular weight 62K, isoelectric point 5.0, binding to phenyl sepharose 
but not to heparin sepharose, transfer of CE, TG and PL and stability to heating at 
56X1 for one hour. This secretion could be completely inhibited by 10pM cycloheximide 
or enhanced about 67% by 16pM phorbol m yristate acetate (PMA).
HepG2 (and Hep3B) cells were also found to secrete CETP [Faust, R.A. & Albers, 
J.J. (1987)]. If human hepatocytes secrete CETP at a similar rate in vivo then they could 
account for all the CETP in plasma. This secretion could be completely inhibited by 
5pM cycloheximide. The transfer protein secreted had similar properties to plasma CETP 
including imm unoinhibition by anti-L T P-I antibodies. Secretion tailed o ff a fter 24 hours. 
This appeared not to be due to instability or down regulation of synthesis since the same
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phenomenon occurred when samples were collected serially from the same dish i.e. the 
cumulative activity from cells incubated with fresh medium each time. Therefore it is 
probably due to lack of serum factors required for synthesis. A fter passage down a 
heparin Sepharose column transfer activity increased. This suggests that HepG2 cells 
also secrete an inhibitor. This inhibitor could inhibit either HepG2 cell secreted or 
plasm a-derived CETP. Apart from its ability to bind heparin Sepharose and to inhibit 
both cell secreted and plasma-derived CETP there is no evidence to positively identify 
it as LTIP.
The secretion of CETP by HepG2 cells was confirmed by Swenson et al [Swenson, 
T.L. et al (1987)]. The secreted CETP could be removed from  the media by precipitation 
with antibodies to plasma CETP and had a similar molecular weight (72-76K ) to plasma 
CETP. The precipitated band was broad and diffuse on sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS PAGE) suggesting that the protein was a gly­
coprotein. Treatm ent of the secreted protein with neuraminidase or glycopeptidase F 
caused the protein to show increased mobility and a sharper band on SDS PAGE with 
a molecular weight of 58000. CETP precipitated from a cellular homogenate had a 
molecular weight of 58000. This suggests that the peptide is processed to give an N -linked 
carbohydrate. It is also known that CETP cDNA codes for a 53000 protein [Drayna, D. 
et al (1987)]. Tunicamycin, which inhibits N -linked glycosylation, reduced CETP 
secretion by 90% and no smaller forms were imm unoprecipitated. Removal of 
carbohydrate from active CETP did not greatly effect its activity.
CaCo2 cells secrete CETP vectorially [Faust, R.A. & Albers, J.J. (1988)] into the 
lower, baso-lateral, chamber of Transwells, a cell culture system whereby cells are grown 
on a membrane and both surfaces of the cell are exposed to culture medium. Over 24 
hours they secrete CETP at twice the rate of HepG2 cells. This secretion is regulated 
by fatty  acids. It was speculated that the intestine may be the principal source of CETP 
and its synthesis is upregulated during the acute lipaemia which follows digestion. Chronic 
lipaemia may also affect its release.
Faust, Cheung and Albers [Faust, R .A ., Cheung, M.C. & Albers, J.J. (1989)] looked 
at the distribution of secreted CETP with nascent lipoprotein particles in HepG2s. Sixty 
percent was associated with apoAI containing particles similar to the distribution shown 
in hum an plasma. However a large amount was also found associated with apoAII 
containing particles. This suggests that CETP distribution is m odified by a post secretory 
process. No CETP was found associated with apoB. Mixing of cell media w ith anti-apoE  
m atrix resulted in an increase in CETP activity. It is possible that there is an inhibitor 
associated with apoE containing particles. The purified inhibitory activity from  heparin 
Sepharose had similar thermostability properties to LTIP.
8 The CETP Gene
The human CETP cDNA was cloned and sequenced in 1987 [Drayna, D. et al 
(1987)]. Nucleotide probes were made using the amino terminal amino acid sequence of 
the purified  74K protein. These probes were used to pull out sequences from  a human
23
cDNA library. The translated sequences closely matched the amino acid sequence 
available. Sequences were eventually found which coded for part of the secretion signal 
prepeptide and 476 amino acids of the mature protein. The sequence of the mature 
protein coded for a protein of molecular weight 53108 with four potential glycosylation 
sites. Sequence analysis showed the protein to be more hydrophobic than any of the 
known apolipoproteins and lipoprotein metabolising enzymes. The C term inus has the 
most hydrophobic stretch which may be consistent with a possible neutral lipid binding 
site. N orthern blots detected a CETP mRNA of 1900 + /-  50 nucleotides. M essenger 
RNA synthesis was detected in human liver, small intestine and adrenal gland to equal 
extents. Spleen also demonstrated a lot of message but this may be due to the macrophages 
residing there since macrophages are known to secrete CETP [Tollefson, J.H. et al (1985)]. 
Little or no message was detected in HepG2 cells, U937 cells, pancreas, leukocytes or 
placenta but CETP mRNA can be detected in isolated hepatocytes. Translation o f the 
full length CETP cDNA in a eukaryotic system (Cos cells), but not a prokaryotic system 
(E coli.) [Hesler, C.B. et al (1989)] produced an active CETP. It is probable that post 
translational processing is required for expression of activity.
Two RFLPs for the TaqI restriction enzyme were found at the hum an CETP locus 
using the 1581 base pair clone as a probe [Drayna, D. & Lawn, R. (1987)]. An 
uncharacterised MspI polymorphism was also found. The chromosomal location o f the 
CETP gene was identified as 16q21 [Sparkes, R.S. et al (1987)].
The hum an sequence was used to pull out the rabbit cDNA from  a liver cDNA 
library [Nagashima, M., McLean, J.W. & Lawn, R.M. (1988)]. The amino acid sequence 
was determined from  the sequences of cloned DNA and genomic DNA. The rabbit amino 
acid sequence was longer than that in human, 496 amino acids compared with 476 amino 
acids and was 81% homologous. The predicted molcular weight is 54400 and there are 
six potential glycosylation sites. The mRNA was 2.2kB and had an unusual polyadenylation 
sequence. CETP mRNA was mainly found in rabbit liver with smaller amounts in the 
adrenals and kidney. In contrast to the human none was found in the spleen though this 
may be due to differences in macrophage content. The human and rabbit probes were 
used to detect CETP message in different species. Message was detected in the hum an, 
rhesus monkey and rabbit but none was found in pig, mouse and rat. This distribution 
agrees with plasma levels of CETP, though plasma levels may only reflect expression of 
inhibitor and not expression of CETP. It is difficult to know to what extent this result 
is influenced by probe cross reactivity.
9 Factors Affecting CETP Activity
Factors affecting CETP activity apart from  amount o f CETP, am ount of inhibitor, 
lipoprotein binding and substrate composition include apolipoproteins, enzymes and 
various pharmacological agents. Nishikawa et al [Nishikawa, O. et al (1988)] dem onstrated 
that apolipoproteins were required to stabilise micellar structures to allow transfer activity 
to take place. Apo D can enhance CETP activity -between an artificial donor and an 
LDL acceptor [Nishida, H.I., Tu, A. & Nishida, T. (1988)]. CETP will transfer between
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HDL and Lp(a) but only at about half the normal rate. If the apo(a) is removed then 
the rate returns to normal. This indicates that transfer may depend on surface area 
[Groener, J.E.M. & Kostner, G.M. (1987)]. Lp(a) blocks the surface availability for 
transfer.
Lipolysis has been shown to enhance transfer between HDL and apoB containing 
lipoproteins [Castro, G. & Fielding, C.J. (1985)]. When post prandial VLDL and LDL 
were incubated with fasting plasma, transfer increased. It therefore seems that the 
properties of the lipoproteins are changed in fed plasma. Studies of transfer of CE from  
HDL to VLDL in vitro revealed that lipoprotein lipase enhances CETP activity [Sammett, 
D. & Tall, A.R. (1985)]. This stimulation of activity was correlated w ith  the accumulation 
of fatty  acids in VLDL remnants. If this accumulation is decreased, by incubation with 
fatty  acid free albumin, then a parallel decrease of the stimulation of CE transfer occurs. 
If sodium oleate is added to VLDL with album in, then stimulation of CETP activity is 
observed. If the pH is lowered from 7.5 to 6.0 the stimulatory effect is abolished probably 
due to protonation of the free fatty acids. Phospholipase A2 and a bacterial lipase that 
lacked phospholipase activity also stim ulated CETP activity. If  VLDL and HDL are 
lipolysed and then isolated and tested in a CETP assay both substrates stim ulate CETP 
activity binding more CETP, though there is greater binding to VLDL than to HDL. 
CETP also binds lipolysed PL/TG  emulsions. Those conditions which decrease stimulation 
of transfer also decrease CETP binding to remnants, emulsions and HDL. Stimulation 
is related to the accumulation of fatty acids in lipoproteins . This accum ulation may 
augment lipoprotein binding and increase the efficiency of transfer. Lipolysis may 
increase CETP binding to VLDL and HDL and facilitate the form ation o f a collision 
complex. Also the relative increase in VLDL binding may oppose HDL to HDL exchanges.
When CETP activities were compared in fasted and postprandial plasma it was 
found that transfer was two to three times greater in the post prandial condition [Tall, 
A., Sammett, D. & Granot, E. (1986)]. Agarose chromatography of fasting plasma showed 
that most CETP was associated with small HDL particles and some CETP was free. Post 
prandial plasma showed increased binding of CETP to large HDL and an increased 
am ount of CETP associated with apoB containing lipoproteins. Total CETP activity was 
1.1-1.7 times higher in post prandial or delipidated post prandial plasma when assayed 
with exogenous lipoproteins. There was increased binding of purified CETP to HDL in 
post prandial compared with fasting plasma but total activity was unchanged. Thus 
increased activity in post prandial plasma may be due to any of these factors; increased 
TG rich acceptor lipoproteins, lipolysis enhanced binding of CETP to lipoproteins 
(especially large HDL), and increased CETP mass.
Prostaglandin E j at concentrations as low as 10_loM, stimulates the transfer of PC 
and CE from HDL3 to LDL [Muzya, G.I. et al (1987)]. This effect is seen with spontaneous 
transfer as well as facilitated transfer. PG E 2 and PGF2a  had no effect. LCAT activity 
is also enhanced probably due to PGEj induced reorganisation of the HDL surface.
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R itter et al [R itter, M.C., Bagdade, J.D. & Subbaiah, P.V. (1989)] studied the 
effects o f treating hypercholesterolaemic subjects with marine lipids , i.e. omega-3 fatty 
acids for three months. Plasma total cholesterol, free cholesterol, VLDL cholesterol and 
LDL cholesterol all decrease. Plasma triglycerides and HDL cholesterol rem ain unchanged. 
Before treatm ent all the patients had accelerated cholesteryl ester transfer activity (CETA). 
Treatm ent decreased this. Experiments combining lipoproteins from treated and untreated 
plasma showed that the acceleration of CETA in untreated patients was due to an 
enhanced avidity of VLDL for CE.
When FH patients are given probucol then their xanthomas regress [Matsuzawa, 
Y. et al (1988)]. This regression correlates with the decrease in HDL cholesterol. The 
HDL fraction in these patients were studied and it was found that the treated patients 
had smaller HDL2. Probucol was given to two familial hyperalphalipoproteinaemic 
(FHALP) patients one who had impaired, but not deficient CETA, and one w ith normal 
CETA. Both showed net transfer of cholesterol from LDL/VLDL to HDL (measured in 
whole plasma with LCAT inhibited) rather than from  HDL to LD L/V LD L as shown in 
seven normal samples. Treatment normalised the net transport of CE and decreased 
HD L 2 cholesterol. The authors suggested that probucol may increase reverse cholesterol 
transport. This finding was confirmed [Sirtori, C.R. et al (1988)] when it was found that 
treating type II hyperlipidaemic patients with probucol resulted in an increase transfer 
rate from  HDL to lower density lipoproteins. The HDL2 fraction was decreased while 
HDL 3 was unchanged. It was suggested that probucol enhances HDL particle in te r­
conversion.
Since hepatic cholesterol secretion is increased in hypercholesterolaemics as is 
CETA, it is possible that CETP activity is regulated by hepatic cholesterol secretion. 
Rabbits were fed a coconut oil diet which lead to a 6 8 % increase in plasma cholesterol, 
a 42% increase in CETA and a 69% increase in hepatic cholesterol secretion [Quig, D.W. 
& Zilversm it, D.B. (a) (1988)]. Treatment o f these rabbits with mevinolin reduced CETA 
and plasma cholesterol but had no effect on the secretion of cholesterol therefore there 
is no regulatory effect on CETP by hepatic cholesterol secretion. Mevinolin had no direct 
effect on CETP.
10 Abnormal Lipoprotein Metabolism
1.10.1 Hypercholesterolaemia
Pattnaik et al [Pattnaik, N.M. et al (1978)] noticed that partially purified  plasma 
from  homozygous familial hypercholesterolaemics (FH) had 3-4 fold greater CETP 
specific activity than normal plasma. In 1984 Groener et al [Groener, J.E.M . et al 
(1984)] found that cholesteryl ester transfer activity (CETA) in delipidated plasma 
was 2  fold greater in hyperlipidaemic plasma than in normal.
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More detailed studies were carried out to determine how CETA was affected 
by hypercholesterolaemia. Three models of hypercholesterolaemia: cholesterol fed 
rabbits, rabbits fed a casein/sucrose diet and Watanabe rabbits, were positively 
associated with C E /T G  transfer activities [Son, Y-C. & Zilversm it, D.B. (1986)]. If 
the cholesterol fed rabbits were put back on a normal diet then the CETP reverted 
back to normal along with plasma cholesterol. When the time course of diet induced 
CETA increases were studied [Quig, D.W. & Zilversmit, D.B. (b) (1988)] it was found 
that CETA increased and reached a new steady state level within about 10 days with 
little change for up to 87 days even when plasma cholesterol continued to rise. The 
greatest increase in CETA occurred about five days after feeding. Low cholesterol 
and coconut oil (cholesterol free) diets were both associated with comparable increases 
in plasma cholesterol and CETA. A single high cholesterol or oil meal led to a twofold 
increase in plasma cholesterol but no change in CETA in 36 hours. Hypercholes­
terolaemia brought about by fasting lowered CETP activity not increased it and 
refeeding returned CETA to prefasting levels. In rats cholesterol feeding did not 
result in increased CETA.
1.10.2 Dyslipoproteinaemias
CETA has been measured in several cases of dyslipidaemia. H yperbetalipo- 
proteinaemics had decreased CETA [Fielding, P.E., Fielding, C.J. & Havel, R.J. 
(1983), Sparks, D.L. et al (1989)] as did dysbetalipoproteinaemics [Fielding, P.E. et 
al (1983)]. hypoalphalipoproteinaemics, familial combinded hyperlipoproteinaemics 
and familial hypercholesterolaemics [Sparkes, D.L. et al (1989)]. Contradictory results 
were found with hypertriglyceridaemics where patients with no sign o f coronary 
heart disease had increased CETA and those with signs of disease had decreased 
CETA [Fielding, P.E. et al (1983)]. Another study found increased CETA in 
hypertriglyceridaemia [Sparkes, D.L. et al (1989)].
Differences in results from these experiments may be explained by the way in 
which the assays were carried out. Fielding measured mass transfer in whole plasma 
using endogenous substrates, a measurement which is more likely to be affected by 
substrate composition and concentration. Other groups, Zilversm it, Groener and 
Sparks, measured cholesteryl ester exchange, Zilversmit and G roener using exogenous 
lipoprotein substrates and Sparks using endogenous substrates bound to a solid phase.
Fielding’s group found that the hyperlipidaemic, dyslipidaem ic and hyper- 
triglyceridaemic plasma could express normal activity using exogenous lipoproteins, 
therefore these patients did not have a deficiency o f CETP. He proposed that the 
problem was the inability of the LD L/YLDL to accept cholesteryl ester. He also 
found in these cases that the net cholesterol transport between fibroblasts and medium 
was reversed i.e. the cells accumulated cholesterol despite normal or near normal 
cholesterol esterification in plasma.
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Pappu and Illingworth added LPDS from abetalipoproteinaemic patients to 
normal plasma and found that it decreased normal CE and TG transfer. This inhibitory 
activity was heat insensitive and trypsin sensitive. They proposed that decreased 
CETA was due either to an increased production of inhibitor or that inhibitor normally 
associates with apoB containing lipoproteins and in abetalipoproteinaemics is found 
free.
Sparks et al found that the patients they studied all had an altered HDL 
composition comprising increased TG and decreased CE. Transfer to the HDL 3 
fraction was reduced (but transfer to HDL2 was increased in dyslipoproteinaemics 
and hypertriglyceridaemics). They concluded that impaired interaction o f CETP with 
the HDL3 pool may contribute to CHD risk in patients with plasma lipid abnormalities. 
They adhere to the idea that CETP is involved in equilibrating CE w ithin the HDL 
subclasses prior to transfer to LD L/VLDL especially since CETP binds most avidly 
to HDL. Since binding of CETP is affected both by surface lipids and by apolipoprotein 
composition, changes in HDL structure may affect equilibration of CE. This im paired 
processing of HDL particles may prevent the form ation of a particle that can be 
rapidly metabolised by the liver.
1.10.3 Hyperalphalipoproteinaemia
Familial hyperalphalipoproteinaemia (FHALP) is an inherited condition marked 
by high HDL cholesterol levels and longevity. Interest in this condition increased 
when two groups published investigations into the CETP activity from  these plasmas. 
Koizumi et al [Koizumi, J. et al (1985)] studied two patients with HDL cholesterol 
levels of 7.83 and 4.52mM. The HDL were large with a high choIesterol:apoAI ratio. 
Transfer activity to VLDL and/or LDL could not be detected in either serum or the 
d> 1 .2 1  g /m l fraction of plasma using either exogenous or endogenous lipoproteins. 
Normal LPDS demonstrated normal CETA using FHALP lipoproteins as substrates. 
It was concluded that these patients had either a deficiency of CETP or an increased 
concentration of inhibitor.
Two further studies confirmed these initial reports. Kurasawa et al [Kurasawa, 
T. et al (1985)] studied a FHALP patient who also had hypertriglyceridaemia. Using 
endogenous lipoproteins to measure the activity it was found that the serum expressed 
low CETP activity. Unlike other HTGs this patient’s HDL had low TG and high CE, 
a composition consistent with low CETA. Yamashita et al [Yamashita, S. et al (1987)] 
found that three patients with FHALP had no detectable CETA. Again HDL particle 
size was found to be increased and CE had accumulated in the HDL 2 fraction which 
was also apoE rich.
These findings were disputed [Groener, J.E.M., daCol, P.G. & K ostner, G.M.
(1987)] when CETP activity was measured in an Italian FHALP family. Two types 
of assay were used to measure this activity: using fixed amounts of LDL and HDL 
after removal of endogenous lipoproteins with polyethyleneglycol precipitation and 
addition of exogenous lipoproteins; and using tracer 3 H-HD L 3  in whole plasma. They
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found no major differences between family members with HDLs of >1.7mM, <1.7mM 
or with their spouses. Using the tracer method to measure activity in d>1.18 g/m l 
LPDP, low CETA was found. However if this was calculated in terms of exchange 
between HDL CE and VLDL/LDL CE then low transfer can be explained by the 
uneven substrate distribution found in these patients. It was concluded that there is 
no connection between FHALP and CETA. A strong negative correlation was seen 
between % CE transfer and HDL cholesterol content.
CETA was measured in a Japanese family [Takegoshi, T. et al (1988)]. The 
patient had one tenth normal CETA using an exogenous donor/acceptor assay. If the 
FHALP plasma is added to exogenous CETP then activity is inhibited therefore it 
is likely that the patient has increased inhibitor levels. I f  the LPDP was chrom ato­
graphed on phenyl Sepharose then normal CETP activity could be measured. These 
studies then seem to confirm  the initial investigations and suggest that the decreased 
CETA observed is due to increased expression of inhibitor. In two Japanese FHALP 
patients the absence o f CETP was confirmed using monoclonal antibodies to measure 
CETP protein [Brown, M.L. et al (1989)]. It was also discovered that these patients 
had a point m utation in a splice site of the CETP premessenger RNA leading to 
abnormal splicing and deficiency of CETP. It is possible that FHALP is a heterogeneous 
condition. FHALP may be secondary to a number of d ifferen t abnormalities e.g. 
reduced CETP protein, increased inhibitor or other unidentified factors. There is 
also a difference in degree of FHALP in the cases studied. HDL cholesterol levels 
for the Japanese families are in the range of about 4-8m M , whereas in the Italian 
family the high HDL group ranged from 2-5mM .
1.10.4 Diabetes
Plasma CETP activities were found to be altered in diabetes. Plasma from 
patients with non insulin dependent diabetes mellitus (NIDDM) had reduced CETA 
[Fielding, C.J. et al (1984)]. If normal LD L/VLDL was incubated with NIDDM 
plasma, CETA was normalised. Conversely, NIDDM plasma reduced CETA in normal 
plasma. Thus it seems that NIDDM LDL/VLDL is somehow deficient in its ability 
to carry out transfer reactions. The LDL/VLDL fraction from  NIDDM plasma studied 
here had an increased FC:PL ratio and spontaneously lost FC to HDL (increased FC 
in lipoproteins caused a concentration dependent inhibition of CETA [Morton, R.E.
(1988)]. This suggested that the decreased CETA in NIDDM is mediated by the 
increased FC content of these lipoproteins and in fact it was found that the block 
in CETA was inversely correlated with the FC /PL ratio in LD L/V LDL. Net transfer 
of cholesterol from LDL/VLDL to HDL was observed in NIDDM which indicated 
that there was a chemical potential gradient of free cholesterol. The size of this FC 
gradient was inversely correlated with CETA. Substitution of. diabetic LDL/VLDL 
into normal plasma increased the FC gradient for normal plasma, and substitution 
of normal LDL/VLDL into diabetic plasma decreased the FC gradient. Dysbetali- 
poproteinaemics and hyperbetalipoproteinaemics also have an increased FC /PL ratio.
29
However, CETA was completely normalised in diabetics by normal LD L/V LD L when 
the FC gradient was only partly reduced so there may be an additional abnormality 
of HDL from NIDDM.
It was reported that in general the FC content o f lipoproteins affects TG and 
CE transfer [Morton, R.E. (1988)]. Using in vitro modified lipoproteins (by incubating 
with FC/PC dispersions) it was shown that if  VLDL or LDL have an increased FC 
content then CE transfer from these particles is decreased while TG transfer was 
unaffected. If HDL FC were increased then CE transfer was not changed but TG 
transfer was increased. These effects would lead to an increased mass transfer . 
Enrichm ent with FC allows VLDL to be a more efficient donor of TG. It is possible 
that FC alters the availability of CE or TG for transfer by affecting their relative 
solubilities at the surface of the lipoprotein. An increase in lipoprotein FC may 
indicate a systemic rise in FC and would stimulate net transfer of cholesterol out of 
HDL and hence from  cells.
Patients with insulin dependent diabetes mellitus (IDDM) have a 2-4 fold 
increased CETA similar to nondiabetic hyperlipidaemic patients [Bagdade, J.D. et al
(1987)]. If diabetic VLDL is incubated with control HDL and CETP source, CETA 
is increased. Therefore it seems that diabetic VLDL is altered functionally. The 
diabetics’ VLDL had a decreased TG /PL ratio and this ratio was increased in the 
HDL fraction. These core lipid changes are consistent with the increased CETA in 
vivo.
1.10.5 Others
CETA has been studied in various other pathological states. M endez et al 
[Mendez, A.J., Perez, G.O. & Hsia, S.L. (1988)] studied patients w ith uraem ia receiving 
maintenance haemodialysis. Many of these patients have serum lipid and lipoprotein 
abnormalities and may be at risk for atherosclerosis. These patients had significantly 
lower CETA than controls. The patient VLDL/LDL fraction appeared to behave 
normally in transfer reactions therefore the defect appears to be in the d>1.063g/ml 
fraction. CETA found in the d>1.25g/ml fraction was lower in patients. Inhibitor 
was separated from  CETP by passage over phenyl Sepharose and it was found that 
the recovery of CETA from patient plasma was two times that of the control. It is 
possible that CETP inhibitor is increased in these patients. In end stage renal disease 
[Dieplinger, H., Schoenfield, P.Y. & Fielding, C.J. (1986)] patients on haemodialysis 
show decreased transfer of CE to LDL/VLDL and low CETA compared w ith controls. 
The LDL/VLDL fraction had increased FC and inhibited CETA when combined 
with normal plasma similar to the effects seen in NIDDM. The investigators suggest 
that saturation of FC at the surface of LDL/VLDL causes inhibition of CETP. Finally 
Gupta et al [Gupta, A.K. et al (1989)], measuring the low rate of CE transfer in 
rats, showed that hypothyroid rats had significantly lower CETA than control rats. 
Hypothyroidism is associated with increased atherosclerotic risk.
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11 Inhibition of CETP Activity by Antibodies
Both polyclonal and monoclonal antibodies have been developed to CETP. 
Monoclonal antibodies to human CETP have been used to verify that mass cholesteryl 
ester transfer is carried out by CETP in plasma in vitro [Yen, F.T. et al (1989)]. It was 
also found that inhibition o f CETP did not affect cholesterol esterification i.e. LCAT 
is not controlled by CETP activity and therefore CETP may not regulate efflux of 
cholesterol from cells. Cholesterol was esterified in both HDL and LDL under conditions 
where CETP was inhibited indicating that both these lipoproteins act as substrates for 
LCAT. Initially the cholesterol esterification rate was four times higher in HDL, but 
this rate decreased after 6-8 hours while the esterification in LDL continued to increase. 
There was a strong positive correlation between transfer o f CE to YLDL and VLDL 
TG. Thus the mass of TG  in VLDL may be a m ajor determ inant of lipid mass transfer. 
The rate of transfer o f CE to TG rich lipoproteins may influence the rate of delivery 
of cholesterol to the liver.
Two studies were carried out looking at the effect of inhibiting CETP activity in 
vivo in the rabbit. The first used a monoclonal antibody and attained 71% inhibition of 
CETP activity in rabbit plasma falling to 45% after 48 hours [Whitlock, M.E. et al
(1989)]. Plasma total CE rose, largely reflected by an increase in HDL CE. HDL CE 
increased twofold and HDL TG fell reciprocally but amount of HDL protein did not 
change. This suggests that a CE for TG exchange process takes place in plasma. VLDL 
C E /T G  ratio decreased. The rate of cholesterol esterification was not affected therefore 
the increase in HDL CE is probably due to decreased CE catabolism. Inhibition of CETP 
was also found to delay the clearance of 3H-cholesteryl ether both from  HDL particles 
and from  the plasma com partm ent as a whole. There was a trend toward decreased 
radiolabel uptake in the liver after CETP inhibition but this was not significant. There 
was a negative correlation between Jiver uptake o f radiolabel and the amount of CE in 
HDL. Thus it seems that in vivo CETP is important in CE metabolism by promoting CE 
exchange for TG and promoting clearance of CE from  plasma probably by transferring 
CE to VLDL which is then catabolised by the liver or by a direct effect on hepatocyte 
uptake of CE. The authors suggest a regulatory role for CETP in reverse cholesterol 
transport. These inhibition studies are consistent with hyperalphalipoproteinaem ia where 
patients also have large CE rich HDL and lack CETP.
The second study of CETP inhibition in rabbits showed similar results [Abbey, M. 
& Calvert, G.D. (1989)]. They used a polyclonal antibody and were able to block CETP 
activity completely for 48 hours. They found similar changes in HDL CE and TG and 
also found an increased HDL particle size. LCAT activity did not change in this study 
either and HDL conversion protein activity, an activity capable of converting HDL3 to 
both larger and smaller particles [Rye, K. & Barter, P.J. (1986)],.was not changed. No 
significant changes were detected in LDL or VLDL. Control animals had a significantly 
decreased proportion of cholesterol in HDL and an increased proportion in LDL. The 
inhibited animals had the converse. This indicates that the blocked animals had a less
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atherogenic distribution of cholesterol in their lipoproteins. This suggested atherogenic 
role for CETP may only be important when plasma cholesterol is elevated. Plasma CETP 
levels in the rabbit needed to return to only 20-30% of the normal plasma CETP levels 
in order to get normalisation of the effects (in fact about the level found in human 
plasma). This indicates that the CETP level in rabbits is 3-5 times higher than necessary 
to have maximum effect.
12 Injection of CETP into Non-CETP Animals
In an in vitro study, rabbit CETP was incubated with pig plasma [Abbey, M., 
Calvert, G.D. & Barter, P.J. (1984)]. VLDL CE increased and TG decreased. LDL and 
HDL TG increased. As there was more apoE in LDL, then either CETP transfers apoE 
or apoE transfer is secondary to TG transfer.
The converse of the antibody inhibition studies, i.e. the addition of CETP to a 
CETP free animal, was carried out in rats. These studies were ham pered by the short 
half life of CETP in rats. Partially purified CETP was injected into rats up to a level 
similar to that found in rabbits [Quig, D.W. & Zilversmit, D.B. (1986)]. Seventy percent 
of activity was lost in 6 hours. There was net transfer o f CE out of HDL but no change 
in total cholesterol or the proportion of total cholesterol that was esterified. No effects 
were seen after 24 hours. All the changes observed here were transient probably due to 
the high turnover of lipoproteins in the rat.
Groener et al [Groener, J.E.M., van Gent, T. & van Tol, A. (1989)] also injected 
partially purified human CETP into rats to give levels between 1.5-4 times that seen in 
human plasma for 6 hours. They observed a biphasic decay of activity. A t 6 hours (there 
was no change between 6 and 24 hours) there was an increase in the am ount of apoB 
but no change in serum total cholesterol, free cholesterol, TG, apo A l, apoE or apoAIV. 
VLDL and LDL had increased total cholesterol and there was a decrease o f total cholesterol 
in the large apoE rich HDL fraction. Smaller apoAI containing particles appeared and 
the mean diameter of HDL decreased. ApoE which is normally only found on the large 
HDL fraction was redistributed to smaller particles. The clearance o f 3H-cholesteryl 
ether apoAI rich HDL particles was increased in CETP treated rats, their half life 
decreasing from 3.9 to 2.2 hours. This was accompanied by an increased accumulation 
o f radiolabel in the liver in treated rats. This may be explained by the redistribution of 
cholesterol to VLDL and LDL which may be cleared by the liver. In the control at time 
zero, the radiolabel was found on apoAI rich particles but after 6 hours it was found 
on the larger apoE rich HDL. This may indicate that the apoAI rich HDL are precursors 
for apoE rich HDL. In the treated rats label was found evenly distributed between all 
lipoprotein fraction at 6 hours.
13 Physiological Roles of CETP
The exact physiological role of CETP and its involvement in the developm ent or 
prevention of atherosclerosis is unknown. There is evidence for the involvement o f CETP 
in the progression of CHD and that decreased expression of the enzyme is beneficial.
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In cases predisposing to atherosclerosis e.g. hyperlipidaem ia [Son, Y.C. & Zilversmit, 
D.B. (1986)] and IDDM [Bagdade, J.B. et al (1987)], plasma CETP levels are increased 
and in a condition associated with longevity, FH ALP, plasma CETP levels may be 
reduced or negligible [Koizumi, J. et al (1985), Takegoshi, T. et al (1988)]. There is also 
the circum stantial evidence from plasma levels of CETP found in certain species. Species 
which are at high risk of CHD e.g. humans and rabbits, have high plasma levels of 
CETP whereas those species which seem to be relatively resistant to CHD e.g. rats and 
dogs, have low levels of plasma CETP [Ha, Y.C. & Barter, P.J. (1982)].
However there is contradictory evidence for its involvement in CHD. In NIDDM 
[Fielding, C.J. et al (1984)], in some dyslipidaemic states [Fielding, P.E. et al (1983), 
Sparks, D.L. et al (1989)] and in uraemia [Mendez, A.J. et al (1988), Dieplinger, H. et 
al (1986)] there is an increased risk for CHD but decreased levels of plasma CETP. The 
pig is a species which has low levels of CETP but is susceptible to atherosclerosis. In 
FH patients who have xanthomas, regression has been shown to occur after treatm ent 
with probucol, a drug that results in the increase of plasma CETP activity [Matsuzawa, 
Y. et al (1988), Sirtori, C.R. et al (1988)].
Thus the physiological role of CETP is undefined. Evidence for its participation 
in various processes is often contrary and inconclusive. CETP may be involved in; reverse 
cholesterol transport (RCT), lipoprotein remodelling, equilibration of CE and TG between 
lipoprotein classes and processing of post prandial lipids.
RCT is the process by which cholesterol is returned from peripheral cells to the 
liver for excretion. There are four stages: picking up cholesterol from peripheral cells, 
esterification of this cholesterol by LCAT, transfer to other lipoproteins and delivery 
to the liver. CETP may play a role at any of these stages. Since CE and TG efflux from 
macrophages is stimulated by CETP [Morton, R.E. (b) (1988)] it appears that CETP can 
directly influence CE efflux from peripheral cells. HDL can act as an acceptor of cellular 
cholesterol [Oram, J.F. et al (1981)]. CETP exists in plasma as a complex with LCAT, 
an enzyme involved in esterifying plasma cholesterol [Fielding, P.E. and Fielding, C.J. 
(1980), Francome, O.J. et al (1989)]. The action of LCAT may be im portant in ’fixing1 
cholesterol which has been picked up from cells by HDL, in the plasma compartm ent 
[Glomset, J.A. (1968)]. HDL is the preferred substrate for LCAT, though LDL has been 
shown to act as a substrate over long incubations [Yen, F.T. et al (1989)]. Most of the 
CE in plasma is LCAT derived. It has also been suggested that CETP relieves substrate 
inhibition of LCAT by transferring CE that accumulates in HDL, reducing cholesterol 
concentration in the acceptor and leading to increased flow of cholesterol out of the cell 
[Chajek, T., Aron, L. & Fielding, C.J. (1980), Fielding, C.J. & Fielding, P.J. (1981)]. 
However there is now evidence that LCAT activity is independent from  CETP activity 
[Stein, O. et al (1986), Yen, F.T. et al (1989)] and relief of substrate inhibition may only 
be im portant in static systems e.g. cell culture. In vivo the free Cholesterol gradient is 
probably maintained by turnover of lipoproteins.
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If macrophages (either J774s or human monocyte derived macrophages) were 
allowed to accumulate labelled CE and TG by incubating them with 3H -oleate/album in, 
and then incubated with CETP, then CE and TG efflux to the medium [Morton, R.E. 
(b) (1988)]. The CE mass of the cell was decreased so there was a net transfer of lipid. 
A lipoprotein acceptor was not required for the effect, though LDL and HDL did 
stimulate efflux but only at high concentration. Label did not transfer from  lipoproteins 
to the cells regardless of whether the cells were cholesterol loaded or not. This may be 
due to inhibition of uptake but it is unlikely since HDL and LDL are taken up by 
d ifferen t receptors. Secreted lipids were associated with large molecular weight com­
ponents of d>1.21g/ml and were not associated with CETP. The lipids were readily 
incorporated into HDL or LDL during or after incubation. CE were transferred in 
preference to TG. The transfer mechanism requires no cell energy, active protein synthesis 
or trypsin sensitive protein.
There is controversy over which lipoprotein(s) are responsible for delivering 
cholesterol back to the liver. If HDL is the main lipoprotein responsible for delivering 
cholesterol back to the liver for excretion [Glomset, J.A. (1968), Tall, A.R. & Small, 
D.M. (1980)], then CETP would not be involved in this part of RCT and indeed would 
divert cholesterol away from this pathway by transferring CE to LD L/V LD L which 
may be redirected to other pools in the liver or may be delivered back to the periphery. 
CETP may promote RCT by increasing the flux of CE to LD L/V LD L, which in turn 
may be taken up by the liver. LDL and VLDL remnants are undoubtedly taken up by 
the liver [Goldstein, J.L. & Brown, M.S. (1975), Norum, K .R . et al (1983)] but it has 
been argued that different cholesterol pools exist in the liver and that HDL is responsible 
for delivering cholesterol to that pool destined for bile acid synthesis and secretion. If 
LD L/V LD L are responsible for delivering cholesterol back to the liver for excretion 
[Gotto, A.M. Jr., Pownall, H.J. & Havel P.J. (1986), Fielding, P.E., Fielding, C.J. & 
Havel, R.J. (1983), Havel, R.J. (1985)], then CETP is an integral com ponent of RCT. 
The rate of transfer of CE to lower density lipoproteins is similar to the rate of cholesterol 
esterification. CETP has also been shown to increase the CE uptake by HepG2s in culture 
[Granot, E., Tabas, I. & Tall, A.R. (1987)] though this has been disputed [Rinniger, F. 
& Pittm an, R.C. (1989)]. In cases where CETP activity has been inhibited by antibodies 
in the rabbit [Whitlock, M.E. et al (1989)], inhibition of CETP was found to delay the 
clearance of 3H-cholesteryl linoleyl ether from HDL and whole plasma and to decrease 
the appearance of radiolabel in the liver. Addition of CETP to rats increased the clearance 
of 3H-cholesteryl linoleyl ether labelled apo-AI rich HDL from  the plasma and increased 
radiolabel accumulation in the liver [Groener, J.E.M. et al (1989)]. This evidence implies 
that CETP is involved in RCT and increases the clearance of cholesterol from  the 
plasma.
Granot et al [Granot, E. et al (1987)] proposed that CETP may be involved in 
cellular uptake of cholesteryl esters. They incubated HepG2 cells with 3H -C E  labelled 
HDL3 and increasing amounts of CETP (either d>1.21g/ml plasma, partially purified or 
purified  protein) and found a progressive increase in CE uptake, to about threefold.
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This process was saturated by both CETP and HDL at relatively low concentrations. The 
uptake increased over 18 hours and protein uptake was not affected. An increased amount 
of labelled cholesterol was found in the cells which indicates that the CE was taken up 
and also degraded. CE degradation was inhibited by chloroquine. This effect was also 
seen in smooth muscle cells and to a lesser extent in fibroblasts but not in endothelial 
cells or J774s. Immunoprecipitation of CETP abolished the effect. In incubations without 
CETP, 0.7% of label was transferred to d< 1.063 g/m l plasma and this was increased to 
1.8% in the presence of CETP. After an 18 hour incubation, the d< 1.063 fraction was 
isolated and reincubated with new HepG2 cells. There was no accum ulation o f radio­
activity into the cells. Therefore although transfer of label to d<1.063g/ml particles did 
take place it is unlikely that this accounts for the accumulation o f labelled CE by the 
cells by uptake of apoB containing particles. Preincubation of the cells with LDL, which 
would cause a downregulation of LDL receptor, decreased the absolute amount of HDL 
CE uptake but did not affect the stimulation by CETP.
Rinniger and Pittman [Rinniger, F. & Pittman, R.C. (1989)] disagreed with the 
conclusions reached by Granot et al. They saw the CETP stim ulated uptake of CE from  
3H -H D L3 in HepG2s in long incubations. However the effect was not seen in shorter, 
4 hour, incubations nor in fibroblasts. This suggested that components secreted by the 
cells in culture e.g. lipoproteins were necessary for the effect. If CE were transferred 
to lower density lipoproteins and then these were taken up by receptors then this would 
explain the effect. To investigate this they used four inhibitors of LDL uptake: heparin, 
monensin, LDL receptor antibodies and anti-apoB and E binding domains. All these 
agents blocked CETP stimulated uptake of CE. Heparin increased the amount of labelled 
CE in the d<1.063g/ml fraction. Granot’s study concluded that not enough CE was 
transferred to d<1.063g/ml particles in order to account for the effect. However they 
looked at the particles left at the end of the experiment which were those which were 
not preferentially taken up. Also since down regulation does not completely abolish the 
amount of receptor expressed if the labelled particles were of high affin ity  they would 
still be taken up.
Lipoprotein remodelling is a process in which CETP may be involved. Decklebaum 
et al [Decklebaum, R.J. et al (1988)] studied the remodelling of lipoproteins in vitro. 
Transfer of CE from  LDL to VLDL and TG back to LDL was detected. The TG in 
LDL could be hydrolysed by lipoprotein lipase. Using a cyclic treatm ent o f HDL2 with 
CETP, causing loss of CE to VLDL and acquisition of TG , and then lipoprotein lipase, 
which hydrolyses the accummulated TGs, the HDL2 could be converted to HDL3. The 
relative amounts of VLDL and LDL/HDL would influence lipid exchanges and hence 
remodelling. CETP could be involved in VLDL to LDL interconversions. CE transfer 
from VLDL would result in replacement by TG. If this TG is hydrolysed by lipoprotein 
lipase then smaller particles will be formed. Abetalipoproteinaemic patients, who had 
decreased CETA, had an increased proportion of HDL2 which ties in with the idea that 
transfer protein may be involved in converting _HDL2 into HDL3 [Pappu, A.S. & 
Illingworth, D.R. (1988)]. FH patients who have been treated with probucol [Sirtori,
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C.R. et al (1988)] have increased CETA and decreased HDL2 while the HDL3 fraction 
is unchanged. This supports the theory that CETP is involved in HDL particle in ter­
conversion.
CETP shows substrate specificity for species of CE [Morton, R.E. (1986)]. D if­
ferences in rates of transfer according to acyl chain would lead to d ifferen t CE com­
positions of lipoproteins. These differences may influence the metabolism of lipoprotein 
particles e.g. enrichm ent with saturated CE would decrease the fluidity  of the lipoprotein 
particle which may affect further transfers or remodelling reactions. CETP may be 
involved in equilibrating CE within HDL subclasses by carrying out particle intercon­
versions prior to transfer to lower density lipoproteins. Impaired processing of HDL 
may also prevent the form ation of a particle that can be rapidly taken up by the liver.
CETP may be involved in the post prandial processing of lipids. Lipolysis of 
lipoprotein particles leads to increased binding of CETP and an increase in its activity 
[Castro, G. & Fielding, C.J. (1988), Sammett. D. & Tall, A.R. (1985)]. CETA increases 
post prandially [Tall, A. et al (1986)] and also Caco2 cells can secrete CETP in a way 
that is regulated by fatty  acids [Faust, R.A. & Albers, J.J. (1988)]. This evidence suggests 
that CETP secretion could be upregulated in both acute and chronic lipaemia and CETP 
may be invoved in both states.
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This project was started in January 1987. At that time much fundam ental knowledge 
about CETP was lacking which was rapidly provided in the intervening years. Therefore 
many of the experiments originally laid out in the aims of the project have been 
superceded and some areas of investigation were introduced as more inform ation became 
available. At the time of embarking on this project the CETP protein had not been well 
characterised to the 74kD form, and no good antibodies with which to carry out in vivo 
inhibition studies were available. LTIP was not characterised until 1989 and up until 
then its existence was putative. Only macrophages had been reported to secrete CETP. 
The CETP gene was cloned and sequenced only in 1987.
The aim of this project was to investigate fu rther the role of CETP. A number of 
approaches were taken:-
1/ CETP activity in plasma is the net result of a num ber of influencing factors 
including CETP mass, concentration of inhibitor and composition and concentration of 
substrate lipoproteins. This last variable can be eliminated by using exogenous substrates 
in an activity assay. It was hoped that by measuring CETA per se in plasma, i.e. the net 
result of inhibitor and CETP, and then by measuring CETP protein mass, using antibodies, 
that the relationship between CETP and its inhibitor LTIP as affecting expressed plasma 
CETA could be investigated.
2 / Inhibition of CETP activity in vivo is a key experim ent which would yield 
inform ation on the role of CETP in the whole animal. In the absence of a good chemical 
inhibitor the best inhibitor to use would be antibodies, either polyclonal or monoclonal.
3 / There are drugs available that affect cholesterol metabolism in vivo. By looking 
at the effects of these agents both on plasma cholesterol and on plasma CETP activity, 
one might be able to infer what effects CETP is having on cholesterol metabolism.
4 / Cells in culture e.g. macrophages, J774, HepG2 and CaCo2 are known to secrete 
CETP. Fatty acids increase CETP secretion by CaCo2 cells. Identifying factors which 
may affect CETP secretion may shed light on what regulates plasma CETP levels in vivo.
5 /  A negative correlation has been found between plasma HDL levels and plasma 
CETP activity. Since probes for the CETP gene are available it is possible to look for 
polymorphisms in the CETP gene and test whether there is any relationship between 
these polymorphisms and plasma CETP activity and HDL levels. I f  CETP has an effect 
on plasma HDL then one might expect to find a relationship between any detected 
polymorphism and plasma HDL levels.
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CHAPTER II
METHODS
1 General Methods 
2.1.1 Buffers
Phosphate buffered saline (PBS) - 80g NaCl (137mM), 2g KC1 (2.7mM), 2g 
K H 2P 0 4 (1.5mM), 11.5g Na2H P 04 (8.1mM) in 10L distilled water.
Tris saline buffer pH 7.4 - 0.15M NaCl, lOmM Tris, ImM  EDTA, 0.05% NaN3.
2.1.2 Analytical Procedures
Total cholesterol was measured using an enzymic colorimetric assay (Cat No 
816302, Boehringer Mannheim GmbH). The same enzymic test was used to measure 
HDL cholesterol after precipitation of plasma LDL and VLDL by heparin manganese 
[Burnstein, M., Scholnick, H.R. & M orfin, R. (1970)]. Triglycerides were measured 
using an enzymic colorimetric test (Cat No 816370 Boehringer M annhein GmbH, or 
Baker Instruments). Tests were carried either automatically (Centrifichem ) or 
manually. Free fatty  acids were measured using an enzymatic colorim etric kit (Wako, 
Alpha Laboratories). Phospholipids were measured as described [D ittm er J.C. & Wells 
M.A. (1969)]. If tissue or lipoprotein samples were used these were first extracted 
with one volume of chloroformrmethanol 2:1 for 1 hour followed by addition of four 
volumes of 0.05M CaCl2 to separate the phases [Folch, J., Lees, M. & Stanley, G.H.S. 
(1957)]. Protein concentrations were determ ined with Biorad Protein Assay according 
to the m anufacturers instructions using bovine serum albumin as a reference standard.
For a more sensitive measurement o f cholesterol a spectrofluorom etric technique 
was used [Heider J.G. & Boyett R.L. (1978)] with the following differences which 
improved reproducibility in our hands. The 0.05M sodium phosphate bu ffe r pH 7.0 
contained PEG 6000 instead of Carbowax and lOmM sodium taurocholate was present 
in both the free and total cholesterol reagent. Cholesterol esterase at 0.8 IU /m l was 
used in the total cholesterol reagent. Standards and samples were diluted in propan-2-ol 
to a volume of 50pl and 1ml of reagent was added. Tubes were incubated for 30 
minutes at 37°C. Fluoresence was measured using a Perkin-Elm er LS-5B luminescence 
spectrometer at excitation wavelength 325nm and emission wavelength 415nm.
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2.1.3 Preparation of Lipoproteins and LPDS/LPDP
Lipoprotein fractions were prepared by d ifferential ultracentrifugation at 
d ifferen t densities. Chylomicrons (CM) were separated by flotation at 1.0063g/ml, 
very low density lipoprotein (VLDL) by flotation at 1.0063g/ml, low density lipo­
protein (LDL) at 1.063g/ml, and high density lipoprotein (HDL) at 1.21g/ml 
[Schumaker, V.N. & Puppione, D.L. (1986)]. HDL can be divided into two subfractions; 
H D L2 by flotation at 1.125g/ml and HDL3 by flotation at 1.215g/ml after removal 
o f the HDL2 subfraction [Anderson, D.W. et al (1978)]. Final densities were achieved 
by adding appropriate amounts of density solutions. Several stock density solutions 
were made:- solution 1 d=1.0063g/ml (34.38g NaCl + 3000ml H 20 ) , solution 4 
d=1.3104g/ml (115.34g NaBr + 250ml solution 1), solution 5 d=1.2160g/ml (75.82g 
NaBr + 250ml solution 1), solution 6 d=1.1816g/ml (63.30g NaBr + 250 ml solution 
1), solution 7 d=1.0670g/ml (20.37g NaBr + 250ml solution 1) and solution 8 
d=1.4744g/ml (193.8g NaBr + 250ml solution 1). Densities of stock solutions were 
m easured using a Paar DMA46 densitometer (Stanton Redcroft).
The main lipoprotein subclasses were separated sequentially as follows. For 
large scale preparations either 25ml polycarbonate bottles were used in a Beckman 
55.2 Ti rotor or 70ml polycarbonate bottles were used in a Beckman 45 Ti rotor (but 
in this rotor the maximum speed for separation of LDL and HDL was only 45000rpm) 
in a Beckman L8-70M  ultracentrifuge. For small preparations either 1ml or 3ml 
samples were centrifuged in a Beckman TL100 ultracentrifuge using a TLA 100.2 
or a TLA 100.3 rotor respectively.
Lipoproteins were prepared at 20°C from  either serum or plasma. To separate 
CM, tubes are two thirds filled, overlaid with solution 1 and centrifuged at lOOOOOg 
for 20 minutes. The top one sixth volume is rem oved using a syringe and blunt needle 
and a fu rther one sixth volume is removed as waste. VLDL was collected by overlaying 
the infranatant with solution 1 and centrifuging at 160000g for 20 hours (45000rpm) 
in L8-70M  or at 350000g for 3 hours (lOOOOOrpm) in the TL100. The VLDL was 
removed as the top one sixth volume and waste was removed as before. The density 
was increased to 1.063g/ml by adding one half the volume of solution 6 to the 
resuspended supernatant. Any space was overlaid w ith solution 7. The tubes were 
then centrifuged as for the VLDL. LDL^was/ harV esfed'm id'the waste removed as 
before. The density was increased to 1.21g/ml by adding one half the volume of 
solution 8 to the resuspended supernatant and overlaying any space in the tube with 
solution 5. This was centrifuged at 200000g for 24 hours (50000rpm) in the L8-70M  
or 350000g for 3 hours (lOOOOOrpm) in the TL100 centrifuge. HDL was harvested 
as the top one sixth volume and one sixth volume was removed as waste. The remaining 
infranatant was lipoprotein depleted plasma (LPDP) or lipoprotein depleted serum 
(LPDS) depending on the starting material.
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To prepare the HDL subfractions, the lower density lipoproteins were firstly 
removed by flotation at 1.063g/ml. The background density was increased to 1.125g/ml 
by adding one quarter the volume of solution 4. HDL2 was isolated by flotation at 
1.125g/ml at 200000g (50000rpm) for 24 hours in a Beckman L8-70M  ultracentrifuge. 
A fter harvesting HDL2 the density was increased to 1.215g/ml by the addition of an 
equal volume of solution 4. Again the tubes were centrifuged at 200000g (50000rpm) 
for 24 hours. HDL3 can be harvested from the top of the tube and after the removal 
of waste, LPDP or LPDS remains.
LPDP or LPDS could be obtained in a one step ultracentrifugation at 
d=1.215g/ml. This final density was obtained by adding two volumes of solution 4 
to one volume of plasma or serum. This was then centrifuged at 200000g (50000rpm) 
for 24 hours in a Beckman L8-70M ultracentrifuge or 350000g (lOOOOOrpm) for 3 
hours in a TL100 centrifuge. A fter centrifugation the top one th ird  volume was 
removed and the infranatant resuspended.
A fter preparation, lipoproteins or LPDP/S were dialysed against 20 volumes of 
Tris saline buffer and then sterilised by passage through a 0.2 m icron filter.
2.1.4 Electrophoretic Techniques
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) was 
carried out according to the method of Laemmli [Laemmli U .K . (1970)]. Briefly, 1M 
Tris pH 8.7 (10ml) was mixed with an appropriate volume of acrylam ide 30%: 
bisacrylamide 0.8% to give the final desired concentration of acrylam ide after adding 
water to bring the final volume to 40ml. 20% SDS (200pl) was added followed by 
N ,N ,N ’,N’,-tetram ethylethylenediam ine (TEMED) (20pl) and freshly prepared 13% 
ammonium persulphate (100pl). Once poured in the mold the gel was overlaid with 
w ater-saturated isobutanol which was rinsed o ff when the gel had set. The stacking 
gel consisted of 5.25% acrylamide. Acrylamide 30%: bisacrylamide 0.8% (3.5ml) was 
mixed with 0.83M Tris HC1 pH 6.8 (3.5ml) and water (12.8ml). 20% SDS (lOOpl), 
TEM ED (10pl) and 13% ammonium persulphate (100pl) were then added. Samples 
for electrophoresis were prepared in sample buffer, 20% SDS (5ml) 0.83M Tris HC1 
pH 6.8 (1.5ml) glycerol (5ml) and water (38.5ml). Bromophenol blue (lpg /m l) was 
added as a dye. Before use, sample buffer was saturated with urea and 2-m ercap- 
toethanol (final concentration 5%) was added. No less than a 1/2 dilution of sample 
buffer was made by adding sample. Gels were run overnight at 35V in running buffer 
(5 x concentrated running buffer = glycine 144g/l, Tris 30g/l, 20% SDS 25m l/l).
Lipofilm kits (Sebia, supplied by Labmedics) were used to analyse lipoproteins 
electrophoretically. The gels were run according to the m anufacturer’s instructions. 
Samples were prestained for 30 minutes in Sudan Black prior to electrophoresis as 
described in the instructions.
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2.1.5 Autoradiography
DNA and RNA blots or air dried Lipofilms were autoradiographed at -20°C. 
Films were developed in Kodak LX24 developer for 1 to 3 minutes until sufficient 
reaction had occured, then stopped in 1% acetic acid for one minute and finally fixed 
for 3 minutes in Kodak FX40 fixer. The films were then washed in water.
2.1.6 Stains
For Coomassie blue staining gels were first fixed for 30 minutes in 10% acetic 
acid, 50% methanol. They were then stained for 5 m inutes in 0.6% Coomassie brilliant 
blue R, 10% acetic acid, 50% methanol and then destained in 10% methanol, 10% 
acetic acid until the background was clear.
Silver staining was carried out according to the method of Morrissey [Morrissey, 
J.H. (1981)]. Gels were prefixed in 50% m ethanol, 10% acetic acid for 30 minutes 
and then 5% methanol, 7% acetic acid for 30 minutes. Fixing was in 10% glutaraldehyde 
for 30 minutes. Gels were then rinsed in distilled water and soaked over 2 to 3 hours 
in several changes of distilled water. A fter washing the gels were then soaked firstly 
in dithiothreitol (5pg/ml) and then 0.1% silver nitrate, each for 30 minutes. Next the 
gels were rinsed quickly two times with distilled water and once with a small amount 
of developer (50pl of 37% formaldehyde in 100ml 3% sodium bicarbonate). Gels were 
then soaked in developer with mixing until the desired staining was reached. 
Development was stopped by adding 2.3M citric acid (5ml) and leaving for 10 minutes. 
Finally gels were washed several times with distilled water.
Protein on nitrocellulose was stained with Ponceau Red S, 0.05% in 3% 
trichloroacetic acid, for 5 minutes and then the filte r was washed in distilled water. 
Staining could be totally removed by destaining in PBS.
2 Enzyme Assays
2.2.1 CETP Assay
3H -H D L3 donor particles were prepared by a m odified method of M orton and 
Zilversmit [Morton, R.E. & Zilversmit, D.B. (1981b)]. Blood was collected in disodium 
EDTA (final concentration 1 m g/m l EDTA) and the plasma separated by centrifugation 
(2800rpm, 1200g, 15 minutes). The d>1.125g/ml fraction of plasma was isolated by 
centrifugation as described previously. Less dense (d<1.125g/ml) lipoproteins were 
quantitatively removed using a syringe and the infranatant dialysed against T ris-saline 
buffer.
A m ixture of 9pl of triolein in hexane (lOmg/ml), 1 5jj1 egg lecithin phosphatidyl 
choline in hexane (lOOmg/ml), 8.8pl of ImM butylated hydroxytoluene in chloroform , 
160pl of 3H-cholesteryl oleate in toluene (160pCi o f a stock at 45Ci/mmol) and 184pl 
of cholesteryl oleate in hexane (1 m g/m l) was dried down in a siliconised glass tube 
under a stream of nitrogen. To label the lipoproteins with a different isotope or to
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label a d ifferent moiety the 3H-cholesteryl oleate was replaced with 14C-cholesteryl 
oleate (20pCi), 14C-triolein (20pCi) or to double label, 3H-cholesteryl oleate and 
14C -triolein were added together. An aliquot of 0.8ml of freshly prepared Tris-EDTA 
buffer (50mM Tris-HCl, pH7.4 and 0.01% disodium EDTA) was added to the mixture 
and the tube flushed with nitrogen. It was then covered with Nescofilm and mixed 
on a vortex for 10 minutes to give a cloudy suspension. Sonication of this in a MSE 
Soniprep 150 using a 3mm probe (2 x 20 minutes, 2 microns amplitude) produced a 
clear solution which was transferred to a siliconised glass conical flask together with 
20ml of dialysed d>1.125g/ml plasma infranatant, 1.66ml of 14mM DTNB and 0.2ml 
of 0.4M disodium EDTA containing 4g/100ml NaN3. The m ixture was incubated for 
18 hours at 37° C under nitrogen. 3H -H D L3 was subsequently isolated by flotation at 
d=1.215g/ml and further purified by a second centrifugation at d=1.125g/ml. The 
infranatant from this was then centrifuged once again at d=1.215g/ml and the 
3H -H D L3 in the supernatant harvested. The labelled lipoprotein fraction was loaded 
onto a 80ml (1.5 x 45cm) Sepharose CL-4B gel filtration column and eluted overnight 
w ith Tris-saline buffer. Samples of the fractions were counted by liquid scintillation 
counting and the radioactive peak pooled. In earlier experiments either the final two 
ultracentrifugation steps or the Sepharose CL-4B gel filtration step were omitted. 
Details are given in the figure legends. To label d ifferen t lipoprotein fractions the 
lipid emulsion could be incubated with either whole plasma or LPDP plus the 
lipoprotein of choice and then subsequently isolated at the correct density. Labelled 
lipoproteins were stored at 4°C after sterilisation by passing through a 0.2 micron 
filter.
A combined LDL/VLDL fraction (d<1.063g/ml) from  pooled normal plasma 
was used as a transfer acceptor. This was isolated by ultracentrifugation at d=l .063g/ml 
after removal of chylomicrons as described previously. The fraction was purified by 
a further flotation at d=1.063g/ml, dialysed against Tris-saline buffer and stored at 
4°C after sterilisation by passing through a 0.2 micron filter. In some experiments 
the second ultracentrifugation was omitted. Details are given in the figure legends.
When initially testing for the optimum precipitation conditions dilutions of a 
stock heparin manganese solution (2500 U /m l heparin (Sigma cat. no. 9133): 1M 
manganese chloride) were used. Once the best precipitation conditions were found 
(described in Chapter III), 2000 U /m l heparin:0.8M manganese chloride solution 
(25pl) was routinely used to precipitate lipoproteins in a 60pl assay, giving final 
concentrations of 213U/m l heparin and 0.085M M nCl2,
3H -H D L3 (5pg protein) and LDL/VLDL (8pg protein) were incubated together 
in the presence of 0.7mM DTNB with the d>1.215g/ml fraction of test plasma (LPDP) 
in a total volume of 60pl. The DTNB was added as 5pl of a 8.4mM solution, pH 7.0. 
The assay was carried out in microtitre plates which had been previously coated by 
incubating in 3% BSA for one hour at 42° C, shaking o ff excess solution and air 
drying. Tris-saline buffer was used for the assay and all LPDP samples had been 
previously dialysed against this buffer. It is essential that samples assayed do not
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contain phosphate as this may interfere with precipitation since manganese phosphate 
can precipitate lipoproteins. Plates were incubated at 42° C for 2.5 hours with shaking. 
The assay was stopped by placing the plate on ice. Chilled plasma (150pl) was added 
to each well with mixing, followed by 25pl o f heparin manganese reagent (heparin 
2000 U /m l in 0.8M MnCl2) [Tollefson, J.H. & Albers, J.J. (1986)]. The plate was left 
to stand for 25 minutes on ice. The precipitate was pelleted by centrifugation (2800rpm, 
1200g, 25 minutes, 4°C) and 3H -radioactivity measured in 150pl o f supernatant. 
A ctivity was expressed as percentage transfer (from  supernatant to pellet) per 2.5 
hours. This was linear to 35% transfer. The protein content of each LPDP sample 
was determined by the Bio-Rad Protein Assay (Bio-rad U.K.) and specific activity 
expressed as percentage transfer/pg LPDP protein/2.5 hours.
The above assay could be made more sensitive by incubating for 8 hours at 
42° C. If  assays were carried out in this way the assay volume was doubled so that 
the assay could be carried out in larger tubes thus avoiding problems with evaporation 
encountered when incubating m icrotitre plates for the longer period of time; 10pg 
of 3H -H D L3 was incubated with 16pg LDL/V LDL. Assay buffer containing 6% BSA 
was added to the assay to give a final BSA concentration of 0.5%. Assays were carried 
out in a volume of 120pl in microfuge tubes and incubated in a shaking w ater bath. 
At the end of the incubation 300pl of cold plasma and 50pl heparin:manganese reagent 
(2000 U /m l heparin: 0.8M MnCl2) were added. Precipitation was carried out in the 
usual way. Samples (300pl) of supernatant were counted.
When samples were to be assayed for their inhibitory effect on CETP activity, 
they were incubated in the usual CETP assay in the presence of a control amount 
of either human LPDS, human post CM52 CETP or rabbit post CM52 CETP. Enough 
protein was added to give a control activity of between 25 to 30% transfer. Inhibition 
was calculated as the percentage inhibition of this control activity.
The solid phase CETP assay was carried out as follows. 3H -H D L was coupled 
to CNBr activated Sepharose (Pharmacia) according to the m anufacturer’s instructions. 
CNBr activated Sepharose (0.285g) was allowed to swell for 15 minutes in Im M  HC1 
and then washed with 5 x 20ml ImM  HC1. The gel was washed with 2.5ml coupling 
bu ffer (0.1M N aH C03 pH 8.3, 0.5M NaCl) and transferred to a solution o f 8.8mg 
3H -H D L (2.7pCi) in coupling buffer. The solution was then mixed end over end for 
two hours at room temperature. The gel was transferred to blocking b u ffe r (0.2M 
glycine pH 8.0) and left to stand for 2 hours at room tem perature. Excess ligand was 
washed away with alternate washes of 4 x 10ml coupling buffer and 4 x 10ml acetate 
(0.1M acetate pH8.4). 3H-HDLrSepharose (10pl, 50000dpm) was incubated w ith 40pg 
LD L/V LD L in the presence of 0.7mM DTNB and LPDS in a volume of 200pl. At 
the end of the incubation, HDL-Sepharose was pelleted by centrifugation (2800rpm, 
1200g, 15 minutes) and the supernatant was sampled (lOOpl) and counted by liquid 
scintillation counting.
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2.2.2 LCAT Assay
Substrate micelles were made by drying down egg lecithin phosphatidyl choline 
(8pl of a lOOmg/ml solution in hexane, equivalent to 0.9pmol) and [4 -14C] cholesterol 
(8.4pCi at 56mCi/mmol, equivalent to 0.15pmol) under a stream of nitrogen in a 5ml 
polypropylene tube (Sarstedt). One ml ’phosphate bu ffer’ (50mM K H 2P 0 4 pH7.4, 
0.025% EDTA, 2mM NaN3) was added and the tube mixed well. The resultant cloudy 
solution was sonicated ( 4 x 5  minute bursts at 2 micron amplitude) in a MSE Soniprep 
150 using a 9mm probe. The resulting substrate vesicles contained approximately 
80000-90000dpm per 5pl. Solutions could be stored at 4°C for 2 weeks without loss 
of activity.
A dialysed LPDP (d>1.215g/ml) fraction was used for measurement o f LCAT 
activity. Tw enty-five pi of substrate vesicles and 45pl of assay buffer (0.15g/a*l 
apoAI, 20g/l BSA, 8mM 2-mercaptoethanol in phosphate buffer) were mixed in a 
m icrofuge tube [Doi, Y. & Nishida, T. (1981)]. The tube was then flushed with 
nitrogen, capped and preincubated at 37° C for 30 minutes. The reaction was started 
with 20pl of an appropriate dilution of LPDP. This dilution was usually 1 in 2 in 
phosphate buffer and was chosen so that the substrate remained in excess during the 
reaction. Tubes were again flushed with nitrogen, capped, mixed and incubated for 
45 minutes at 37°C. At the end of the incubation the assay was stopped by the addition 
of 750pl hexane/isopropanol 3:2 v/v followed by lOOpl of 60% ethanol containing 
0.02% Coomassie blue [Belfrage, P. & Vaughan, M. (1969)]. The tubes were thoroughly 
mixed on a vortex mixer and centrifuged (1750rpm for 3 minutes) to separate the 
phases. The upper organic colourless layer was sampled (350pl) and transferred to an 
HPLC autosampler vial. The samples were dried down and then dissolved in 1.25ml 
injection solvent (0.5g/l cholesterol, 0.5g/l cholesteryl oleate, lg/1 oleic acid in 
methanohisopropanol 145:55 v/v). The cholesteryl ester content was determ ined by 
reversed-phase HPLC with radiochemical detection using a column of Spherisorb 5 
micron ODS2 (15cm x 4.6mm id) and a mobile phase o f propan-2-ol/m ethanol 55:45 
v /v  at a flow rate of 0.6ml/minute. The column eluant was mixed with Ecoscint 
scintillation fluid (National Diagnostics) in a 1:1 ratio prior to detection with a 
BETAcord 1208 radioactivity monitor (LKB). Two product cholesteryl ester peaks 
were separated and quantified against a 14C-cholesteryl oleate standard curve, 
Dectection of cholesteryl ester was linear between sensitivity limits o f 1000-10000 
dpm /m l (8.13-81.3 pmol/ml).
3 Purification Techniques
2.3.1 CETP Purification
Partial purification was carried as described in previously published methods 
[Morton, R.E. & Zilversmit, D.B. (1982), Hesler, C.B. et al (1987)]. All purification 
steps were carried out at 4°C. LPDS or LPDP (200-300ml) was used as a starting 
material. This was adjusted to 4M NaCl by the addition of solid NaCl. If  LPDS was
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used directly after preparation by ultracentrifugation it was not dialysed but was 
adjusted to a final salt concentration of 4M taking into account the starting NaBr 
concentration. The LPDS was then centrifuged (35000rpm, 30 minutes, in a Beckman 
45Ti rotor) before loading onto a 200ml phenyl Sepharose CL4B column, at 30 
m l/hour, which has previously been equilibrated with lOmM Tris HC1 pH 8.0, 2M 
NaCl. The column was then washed at 30m l/hour with lOmM Tris HC1 pH 8.0, 0.15M 
NaCl until the absorbance of the eluant at 280nm was 0.3, usually overnight. CETP 
activity was eluted at 30m l/hour in distilled water, 0.02% NaN3. Fractions were 
assayed and the active fractions pooled. This pool from the phenyl Sepharose column 
was adjusted to 50mM sodium acetate by the addition of 1/19 volume of 1M sodium 
acetate pH 4.5. The pool was then centrifuged (35000rpm, 30 minutes, in a Beckman 
45Ti rotor). The supernatant was loaded onto a 200ml CM52 ion exchange column 
(Whatman) prequilibrated with 50mM sodium acetate, 0.02% NaN3, lm g/m l EDTA, 
pH 4.5. Activity was eluted at 30m l/hour with a 0-200mM  NaCl gradient in sodium 
acetate buffer. The solutions used to form the linear gradient were 300ml sodium 
acetate, 0.02% NaN3, lm g/m l EDTA pH 4.5 and 300ml of the same buffer containing 
200mM NaCl. Fractions (10ml) were collected into tubes containing 1ml 1M Tris 
phosphate pH 7.4 to neutralise the acetate buffer. Fractions were assayed and the 
peak of activity pooled, concentrated under nitrogen using an Amicon PM 10 
membrane and dialysed against Tris-saline buffer. This partially purified  post CM52 
fraction was stored at -20° C. Rabbit CETP was purified in an identical m anner to 
human CETP.
The preparation of the lipid emulsion for CETP purification was according to 
the method of Hesler et al [Hesler, C.B. et al (1987)]. Egg lecithin phosphatidyl 
choline (60mg), triolein (300mg) and oleic acid (40mg) were mixed in a polypropylene 
tube with 3.5 pmoles of butylated hydroxytoluene. The solvents were evaporated 
under a stream of nitrogen for 2 hours. Solution 7 (d=1.063g/ml) (5ml) was added 
and the tube mixed. The m ixture was then sonicated under nitrogen on ice in a MSE 
Soniprep 150 for lOx 15 second bursts at 2 micron amplitude at 3 m inute intervals. 
The emulsion was then centrifuged (2800rpm, 1200g, 10 minutes) to remove any 
particulate matter. Emulsion (2ml) was put into a 5ml Beckman polyallomer tube and 
overlaid with 3ml solution 1, d=1.0063g/ml. The tubes were centrifuged (48000 rpm , 
200000g, 1 hour) in a Beckman SW 50.1 rotor. A fter the centrifugation, the top 2ml 
were removed and loaded onto a 200ml Sepharose CL4B column. Emulsion was eluted 
in Tris-saline buffer. The milky emulsion peak was pooled and its composition 
assayed.
Post CM52 CETP (8mg) was incubated with either emulsion (12% phosphatidyl 
choline, 80% triolein, 9% oleic acid) or Intralipid 10% (KabiVitrum  Ltd), (50mg). 
Mixes were incubated at 37° C under nitrogen for 30 minutes. The lipid CETP m ixtures 
were then loaded onto a 100ml Sepharose CL4B column and eluted at 10 to 20 m l/hour 
with 50mM ammonium bicarbonate, 0.5M EDTA pH 8.5. Fractions (2ml) were 
collected and assayed for CETP activity and also examined by SDS PAGE.
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CETP bound to Intralipid or emulsion was delipidated with ethanol; diethyl 
ether extraction [Hesler, C.B. et al (1987)] or with Cabosil (Kodak). Cabosil (1.5g) 
was stirred for 20 minutes at room tem perature in 37.5ml acetone. This was then 
filtered  through a sintered glass funnel. These last two steps were repeated. The 
washed Cabosil was transferred to a beaker and spread out over the bottom surface. 
The Cabosil was left so that the acetone could evaporate overnight and was then 
crushed to a fine powder with a mortar and pestle. For delipidation Cabosil (1.5g) 
was added to CETP bound to Intralipid (10.5ml) and stirred slowly overnight at 4°C. 
The slurry was centrifuged (17000rpm, 25000g, 60 minutes, 4°C) and the supernatant 
decanted and tested for CETP activity.
For the batch hydroxyapatite binding of post CM52 CETP [Jarnagin, A.S. et 
al (1987)] hydroxyapatite gel was washed two times with 3ml of lOmM Tris HC1 
pH7.4. At each wash, gel was collected by centrifugation (2800rpm, 1200g, 5 minutes, 
4°C). Post CM52 CETP (3mg) was added to the gel and mixed for 2 hours at 4°C on 
a Spiralmix (Denley). Gel was pelleted and the supernatant retained. The gel was 
washed two times with lOmM Tris HC1 pH7.4 (3ml) and then eluted two times with 
lOmM Tris HC1, 20mM phosphate pH 7.4 containing 5mM dithiothreitol (3ml). 
Supernatant, washes and eluates were assayed for CETP activity.
For the Concanavalin A (con A) Sepharose purification of post CM52 CETP, 
a 5ml (0.8 x 10cm) con A Sepharose column was equilibrated with 50mM sodium 
acetate, 90mM NaCl pH 4.5 at 20 m l/hour. Post CM52 CETP (20ml) was loaded onto 
this column and the column washed with sodium acetate/NaCl buffer. The column 
was eluted first with buffer containing lOmM a-m ethyl-D -m annoside and then with 
bu ffe r containing 150mM a-m ethyl-D -m annoside.
A nti-hum an albumin (Sigma, 1ml, 5.65mg) was coupled to CNBr activated 
Sepharose CL4B gel (1ml, 0.286g) as described previously for HDL. The column was 
washed four times with Tris-saline buffer and then post CM52 CETP (lm g) was 
loaded. The column was washed two times with Tris-saline buffer and then eluted 
w ith two times 1ml 0.2M glycine pH3.2. Washes and elution fractions were assayed 
fo r CETP activity.
For the chromatofocussing procedure, post CM52 CETP was dialysed against 
25mM Tris HC1 pH 7.4 and loaded in 15ml at 30 m l/hour onto a PBE-94 chro­
matofocussing gel (Pharmacia) equilibrated at room temperature in 25mM histidine 
base HC1 pH 5.7 [Morton, R.E. & Zilversm it, D.B. (1982)]. This was followed by a 
cushion of 25mM histidine HC1 (5ml). The column was eluted with 200ml Polybuffer 
74 (Pharmacia, 25ml diluted to 200ml and adjusted to pH 3.5 with HC1). Fractions 
were collected and assayed for CETP activity.
2.3.2 Apolipoprotein Al Purification
Human HDL was prepared by ultracentrifugation as described previously. The 
HDL was then delipidated using ethanokdiethylether. Tw enty-five ml extraction
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solvent was required per 1ml HDL. All solvents were precooled to -20°c. E tha- 
nol:diethylether (2:3 v/v) was added to HDL, mixed thoroughly and left to stand 
overnight at -20°C. As much solvent as possible was removed from above the white 
precipitate. Ethanokdiethyl ether (3:1 v /v) was added to the precipitate, mixed and 
left to stand overnight at -20°C. Again the solvent was removed, ethanokdiethyl ether 
1:1 (v/v) added and the precipitate left to stand for 30 minutes. This last step was 
repeated using ethanokdiethylether (1:3 v/v). The protein precipitate was finally 
washed twice with diethylether and dried under a stream of nitrogen.
Delipidated protein (150mg) was dissolved in 0.1M Tris HC1 pH 7.4, 0.01% 
EDTA, 5.4M urea (10ml) and loaded onto a Sephadex G-150 column (Pharmacia, 60 
cm x 3cm) which had previously been equilibrated with the same buffer [Jackson, 
R.L. et al (1973)]. The column was eluted at 60m l/hour at room tem perature with 
1000ml buffer, collecting 10ml fractions. SDS PAGE was carried out on the fractions 
to detect those containing apoAI. Fractions containing apoAI, identified by the 
expected molecular weight o f 28000, were pooled, dialysed against distilled water 
and then freeze-dried.
4 Immunological Techniques
2.4.1 Antibody Production
Secondary structure predictions were carried out by Mike Hann (Glaxo Group 
Research Ltd, Greenford). Chou & Fasman and Robson predictions were carried out 
with the aid of the computer program ’Predict’ written by Peter M urray-R ust (Glaxo 
Group Research Ltd, Greenford). The eight secondary structure predictions used to 
give the consensus plot were the Burgess, Dufton, Fasman, G arnier, K abat, Lim, 
McLauchlan and Nagano models using a computer program written by Elios Eliopolous 
(Leeds University).
The CETP peptide (residues 351-360, see Fig. 4.12) was synthesised by Dr 
Munns at Peptide and Protein Research, University of Reading. The peptide was 
coupled to keyhole limpet haemocyanin (KLH) via the N terminal cysteine according 
to the m anufacturers instructions (CRB). KLH was dialysed against lOmM potassium 
phosphate pH 7.2 and then adjusted to a protein concentration of 20m g/m l. K LH  
8mg (0.4ml of a 20mg/ml solution) was conjugated to lOmg peptide as follows. 
m -M aleimido benzoic acid N-hydroxysuccinim ide ester (170pl of 3m g/m l, in dim ethyl 
formamide) was added dropwise to 8mg KLH in lOmM potassium phosphate pH 7.2. 
The mixture was stirred for 30 minutes at room temperature. The activated K L H  
was desalted on a 20ml P30 column (Bio-Rad). The column was preequilibrated and 
run in 50mM potassium phosphate pH 6.0 at lOml/hour. Fractions (1ml) were collected 
and the protein peak at fractions 13 to 16 was pooled. The activated K L H  solution 
was added to a 5mg/ml peptide solution in lOmM potassium phosphate while stirring 
at room temperature. The pH was adjusted to 7.4 and the mixture was left to stir 
for 3 hours at room temperature.
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K L H -peptide conjugate (2.6mg/ml) was mixed with an equal volume of Freund’s 
complete adjuvant and sonicated at maximum amplitude to give a stable emulsion 
(6-10 seconds). Four subcutaneous injections of a preparation containing approxi­
mately 10pg peptide were given to a Black Face sheep; two injections were 
suprascapular and two were on the haunches. The sheep was boosted four weeks later 
with the same amount of antigen but using incomplete Freunds adjuvant. The sheep 
was bled two weeks after the boost. Immunisation was carried out by Peter Boulton 
(Glaxo Group Research Ltd, Greenford).
Mice were immunised with either post CM52 CETP (rabbit or human) or CETP 
bound to nitrocellulose prepared as follows. CETP bound to Intralipid was run 
overnight on a 10% SDS polyacrylamide gel loaded at approximately 35 to 135pg per 
well, and then blotted onto 0.2 micron nitrocellulose (as described later). Protein 
bands were stained with Ponceau Red and the band corresponding to the correct 
molecular weight for CETP was cut out and destained in PBS. Nitrocellulose was 
dissolved in a minimum volume of DMSO and excess DMSO was evaporated overnight 
under a stream of nitrogen in a 37° C water bath.
Mice were immunised with 1 to 10pg antigen by Paul Hissey (Glaxo Group 
Research Ltd, Greenford). The CETP preparations were diluted in PBS and mixed 
with an equal volume of incomplete Freunds adjuvant. This was sonicated at 10 
microns amplitude for 30 seconds. Immunisation was by subcutaneous injection. Mice 
were tested and boosted at approximately four weekly intervals until serum samples 
from  tail bleeds from the mice showed inhibition of CETP activity. Tail bleeds from 
mice immunised with human CETP were also tested by ELISA. Positive bleeds were 
achieved from  the rabbit CETP immunisation in two months and from  the human 
CETP immunisation in three months.
Monoclonal antibody production was carried out by Peter Boulton (Glaxo Group 
Research Ltd, Greenford). Mice were boosted with 10pg antigen before fusion. Mouse 
spleen cells were fused with NS1 cells (P 3 /N S l/l-A g 4 -l)  and cultured in Biocult 
DMEM containing 10% foetal calf serum. Cell supernatants were tested for their 
inhibition of a CETP assay, with the addition o f screening by ELISA for the cells 
from  the human CETP immunisation. R abbit clones were tested for inhibition of 
both CE and TG transfer. Cultures were cloned three times to 0.3 cells per well. 
Wells were checked by eye under a microscope for growing clones. Seven days prior 
to innoculation of mice for antibody production in the ascitic fluid, mice were treated 
with Pristane (2,6,10,14, tetram ethylpentadecane, 200pl) intraperitoneally. Mice were 
innoculated with a minimum of 106 cells per mouse. Ascitic fluid was tapped after 
10 to 14 days and the cells removed by centrifugation. To purify the antibodies from 
the ascites, a 40% ammonium sulphate precipitation was carried out and then the 
precipitate was dissolved in PBS. This was then run on a Sephadex G200 column 
(Pharmacia) where the antibodies elute in the exclusion volume.
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2.4.2 ELISA
A general method for ELISA is detailed here followed by descriptions of the 
particular applications used. An ELISA plate (Maxisorp, Nunc) was coated with 
antigen at lpg/m l in 0.1M carbonate/bicarbonate buffer pH 9.6, lOOpl per well. The 
plate was incubated with shaking for 1 hour at 37° C and washed three times with 
PBS 0.1% Tween 20. Plates were then blocked with 1% BSA in PBS 0.1% Tween 20 
for 30 minutes at 37°C followed by three washes with PBS 0.1% Tween 20. The first 
antibody is added in PBS Tween, lOOpl per well and incubated for 1.5 hours at 37°C. 
Again the plate was washed three times with PBS Tween. Second antibody, conjugated 
to horse radish peroxidase, usually lOOpl of a 1/1000 dilution, was added in PBS 
Tween. The plate was incubated for 1.5 hours at 37° C. A fter washing three times 
with PBS Tween the plate was developed by adding 100pl of developing solution. 
Developing solution contained 100pl lOmg/ml tetramethyl benzidine, lOOpl H20 2 (10pl 
30% H20 2 in 670pl 0.1M citrate pH 6.0) in 10ml citrate buffer. The plate was then 
incubated for 15 minutes at room tem perature and the reaction was stopped with the 
addition of 25pl of 2.5M H2S 04. The absorbance of the plate was read at 450nm and 
the background reading at 650nm was subtracted.
For testing for antibodies to the K LH -CETP peptide conjugate in sheep, an 
ELISA plate was coated with CETP peptide, KLH, human post CM52 CETP or rabbit 
post CM52 CETP at lpg/m l. Sheep an ti-K L H  peptide serum was added in half-log 
dilutions starting at 1/300. Second antibody was donkey anti-sheep IgG peroxidase 
linked (Sigma) at a dilution of 1/1000.
For screening tail bleeds from  mice immunised with hum an CETP, the tail 
bleed sera were added in doubling dilutions starting at 1/10. The second antibody 
used was goat anti-m ouse IgG (Sigma) at a 1/1000 dilution.
When cell supernatants were tested for antibodies to hum an CETP, plates were 
coated with human post CM52 CETP at 50pg/ml (or 2pg/ml hum an serum album in 
(HSA) for control). Plates were blocked with 0.5% Marvel and antibodies were added 
in PBS TWEEN containing 1% BSA. Supernatants were tested undiluted (or 1/3000 
monoclonal anti-HSA (Sigma) was used as a control). The second antibody used was 
goat anti-mouse IgG at a dilution of 1/1000.
2.4.3 Western Blots
The basic method used for Western blotting is described below. Gels were 
blotted onto nitrocellulose (usually 0.2 micron) for 3 hours at 250mA in transfer 
buffer (25mM Tris pH 8.3, 192mM glycine, 20% methanol). A fter electroblotting, 
membranes were blocked for 30 minutes at 37°C in PBS, 0.05% Tween 20, 5% BSA. 
The membrane was then incubated with first antibody diluted in blocking buffer 
fo r 2 hours at room tem perature. This was followed by one wash for 10 minutes in 
water and two washes for 10 minutes each in PBS, 0.05% Tween 20. The membrane 
was then incubated with second antibody for 1 hour at room tem perature and then
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washed once with water for 10 minutes, two times with PBS 0.05% Tween 20 for 10 
minutes each and a further 10 m inute wash in water. Substrate was then added for 
development (2mg/ml 4 -ch lo ro -l-nap tho l in methanol, 6.5ml, 30% H20 2, 12.5pl, and 
18.75ml PBS). The reaction was allowed to develop for 10 to 40 minutes and was 
stopped by dilution in water.
For the blot to check the identity of the CETP protein using an anti-hum an 
CETP mouse IgM (Hans Dieplinger, Innsbruck), TBS (20mM Tris, 500mM NaCl 
pH7.5) was used instead of PBS. The first antibody dilution was 1/50. The second 
antibody was goat anti-mouse IgM conjugated to horse radish peroxidase (Sigma) at 
a dilution of 1/500.
For the blots using sheep antiserum  the membrane was washed in 0.01% Tween 
20, 0.025% Sarkosyl in PBS. The menbranes were blocked in 5% BSA and 0.5% 
Marvel. The first antibody was a 1/100 dilution of sheep antiserum  and the second 
conjugated antibody was 1/1000 donkey anti-sheep IgG.
For the blot using antibodies from  the mouse ascitic fluid, a 40% ammonium 
sulphate precipitate of mouse ascites was used. The Western blot used 1/50 dilution 
of the mouse antibody preparation and 1/500 dilution of goat anti-m ouse IgG was 
used as the conjugated second antibody.
5 Animal Diets
2.5.1 Rabbits
Froxfield rabbits were obtained from  Froxfield, Southampton. These rabbits 
have a deficiency in their LDL receptor inherited in a M endelian m anner, transm itted 
as an autosomal dominant characteristic. These rabbits have high serum cholesterol 
and spontaneous atheroma. The animals were 8 to 12 weeks of age at the start of 
experiments. Only male homozygotes were used. When rabbits were allocated to 
control and treatm ent groups they were divided such that each group had similar 
mean cholesterol. For the probucol experim ent Froxfield rabbits were fed 1% probucol 
incorporated into FD1 diet for 12 weeks. The AC AT inhibitor was adm inistered 
orally as an emulsion in 5% corn oil and 1% Tween 80. The final concentration fed 
was 3% GR69918X. The antioxidant GR44966X was dissolved in chloroform , sprayed 
over FD1 diet and the chloroform allowed to evaporate. Salbutamol was incorporated 
at 0.03% into the FD1 diet and fed to rabbits for 12 weeks. All animal diets were 
obtained from Special Diet Services Ltd (SDS).
Dutch Belted Rabbits were used for the fat feeding experiment. Control diet 
was FD1 and the treatment was high fat and low cholesterol (0.1%) SDS diet. Dutch 
Belted rabbits were used at 12 weeks of age and fed the diet for 11 weeks. All rabbit 
blood samples were taken from the marginal ear vein.
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2.5.2 Marmosets
Marmosets were fed according to the following regime:- 
Monday - AM dry pellets and 1/6 slice bread; PM 1/8 orange, apple, 2 slices of 
banana. Tuesday - AM pellet mash and 1/6 slice bread; PM treat. Wednesday - AM 
dry pellets and 1/6 slice bread; PM 1/8 orange, apple, 2 slices banana. Thursday - 
pellet mash and 1/6 slice bread; PM treat. Friday - AM dry pellet and 1/6 slice 
bread; PM 1/8 orange, apple, 2 slices banana. Saturday - pellet mash, 1/6 slice bread 
and treat. Sunday - pellet mash, 1/6 slice bread and 1/8 apple. All fru its were washed 
prior to feeding. Pellet mash - per marmoset = 20g M arzuri marmoset pellets mixed 
with 1 pint of U H T milk and Glucodin. Bread = wholemeal bread. Fresh water was 
provided daily. Treats included grapes, marmoset jelly, monkey nuts and sugar puffs.
Marmosets were dosed intragasrically with GR92549 dissolved in water for 
injection. Blood samples were taken from the tail vein.
6 Cell Work 
2.6.1 Cell Culture
CaCo2 cells were cultured in Transwells (Costar) in MEM (with H ank’s salts), 
10% foetal calf serum, 1% non essential amino acids, 1% glutamine, 0.1% penicillin 
and 0.1% streptomycin. Transwells were incubated overnight with m edium  before 
use. CaCo2 cells were harvested by trypsinisation and resuspended at a concentration 
of lxlO 6 cells per ml. Cells (2ml) were put in the top compartm ent and medium (2ml) 
in the bottom. Cells were used at 15 days post confluence.
HepG2 cells were cultured in MEM, H ank’s salts with 8.8mM glycine. Medium 
was supplemented with 1% glutamine, 0.1% penicillin, 0.1% streptom ycin, 1% non 
essential amino acids and 10% heat inactivated foetal calf serum [Faust, R.A. & 
Albers, J.J. (1987)]. Cells were harvested by trypsinisation and subcultured every 
five days.
J774 cells were cultured in RPMI 1640 medium containing 1% glutam ine, 0.1% 
penicillin, 0.1% streptom ycin and 10% foetal calf serum. Cells were harvested by 
scraping and subcultured every three days at a density of 0.5 x 106 cells/m l.
To Trypan blue stain cells, Trypan blue (50pl of a 5m g/m l solution of Trypan 
blue (BDH) in PBS stored after filtering) was added to a cell sample (50pl) and mixed. 
Cells were viewed on a haemocytometer under a microscope and total cells and blue 
stained (dead cells) were counted.
2.6.2 Isolation of Human Monocyte-Derived Macrophages
Blood (250ml) from  one donor was collected into 5 x 50ml tubes, three o f which 
contained 50mg solid EDTA as anticoagulant and two of which contained no anti­
coagulant. The tubes with EDTA were mixed on a Spiralmix (Denley) fo r 5 minutes.
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The two tubes without anticoagulant were used to prepare serum which was then 
filter sterilised through a 0.2 micron filter. Subsequent stages were carried out in a 
laminar flow cabinet. The whole blood from the three tubes containing EDTA was 
transferred into plastic universals (10ml per tube) and underlayed with an equal 
volume of Ficol-Paque (Pharmacia) using a syringe and a 19 gauge needle [Fogelman, 
A.M. et al (1979)]. The tubes were centrifuged at 4°C (1600rpm, 400g, 30 minutes). 
The top layer of plasma (4ml) was removed to just above the interface. The cells at 
the interface were removed in 2-3m l, using a syringe and needle, and pooled. The 
cells were diluted 1 to 1 in PBS and centrifuged (16000rpm, 400g, 20 minutes). The 
cell pellet was washed two times with PBS and suspended in 20ml RPM I 1640 medium 
supplemented with 0.1% penicillin and 0.1% streptomycin. The cell suspension was 
aliquotted into flasks precoated with O.lmg/ml poly-d-lysine. Usually cells from 
150ml blood were put into one large (175 cm2) flask or two medium (75cm2) flasks 
or 40 wells from six well plates. The flasks were incubated overnight at 37°C. 
Non-adherent cells were then poured off. The adherent monocytes (some platelets 
remain also) were cultured in RPMI 1640, 0.1% penicillin, 0.1% streptom ycin, 1% 
glutamine, 20% autologous human serum for 7 to 15 days before use.
2.6.3 Oleate Albumin Preparation
Oleic acid (lg) was washed into a beaker with a minimum volume of ethanol. 
Two drops of phenolthalein (0.1g/250ml in 70% ethanol) was added. The acid was 
neutralised with 1M NaOH until the solution was just pink. The ethanol was then 
evaporated under nitrogen. PBS (50ml) was added and the m ixture boiled. The final 
concentration was adjusted to 20mg/ml oleic acid. Equal volumes of 20m g/m l oleate 
mix and 20% BSA in PBS were mixed and filter sterilised. The final concentration 
was lOmg/ml (32.5mM) oleate 10% BSA [Patsch, W., Tamai, T. & Schonfield, G. 
(1983)].
2.6.4 Preparation of Acetyl LDL
LDL (15mg protein in 10ml) was concentrated to 2ml by placing in dialysis 
tubing and covering it with sucrose crystals (about 1 hour). Concentrated LDL was 
dialysed overnight against 1L of 0.9% saline at 4°C. LDL was then added dropwise 
with stirring to an equal volume of cold (4°C) saturated sodium acetate solution [Basu, 
S.K. et al (1976)]. A fter stirring for 10 minutes on ice, acetic anhydride with a total 
mass equal to five times the weight of LDL protein present was added in 0.5pl aliquots 
over 1 hour. For 15mg protein, 0.5pl was added every 15 seconds for 10 minutes and 
every 30 seconds for 50 minutes (total of 70pl). The mixture was left to stir on ice 
for a further 30 minutes before overnight dialysis against 1L PBS at 4°C.
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7 Molecular Biology Methods
2.7.1 Purification of DNA and RNA
DNA was prepared according to the method of Kunkel et al [Kunkel, L.M. et 
al (1977)]. Cells from  10ml blood were mixed with 0.32M sucrose, lOmM Tris HC1 
pH 7.5, 5mM MgCl, 1% Triton X-100 (80ml) at 4°C. Nuclei were collected by 
centrifugation (lOOOOrpm, 10 minutes, 4 °C). The pellet was suspended in 0.075M 
NaCl, 0.024M EDTA pH 8.0 (4.5ml) using a pasteur pipette. 10% SDS (250pl) and 
freshly made proteinase K solution in water (lOmg/ml, 50pl) were added and the 
resuspended nuclei incubated overnight at 37° C. Water saturated phenol (5ml) was 
added and the tube then centrifuged (lOOOOrpm, 5 minutes, room tem perature) and 
the upper phase removed. Chloroform:isoamylalcohol (24:1, 5ml) was added, the tube 
mixed gently and centrifuged. The upper phase was removed and re-extracted  with 
chloroform:isoamylalcohol. Sodium acetate (3M, pH 5 ,0.5ml) and 100% ethanol (11ml) 
were added to the upper phase at room tem perature. The tube was inverted several 
times and the DNA removed with a pasteur pipette. DNA was dissolved in lOmM 
Tris pH 8.0, ImM  EDTA (1ml) at 4°C and the concentration was determ ined by 
absorbance at 260nm.
For RNA isolation from cells in culture one large (175cm2) tissue culture flask 
(10-40 x 106 cells) was lysed with 2.5ml 4M guanidium isothiocyanate, 5mM sodium 
citrate pH7.0, 0.1M (3-mercaptoethanol, 0.5% Sarkosyl [Maniatis, T., Fritsch, E.F. & 
Sambrook, J. (1982)]. I f  tissue was used then lg  was homogenised in 2.5ml of the 
guanidium isothiocyanate solution. Caesium chloride (lg) was added to each 2.5ml 
of dispersed tissue or cells. The homogenate was layered onto a 1.2ml cushion of 
5.7M CsCl in 0.1 M EDTA pH 7.5 in a Beckman SW50.1 polyallomer tube and overlaid 
with mineral oil. The tubes were centrifuged (35000rpm, 65 hours, 20° C) using slow 
acceleration and deceleration profiles in a SW50.1 rotor in a Beckman L8-70M  
ultracentrifuge. The supernatant was discarded and the tube inverted on a paper 
towel. The RNA pellet was dissolved in lOmM Tris HC1 pH 7.4, 5mM EDTA, 1% 
SDS (300pl). This was transferred to a microfuge tube and extracted with chloro- 
form.T-butanol 4:1 (300pl). The phases were separated in a m icrofuge (13000rpm, 5 
minutes). The upper aqueous phase was removed and the organic phase re-extracted 
with lOmM Tris HCl pH 7.4, 5mM EDTA, 1% SDS (300|j1). The two aqueous phases 
were combined. A one tenth volume of 3M sodium acetate pH 5.2 and 2.2 volumes 
o f ethanol were added and the mixture stored overnight at -20° C. The RNA was 
recovered by centrifugation in a microfuge (13000rpm, 15 minutes). The RNA was 
dissolved in diethyl pyrocarbonate (DEPC) treated water and the RNA concentration 
determined spectrophotometrically. mRNA was purified on oligo (dT)-cellulose using 
the Pharmacia mRNA Purification K it as described by the m anufacturer.
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2.7.2 Gel Electrophoresis of RNA and DNA
A 5pg sample of DNA was digested overnight with restriction enzymes according 
to the m anufacturers’ instructions in the presence of 4mM sperm idine. The digested 
DNA was electrophoresed through 0.8% agarose gels (10.5 x 13cm) in 1 x TAE buffer 
(50 x TAE = 0.04M Tris, 57.1 ml/1 glacial acetic acid, Mm K 2EDTA pH  8.0) overnight 
at 40mA alongside markers from lambda DNA cut with H indlll. A fter electrophoresis 
gels were stained in ethidium  bromide (2.5pg/ml, 5 minutes) and photographed.
For RNA gels samples were dried down in a Savant vacuum drier and then 
DEPC treated water (llp l) , formamide (25pl), formaldehyde 37-40% (9pl) and 15 x 
MOPS (5pl, 5 x MOPS = 0.2M morpholinopropane sulfonic acid pH 7.0, 50mM sodium 
acetate, 5mM EDTA pH 8.0) were added. Tubes were heated at 55°C for 15 minutes. 
Sample buffer was added (3pl, 6 x sample buffer = 0.25% bromophenol blue, 0.25% 
xylene cyanol, 30% glycerol in water) and the samples were electrophoresed in a 
1.2% agarose gels (20 x 25cm) containing 1 x MOPS buffer and 2.2M final concentration 
formaldehyde [Maniatis, T, et al (1982)]. Formamide and form aldehyde were deionised 
before use by stirring for 1 hour with 5g/100ml AG 501 X8 (D) ion exchange beads 
(Bio-Rad). Gels were run overnight at 60V with the buffer tanks stirred. Gels were 
stained in 0.5pg/ml ethidium  bromide, 30 minutes and then destained 3 x 1 hour in 
3 x SSC (20 x SSC = 0.3M sodium citrate, pH7.0, 3M NaCl).
2.7.3 Blotting
DNA was transferred to Hybond-N  (Amersham) by Southern blotting [Maniatis, 
T. et al (1982)] and the hybond-N  was UV irradiated for 3 m inutes to bind DNA. 
RNA gels were soaked in 50mM NaOH, lOmM NaCl (45 m inutes, room tem perature), 
neutralised in 0.1M Tris HC1 pH 7.5 (45 minutes) and then soaked in 20 x SSC before 
Southern blotting.
Slot blots were carried out using a Schleicher and Schuell M inifold II slot blot 
apparatus. Filter paper and Hybond-N were presoaked in 6 x SSC. RNA samples 
were prepared in 2.2M formaldehyde, 50% formamide in D EPC -treated water and 
heated at 65° C fo r 15 minutes, whereas DNA samples were loaded in 0.2M NaOH. 
Samples (500pl) were loaded over about 1 hour. Membranes were UV irradiated for 
3 minutes and baked in an oven for 2 hours at 80° C.
2.7.4 Probe Labelling
Three probes were used for hybridisation as described in Chapter VI. The 
1581 bp cDNA probe comprising the coding sequence for amino acid 8 to 476 of the 
protein [Drayna, D. et al (1987)] was prepared from the plasmid C ETP-II which was 
a gift from Dr D. Drayna (Genetech Inc. CA). This was prepared by digestion of 
the plasmid with EcoRI and cutting the appropriate fragm ent out o f a low melting 
point gel. Subfragments, 732bp and 362bp, of this probe were prepared as described 
in Chapter VI by Dr D. G affney (Glasgow Royal Infirm ary). The 75 bp oligonucleotide
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probe GR91788X was synthesised by Dr Barry Coomber (Glaxo Group Research 
Ltd, G reenford). The actin probe obtained from Oncor (cat. no. P7000) was a 770bp 
probe from the chicken sequence. A further probe was used for apoAI RFLP analysis. 
This was a 2.2kb Pstl genomic DNA fragment of apoAI and was a g ift from  Dr S. 
Humphries (Charing Cross Sunley Research Centre, Hammersmith, London). The 
hybridisation conditions used for this probe were identical to those used for the 
1581 bp CETP cDNA probe. Hybridisation conditions for these probes are detailed 
in Table 6.4.
CETP cDNA and apoAI probes were labelled using the random prim ing method 
[Feinberg, A.P. & Fogelstein, B. (1984)] and purified on a G50 (Pharmacia) column 
in lOmM Tris pH 8.0, ImM  EDTA, 0.1% SDS. These two probes were labelled to 
specific activity 4-9 x 105 cpm /ng and added to a minimal volume of hybridisation 
mixture [Maniatis, T. et al (1982)] at a radioactive concentration of 2.5-5 x 106 cpm 
per blot. Probes prepared in this way were used for hybridisation to DNA blots as 
described in Chapter VII. Actin and latterly the CETP cDNA probe were labelled 
using the M ultiprime DNA Labelling System K it (Amersham) as described in the 
m anufacturer’s instructions. For labelling GR91788X, components of this kit were 
used but the Primer Solution was replaced with a synthetic prim er GR91789X 
(synthesised by Dr B. Coomber, Glaxo Group Research Ltd, G reenford) in an 
equimolar amount to GR91788X (i.e. 5.5 pmol/250pl labelling preparation) and 
nuclease-free BSA at a final concentration of 200pg/ml. Briefly, 125ng probe was 
denatured by boiling for 2 minutes and placed on ice. Amersham B uffer Solution 1 
(50pl) and Prim er Solution 2 (25pl) or GR91788X plus BSA were added and the 
volume made up to 11 5jj1 with DEPC water. 32P-dCTP (25pi, 3000Ci/pmol, 250pCi) 
was added and then Amersham Solution 3 (DNA polymerase I Klenow fragm ent, 
10pl). The solutions were mixed by pipetting and incubated at room tem perature for 
5 hours. Sodium acetate 3M (25pl) and sheared herring sperm DNA (167pl, lOmg/ml) 
were added and the tube mixed. The probe was left to stand overnight at -20°C to 
precipitate. Probe was recovered by centrifugation (13000rpm, 10 minutes). The 
supernatant was removed and the pellet dissolved in D EPC-treated water (500pl) by 
boiling and mixing with a pipette. If necessary, the labelled probe preparation could 
be stored at -20°C. Typical specific activities of these probe are shown in Table 6.3. 
Probes prepared in this way were used for hybridisation to RNA blots as described 
in Chapter VI.
2.7.5 Hybridisation and Washing Blots
For DNA blots, gels were prehybridised in 5 ml hybridisation mix (6 x SSC, 
5 x Denharts solution, 0.5% SDS, 20pg/ml denatured salmon sperm DNA) [Maniatis, 
T. et al (1982)] for four hours and then hybridised in the same solution containing 
denatured radiolabelled probe. A fter hybridisation, blots were washed in 2 x SSC,
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0.5% SDS at room tem perature for 10 minutes, 2 x SSC, 0.1% SDS at room temperature 
for 15 minutes, 2 x SSC, 0.5% SDS at 65°C for 1 hour and finally in 2 x SSC, 0.5% 
SDS at 65° C for 30 minutes.
For the RNA blots, hybridisation conditions were as described in Table 6.4. 
Blots were prehybridised in hybridisation fluid with or without form am ide (Hybrisol 
I or II respectively, Oncor) at the appropriate tem perature overnight. Hybridisation 
was carried out overnight in 25ml Hybrisol containing 125ng labelled probe. Blots 
were then washed in 1L 2 x SSC at room tem perature, 1L 2 x SSC, 0.1% SDS at room 
temperature and 1L 0.1 x SSC at 35m l/hour in a automated washing system (Hybaid). 
Blots were autoradiographed for 1 to 7 days.
2.7.6 Polymerase Chain Reaction (PCR)
DNA (O .lpg-lng) was incubated with 10pl of 10 x concentrated PARRS 
Excellence buffer (Cambio), 5ng/ml final concentration of sense and antisense primers 
(British Biotechnology Ltd, primers shown in Fig 6.11, lOpl of 50ng/pl solution of 
each), and deoxyribonucleotides (dNTPs 16pl of stock solution containing 1.25mM 
of each dNTP) [Erlich, H.A. (1989)]. The volume was made to 100pl with DEPC 
treated water. The m ixture was overlaid with mineral oil (lOOpl) and heated for 6 
minutes at 92° C and then cooled on ice. Taq polymerase (Cambio, 5U, lpl) was added 
and the tube put through 30 heating cycles. One cycle comprised heating at 92°C for 
1 minute, 50°C for 1 m inute and 70° C for 2 minutes.
PCR reaction mix (10pl) was mixed with sample buffer (5pl, 1.25% SDS, 2.5M 
EDTA, 15% Ficoll, 0.15% bromophenol blue). This was loaded onto a 2% agarose 
horizontal gel containing 0.5pg/ml ethidium  bromide. A 123bp DNA ladder (Phar­
macia) and a track o f DNA sample buffer were also run on the gel. The gel (11 x 
13,5cm) was electrophoresed for 3 hours at 70 V, using Tris borate running buffer 
(5 x TBE = 445mM Tris base, 445mM boric acid, lOmM EDTA, Sigma). The gel 
was then photographed under UV illumination.
8 Population for RFLP analysis
A group of 56 subjects (34 men and 22 women) aged 20 to 59 were selected from 
an opportunistic screening programme in Glasgow on the basis of their HDL levels. 
Normotryglyceridaemic (<3.0mM) individuals with low HDL levels (less than ImM) or 
high HDL levels (greater than 2.5mM for females and greater than 2.0mM for males) 
were recalled after the initial screening visit and measurements made of total cholesterol, 
HDL cholesterol, CETP activity and LCAT activity from  fasting samples. Blood (10ml) 
was collected into potassium EDTA tubes and separated into plasma and cells by cen­
trifugation. Both fractions were frozen at -20°C. The cell fraction was used for leukocyte 
DNA extraction as described in section 2.7.1. and the plasma was used to prepare 
lipoprotein deficient plasma for CETP and LCAT determinations.
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CHAPTER III
DEVELOPMENT OF A CHOLESTERYL ESTER TRANSFER PROTEIN ASSAY
1 Introduction
The assay o f  CETP activity is complex and its activity can be measured in d ifferen t 
ways. CETP can be assayed either as an exchange activity or as a net transfer activity. 
CE and TG can be transferred in both directions between lipoprotein substrates and this 
exchange can be measured. A radiolabelled assay measures the rate of exchange of lipids 
by measuring accummulation of radiolabel in an acceptor lipoprotein after transfer from 
a labelled donor particle. It does not measure the absolute amount of lipid transferred 
because any CE or TG in the acceptor particles is free to be transferred back to the 
donor particle by the same exchange activity. A mass transfer assay measures the actual 
mass o f CE and TG that is transferred from one lipoprotein to another. This therefore 
measures the net result of forward and back transfer. An exchange reaction does not 
necessarily alter lipoprotein composition whereas net transfer does due to unidirectional 
transfer of lipids.
An exchange assay using radiolabel is quick with easily detectable amounts of 
exchange. This assay still provides a measure of the amount of enzyme present. A mass 
transfer assay requires accurate measurement o f small changes in lipid but provides 
inform ation on a particular aspect of CETP activity [Ogawa, Y. & Fielding, C.J. (1985)].
When measuring CETP activity in plasma samples, other factors may influence the 
level o f activity measured. Endogenous lipoproteins may affect transfer rates since the 
rate o f exchange is affected by the concentration and composition of substrate lipo­
proteins. In the assay used here, CETP activity was separated from the endogenous 
lipoproteins by ultracentrifugation. Some CETP may remain in the HDL fraction when 
LPDP is separated and hence it is important to compare activities between samples 
prepared in the same way. Activity was measured in the LPDP using standardised amounts 
of exogenous lipoprotein substrates. Thus the maximum amount of exchange that occurs 
when optimum substrate concentrations are chosen is determined.
Since LPDP samples also contain CETP inhibitor protein [Tollefson, J.H. et al
(1988), Nishide, T. et al (1989)], therefore any activity measured will be the net result 
o f CETP plus inhibitor protein. This will not give an indication of how much CETP 
protein is present but does measure the amount o f CETP activity that is normally
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expressed in a particular LPDP sample. It is not known how inhibitor is distributed in 
vivo. It has been purified  from HDL and seems to bind HDL as does CETP. It is yet to 
be ascertained whether inhibitor is removed from  HDL by ultracentrifugation like CETP 
and also which is the more physiologically relevant fraction of each of these proteins. 
O ther plasma enzyme activities may affect CETP. Lipoprotein lipase has been shown to 
stimulate CETP activity and LCAT can produce CE from  cholesterol and may affect 
the specific activity of the CE in the assay.
It was decided to develop an assay which measured exchange activity. This type 
of assay enabled handling of large numbers of samples more easily and would still give 
an indication o f relative amounts of transfer activity in d ifferen t samples when standard 
donor and acceptor particles were used. The assay developed was based largely on a 
m ethod previously reported by Tollefson and Albers [Tollefson, J.H. & Albers, J.J. 
(1986)]. The principle of the assay is to measure accumulation of radiolabelled CE in 
an acceptor particle after transfer from a labelled donor. Donor lipoproteins are labelled 
by incubation of lipoprotein and a lipid emulsion containing radiolabelled CE (or TG) 
with a CETP source. The CETP transfers labelled lipid into the lipoprotein particle and 
the lipoproteins are reisolated. To assay CETP activity, labelled donor lipoprotein is 
incubated with a non-labelled acceptor lipoprotein in the presence of CETP. At the end 
o f the incubation the lipoproteins are separated and the loss o f label from  the donor 
lipoprotein is determ ined. In the technique described here the lipoproteins are separated 
by heparin manganese precipitation which relies on the precipitation of the larger apoB 
containing lipoproteins. Thus the LDL and VLDL are precipitated leaving HDL behind 
in the supernatant. HDL3, a subfraction o f HDL, was used since it contains no apoE 
which can interact with heparin and possibly precipitate. Transfer was calculated as the 
amount of radioactivity lost from the donor particle as a percentage of the total 
radioactivity, and expressed as percent transfer per volume of sample or per pg sample 
protein. Various adaptations were used which improved the assay in our hands. These 
changes included using a different technique for labelling lipoprotein donors [Morton, 
R.E. & Zilversmit, D.B. (b) (1981)] and adapting assay volumes to suit our needs.
2 Preparation of Substrates
3.2.1 Radioactive Labelling of Donor Particles
The labelled donor particle used for the assay was an HDL fraction labelled 
w ith radioactive cholesteryl oleate. This was prepared according to the method of 
Morton and Zilversmit [Morton, R.E. & Zilversm it, D.B. (b) (1981)]. The technique 
used the endogenous CETP activity in a plasma sample to label the endogenous 
lipoproteins in the plasma using a synthetic lipid emulsion as a donor. This process 
is described in detail in the Methods.
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Using whole plasma in the labelling procedure, the VLDL, LDL and HDL 
lipoprotein fractions were labelled to d ifferen t extents (Table 3.1). The labelled 
lipoprotein fraction required for the CETP assay was a subfraction of HDL, HDL3. 
In an attem pt to make labelling of the required HDL fraction more efficient, the 
unwanted lipoprotein fractions were removed from  plasma by ultracentrifugation 
prior to incubating the sample with the labelled synthetic emulsion. This resulted in 
increased incorporations and specific activities of labelled substrates (Table 3.2). It 
is possible to label lipoproteins with [3H] or [14C] labelled either in the CE or TG 
moiety. Table 3.2 compares the specific activity of, and percentage incorporation 
into, d ifferent labelled HDL preparations. Tritiated cholesteryl oleate was used in 
preference to 14C labelled cholesteryl oleate since it was supplied at a higher specific 
activity resulting in more incorporation of radioactivity into the substrate and thus 
allowing for more accurate determination of transfer of labelled lipid. When labelled 
lipoproteins were run on a Lipofilm gel, stained for lipid and protein and then 
autoradiographed, it can be seen (Fig 3.1) for the labelled LDL and HDL fractions 
that the radioactivity is coincident with the LDL and HDL bands visualised by the 
stains. Routinely 3H -C E HDL3 was used as this HDL fraction was not appreciably 
precipitated by heparin manganese, showed high specific activity and had good 
incorporation of label.
3.2.2 Removal of Contaminating Transfer Activity From 
Substrates.
An early problem encountered was the detection of substantial exchange activity 
in the absence of any added CETP source i.e. the blank transfer rate was too high. 
Rates as high as 30% transfer over the duration of the assay incubation could be 
detected - much too high for an assay which is only linear to about 30% transfer.
At first it was thought that this phenomenon may have been due to release of 
labelled lipid from the substrate into the assay medium due to instability  of the 
prepared substrate especially at the higher assay tem perature of 42° C. In order to 
stabilise the assay components the assay was carried out in the presence and absence 
o f bovine serum albumin (BSA, 3% w/v). As can be seen from  Fig. 3.2 blank rate 
transfer over 6 hours at 42°Cin the absence of BSA was 25%. This was little improved 
by the inclusion of 3% BSA in the assay (16% transfer).
Another possible explanation for the high blank transfer rate was that CETP 
from  plasma remained bound to either of the lipoprotein substrates during their 
isolation and could therefore stimulate lipid exchange in the assay. There are reports 
that CETP is found bound to lipoprotein fractions especially HDL [G roener, J.E.M. 
et al (1984), Pattnaik, N.M. & Zilversmit, D.B. (1979)].
LIPOPROTEIN FR A C ­
TION
% TOTAL 14C-CE 
RECOVERY
SPECIFIC ACTIVITY OF 
FRACTION 
(dpm/pg protein)
VLDL 3 3315
LDL 30 1720
HDL 20 396
TABLE 3.1 RECOVERY OF RADIOACTIVITY IN LIPOPROTEIN FRACTIONS 
FROM A LIPOPROTEIN LABELLING PREPARATION. 14C-cholesteryl 
oleate (20pCi) was used to label whole plasma (25ml) as described in the 
methods. A fter an 18 hour incubation with lipid emulsion, the lipoprotein 
fractions VLDL, LDL and HDL were harvested by ultracentrifiigation at 
d=1.0063g/ml, d=1.063g/ml and d=1.21g/ml respectively after removal of 
chylomicrons. The percentage recovery of 14C-CE was calculated as the 
amount of radioactivity recovered in each lipoprotein fraction as a 
percentage of the total used to label them. Specific activity o f each fraction 
was calculated as the amount of radioactivity per microgram protein.
n SPECIFIC ACTIVITY 
(dpm/pg protein)
INCORPORATION
(%)
3H -C E HDLTotal 2 1958
3H -C E  HDL3 21 9724 + /-  5054 19.5 + /-  8.7
14C-CE HDL3 2 327 20
14C -T G  HDL3 2 1696 14
3H -C E ,14-T G  HDL3 2 3230 24
2072 19
TABLE 3.2 SPECIFIC ACTIVITIES OF LABELLED HDL PREPARATIONS. Total 
HDL, using d>1.063g/ml plasma (20ml), or HDL3, using d>1.125g/ml 
plasma (20ml), were labelled with either 3H -CO  (160pCi), 14C -C O  (20pCi), 
14C-triolein (TO) (20pCi) or 3H-CO (160pCi) and 14C-TO  (20pCi) together. 
Specific activities were calculated as amount of radioactivity  per 
microgram HDL protein. Incorporation was calculated as am ount of 
radioactivity in HDL fraction as a percentage of that used to label it.
P V L H  P V L H
FIGURE 3.1 LIPOFILM AND AUTORADIOGRAPH OF LABELLED LIPOPROTEINS.
Samples (5pl) of plasma (P), 14C-VLDL (V), 14C-LDL (L) and 14-HDL (H) 
were run on a Lipofilm gel in duplicate sets. One half of the gel was stained 
with Sudan black (1) and the other with Coomassie blue (2). After staining 
the Lipofilm gel was autoradiographed for one week at -20° C  (3).
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FIGURE 3.2 CETP BLANK TIME COURSE AT 42°C -  EFFECT OF BSA IN BUFFER.
3H -H D L 3 (5pg) was incubated at 42° C for varying lengths of time with cold 
LD L/V LD L (8pg)in the presence of Tris-saline buffer ( • )  or Tris-saline 
bu ffer containing 3% BSA final concentration $(). At the end of the incubation 
the lower, density lipoproteins were separated by precipitation with heparin 
manganese reagent and the tritium  left in the supernatant was determ ined. 
Counts remaining in the supernatant were expressed as a percentage of those 
added to the incubation.
FIGURE 3.3 CETP BLANK TIME COURSE AT 42°C USING TREATED SUBSTRATES.
3H -H D L 3 (5pg) and LDL/VLDL (8pg) were incubated together for up to 6 
hours at 42° C. At the end of the incubation high and lower density lipoproteins 
were separated by heparin manganese precipitation. 3H -H D L3 was counted 
in the supernatant. (• )  - HDL3 was subjected to ultracentrifugation at 
d=1.125g/ml followed by ultracentrifugation at d=1.215g/ml and LD L/V LD L 
was subjected to an extra centrifugation at d=1.063g/ml. (□) -  HDL3 was 
centrifuged, LDL/VLDL was untreated. (*) - LD L/V LDL was subjected to 
centrifugation, HDL3 was untreated.
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A possible way of removing this contaminating CETP was to subject the 
lipoprotein substrates to a further ultracentrifugation at their final density (see 
methods for details) to remove other contaminating lipoprotein fractions and to 
dissociate the CETP lipoprotein interactions [Groener, J.E.M. et al (1984)]. Fig. 3.3 
shows the effect o f centrifuging either the donor HDL or the acceptor LDL/VLDL 
or both to remove the contaminants. Assays where only LD L/VLDL was treated still 
showed a high blank rate of 11%. Assays where either HDL alone was treated or 
both HDL and LD L/V LD L were treated showed a much improved blank rate of 7% 
transfer. It was decided to treat both HDL and LDL/VLDL substrates by ultra­
centrifugation before use in the assay.
Ideally the blank rate should be as low as possible, therefore a fu rther approach 
was used to separate any CETP from HDL particles, Since there is a large size 
difference between the CETP molecule (74K) and an HDL particle (200-400K), these 
two entities may be separable by gel filtration. A fter harvesting the labelled HDL3 
fraction from the second d=1.215g/ml density ultracentrifugation step, the lipoprotein 
was passed down a 100ml Sepharose CL-4B gel filtration column. A typical column 
profile is shown in Fig. 3.4. The HDL peak eluted at 70mls. When labelled HDL3 is 
mixed with cold HDL3 the peaks are coincident showing that at least with regard to 
behaviour on a gel filtration column, the labelling process does not alter the HDL3 
particle (Fig. 3.4). When double labelled HDL3, labelled with 3H -cholesteryl oleate 
and 14C-triolein, is passed down the CL-4B column the 3H and 14C peaks are also 
coincident (Fig. 3.5). Experiments where CETP is passed down such a CL-4B column 
on its own (see Fig. 4.3A) show that free CETP would elute just a fte r the HDL3 
peak at fraction 30 (79ml).
Fig 3.6 compares the effects of these various treatments for the removal of 
contaminating CETP activity on the blank transfer rates. If the HDL3 is cleaned by 
gel filtration only the blank transfer rate is high (19% transfer). Cleaning by double 
ultracentrifugation improved this. However if  the HDL3 was cleaned by ultracen­
trifugation and then passed through a gel filtration column then the transfer rate 
was only 6% for at least 4 hours of the assay. Thus for all CETP assays the HDL3 
substrate was subjected to two ultracentrifugation steps, a gel filtration step and 
tested in a blank time course to check the blank rate.
3 Assay Incubation
3.3.1 Separation of Donor and Acceptor Particles
In order to measure the amount of labelled lipid transferred from  the labelled 
donor lipoprotein particles to the unlabelled acceptor lipoprotein particles, these two 
entities must be separated efficiently at the end of the experiment. There are two 
main ways of doing this; separation by ultracentrifugation at d=1.063g/m l to remove 
the lower density lipoproteins, and precipitation by a technique which will discriminate 
between the donor and acceptor particles. Of the two techniques/precipitation lends
FIGURE 3.4
FIGURE 3.5
SEPHAROSE CL-4B GEL FILTRATION COLUMN - CHROMATOGRAPHY 
OF LABELLED AND UNLABELLED HDL3. 3H -H D L3 (2mls, 0.25mg/ml, 
2500dpm/pl) was mixed with HDL3 (2ml, 6mg/ml) and loaded onto a 100ml 
Sepharose CL-4B gel filtration column. Protein was eluted at 11 m l/hour with 
Tris-saline buffer, fractions (2.75ml) were collected and samples were counted 
by liquid scintillation counting.
SEPHAROSE CL-4B GEL FILTRATION COLUMN - CHROMATOGRAPHY 
OF DOUBLE LABELLED 3H /14C -H D L3. 3H-CO, 14C -TG  double labelled 
HDL3 (8ml, 0.17mg/ml; 1500dpm/pl 3H; 140 dpm /pl 14C) was loaded onto a 
100ml Sepharose CL-4B column and eluted at lOml/hr with Tris-saline buffer. 
Fractions (2.5ml) were sampled (50pl) and counted in a liquid scintillation 
counter.
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FIGURE 3.6 CETP BLANK TIME COURSE - REMOVAL OF CONTAMINATING 
..ACTIVITY-FROM  HDL3. 3H-HDL3 (5pg) and LD L/V LD L (8pg) were 
incubated together for up to 6 hours at 42° C and then separated by heparin 
manganese precipitation. (9) - HDL3 was harvested at d=1.215g/ml and then 
passed through a Sepharose CL-4B gel filtration column, (□) HDL3 was 
harvested at d=1.215g/ml and then subjected to centrifugation at d=1.125g/ml 
followed by centrifugation at d=1.215g/ml, (x) HDL3 was subjected to 
centrifugation at d=1.125g/ml and d=1.215g/ml and was then passed down a 
gel filtration column.
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itself to rapid processing of large numbers of samples so it was on this technique 
that effort was concentrated. The ultracentrifugation method however is useful to 
check the validity of the precipitation technique since 1) the methods of separation 
are based on different physical principles and 2) ultracentrifugation is an accepted 
method for separating high and low density lipoproteins.
The precipitation method used was that described by Tollefson and Albers 
[Warnick, G.R. & Albers, J.J. (1978), Tollefson, J.H. & Albers, J.J. (1986)]. Heparin 
and manganese form a complex with lipoproteins. Complex form ation is favoured 
with larger lipoproteins or larger sulphated polysaccharides. The manganese cation 
is one which forms particularly stable complexes. Selective lipoprotein precipitation 
can be achieved by altering the sulphated polysaccharide to cation ratio. HDL3 which 
contains little or no apoE is used in these assays since this protein may bind to 
heparin. Plasma is also added to improve the separation by adding bulk cold lipo­
proteins. An amount of bulk plasma (150pl) greater than that recom mended by the 
published method was used as it led to better separation (Tollefson, personal 
communication). In practice some HDL3 is precipitated and some LD L/V LD L is not. 
Experiments were carried out using labelled HDL3 or LDL/VLDL to test which were 
the optimum precipitation conditions in our hands. Table 3.3 shows precipitations 
carried out in d ifferent containers with different final assay volumes. The best 
precipitation, with 85% 3H -H D L3 counts left in supernatant, occurred when the 
precipitation was carried out in m icrotitre plates. These plates were also convenient 
for carrying out large numbers of assays.
Using 3H -H D L3 to calculate the proportion of counts left behind in the 
supernatant, various concentrations o f heparin manganese reagent were tested for 
their effectiveness. From the results shown in Table 3.4, final concentrations of 
213U/m l heparin: 0.085M MnCl2 were decided upon as the conditions for optimum 
separation. U nder these conditions 11% HDL3 was precipitated (though this was later 
improved, see Table 3.5) and 1% LD L/V LD L was left in solution.
Once a concentration of precipitating reagent was decided upon, the other assay 
components were added and precipitation carried out at time zero to see whether the 
other assay components would interfere with the precipitation. Using 3H -H D L 3 only, 
counts not precipitated could be refined to >95% and using 3H -L D L /V L D L  only 
counts not precipitated could be refined to <1% (Table 3.5). This im provem ent in 
definition probably reflects improved sampling. In the course o f determ ining vari­
ability between operators (data not shown) it was found that the biggest source of 
error was in sampling the supernatant after precipitation probably because the pellet 
is soft. Using one labelled substrate and adding the other substrate unlabelled, these 
precipitation blanks were not altered greatly by the presence o f the other substrate 
(Table 3.5).
CONTAINER ASSAY VOLUME 
(Ml)
BLANK 
(dpm in S/N)
GLASS TUBE 600 66%
M ICROFUGE TUBE 600 69%
M ICROTITRE
PLATE
120 85%
TABLE 3.3 CHOICE OF CONTAINERS FOR CETP ASSAY. 3H -H D L3 (0.04ng/nl 
final concentration) and LDL/YLDL (0.07pg/pl final concentration) were 
made to the appropriate final volume with Tris-saline buffer in either 
glass tubes, microfuge tubes or m icrotitre plates. Heparin manganese 
reagent (266U/ml heparin: 0.106M M nCl2) was used to precipitate the 
lower density lipoproteins. Percentage counts remaining in the supernatant 
were calculated.
HEPARIN MANGANESE 
REAGENT 
(final concentration 
heparin:MnCl2 
U/ml:M)
HDL BLANK 
(% dpm in pellet using 3H - 
HDL3)
LD L/V LD L BLANK 
(% dpm in S /N  using 3H - 
LD L/V LD L)
106:0.043 9 3
+ LPDS 7 + LPDS 23
160:0.064 12 2
+ LPDS 9 + LPDS 2
213:0.085 11 1
+ LPDS 12 + LPDS 1
239:0.096 12 0.9
+ LPDS 12 + LPDS 1
266:0.106 22 0.7
+ LPDS 13 + LPDS 0.7
TABLE 3.4 REFINEMENT OF THE HEPARIN MANGANESE PRECIPITATION.
HDL3 (5pg) and LDL/VLDL (8pg) in the presence or absence of LPDS 
(lOpl) were made up to a volume of 60pl with Tris-saline buffer. Carrier 
plasma (150pl) was added and then 25pl of a dilution of a 2500U/ml: 1M 
heparin:M nCl2 solution. M icrotitre plates were left to stand for 25 minutes 
on ice and then centrifuged at 2800rpm for 25 minutes. The supernatant 
was sampled (150pl) and counted. For determ ination of the HDL blank, 
3H -H D L 3 was incubated with unlabelled LD L/V LDL; and for the 
LD L/V LDL blank, unlabelled HDL3 was incubated with 3H -LD L/V LD L .
REAGENTS % dpm in S/N
3H -H D L 3 only 102
3H -LD L/V LD L only 0.7
3H -H D L 3 and cold LDL/VLDL 96
cold HDL-total an(3 3H - 
LD L/V LDL
0.9
TABLE 3.5 HEPARIN MANGANESE PRECIPITATION. HDL3 (5pg) and 
LDL/VLDL (8pg) were made to a final volume of 60pl with Tris-saline 
buffer. To precipitate, plasma (150pl) and heparin manganese reagent 
(25pl of 2000 ;U /m l heparin:0.8M MnCl2) were added. Supernatants were 
sampled after precipitation and radioactivity determined by scintillation 
counting.
COM PONENT HDL BLANK 
(dpm in pellet)
LD L/V LDL BLANK 
(dpm in S/N)
BLANK 11% 0.8%
LPDS (dialysed 
against PBS)
22% 1.3%
LPDS (dialysed 
against 
Tris-saline)
13% 0.7%
0.7mM DTNB 6% 0.9%
TABLE 3.6 EFFECT OF ASSAY COMPONENTS ON PRECIPITATION. P recip ita­
tions were carried out as for Table 3.5 but the incubations contained 
either buffer only, LPDS dialysed against phosphate buffered saline (10pl), 
LPDS dialysed against Tris-saline buffer (10pl) or 0.7mM DTNB.
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As shown in Table 3.6 inclusion of DTNB (0.7mM) or LPDS which had been 
dialysed against Tris-saline buffer did not significantly affect precipitation at time 
zero. LPDS which had been dialysed against phosphate buffered saline doubled the 
amount of HDL3 precipitated by the reagent. Manganese phosphate on its own can 
precipitate lipoproteins and this effect is probably interfering with the heparin 
mediated precipitation. Before CETP assay, all samples are dialysed against Tris-saline 
buffer.
3.3.2 Measurement of CETP Activity
Having prepared the substrates and defined the conditions for their separation 
CETP assays were carried out. Substrates were incubated together with a source of 
CETP in the presence of DTNB. DTNB, an LCAT inhibitor, was included so that 
transfer activity would not be influenced by the amount of CE synthesised by the 
enzyme. If there were greatly different amounts of LCAT between samples then it 
is possible that the specific activity of the donor HDL3 may be affected by the 
amount of synthesis of cold CE. A concentration of 0.7mM was sufficient to inhibit 
LCAT (Fig 3.7). Concurrent with incubations containing a test CETP source, two 
control incubations were also run with every assay. One, a blank, had no CETP source 
and indicates the background rate of spontaneous (or contaminating) transfer taking 
place. This is always subtracted from the values obtained to give a true transfer rate. 
A second control incubation is that of a standard LPDS, included to try and m aintain 
consistency between assays. Since the substrates used and the control CETP are all 
from  different individuals it is important to try and rule out any variability between 
donors of the assay components affecting assay rates. To overcome this, new substrate 
preparations or control LPDSs were introduced one at a time, and before use, each 
new batch was tested in a control incubation and only used if  they showed similar 
activity to the previous batch of reagents. Each assay is carried out in triplicate to 
avoid error introduced by bad sampling of supernatant as mentioned earlier. Coating 
the microtitre plates with BSA (as described in the methods) seemed to improve 
replication within an assay and so this was carried out as a general practice (data not 
shown).
Time courses were carried out to determ ine the period of time over which 
transfer was linear. Originally assays were carried out at 37°C. However it was found 
that it took approximately 10 hours to achieve 30% transfer, an assay duration that 
is not convenient. In order that an assay may be carried out easily within one day, 
activity was assayed at 42° C and took approximately 3 hours for an equivalent amount 
of protein to express 30% transfer. Fig. 3.8 illustrates the time course o f the same 
amount of CETP at the d ifferent temperatures.
A typical standard protein curve and time course of activity for hum an LPDS 
are shown in Fig. 3.9. The protein curve is linear to 35% transfer and then transfer 
saturates. Originally amounts of substrates were varied relative to each other to 
optimise transfer rates. It was found that 5pg protein 3H -H D L3 and 8pg protein
NOIlIfflHNI
1 0 0
80
60
40
20
0
0 0 . 2 5 0 . 5 0 . 7 5 1 . 2 51 . 0
mH DTINB
FIGURE 3.7 LCAT ACTIVITY - DTNB CURVE. LCAT assays were carried out as described 
in Methods but mercaptoethanol was omitted from the assay buffer. DTNB 
in water was added to the assays at various concentrations.
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FIGURE 3.8 CETP TIME COURSE AT 37°C AND 42° C. CETP assays were carried out in 
the presence o f LPDS at 37°C (O) or 42°C (#).
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FIGURE 3.9 CETP PROTEIN CURVE AND TIME COURSE - 18 /8 /89  LPDS. A) CETP 
assays were carried out in the presence of different amounts o f hum an LPDS 
(18/8/89) for 2.5 hours at 42°C. This graph represents the average o f five 
separate protein curve determinations. B) Assays were carried out in the 
presence of 0.16mg human LPDS (18/8/89) for various lengths o f time at 
42° C.
i
1
62
LD L/V LDL were suitable concentrations of substrates to give maximal transfer for 
a given CETP sample. Fig. 3.9A is the average o f 5 experiments carried out on 
separate days. As can be seen from the standard deviation bars variation can be as 
great as + \-  5% transfer. To determine CETP activities in unknown samples, activity 
was measured at at least three d ifferen t protein concentrations at a dilution giving 
activity well within the range of the standard curve. Activity was calculated as % 
transfer per microlitre using regression analysis to calculate the slope. To account 
for any dilution which may have occurred during sample preparation, activity was 
then expressed as % transfer per microgram of sample protein. The time course. Fig. 
3.9B, shows linearity to 2.5 hours at 42°Cand this was chosen as the assay incubation 
time.
Assays carried out using HDL3 substrate labelled either with 3H-cholesteryl 
oleate or 14C-triglyceride, or both show very similar transfer rates, Fig. 3.10. Thus 
it appears that triglyceride is being transferred in similar fashion to CE and transfer 
o f both can be seen simultaneously. The activity measured here is an exchange 
activity, and it can be seen that both CE and TG can be transferred from HDL to 
lower density lipoproteins. However there is no indication as to how much mass of 
CE or TG will end up in the lower density lipoproteins since back transport from 
LD L/V LDL to HDL3 is not measured.
Fig. 3.11 shows the effect of keeping the concentration of one substrate constant 
and varying the concentration of the other. When LD L/V LD L concentration is kept 
constant and HDL3 is increased then the amount o f CE transferred increases in a 
linear fashion up to at least 8pg (Fig. 3.11 A). This shows that the amount of HDL3 
used in the assay is rate limiting. When the amount of HDL3 is held constant and 
LD L/V LDL is increased then the activity starts to saturate at about 6pg LD L/VLDL, 
(Fig. 3.1 IB). Thus this substrate is not rate limiting. If this data is expressed as a 
double reciprocal plot (Fig. 3.11C), then the values for the Km and Vmax obtained 
are 5.2pg and 44.4% transfer respectively.
A comparison of the rates of transfer to d ifferen t low density lipoprotein 
fractions was carried out (Fig. 3.12). LDL was the best acceptor followed by an 
LD L/VLDL mix and then by VLDL. It might be expected that VLDL would be a 
better donor than LDL since it has a greater CE plus TG to protein ratio. It is possible 
that this particular VLDL may not have been a good acceptor because it had low 
triglyceride if  it was prepared from blood collected from  a fasting subject, or it had 
an unusual composition or its protein content was underestim ated due to an interfering 
effect of TG in a Bradford assay. Smaller particles have a larger surface to volume 
ratio and if  interaction of CETP with the lipoprotein surface is im portant then LDL 
may be a better acceptor because it is smaller than VLDL. Despite LDL being a 
better acceptor, the use of LD L/V LDL was continued as in' the original method 
[Tollefson, J.H. & Albers, J.J. (1986)] since it was thought that the LD L/V LD L might 
represent a more physiological substrate since CETP can transfer to both these 
lipoproteins in vivo.
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FIGURE 3.10 CETP PROTEIN CURVES WITH 3H -C O , 14C-TO  AND 3H -C O /14C -T O  
HDL3. Similar CETP assays were carried out for 2.5 hours at 42° C w ith H D L3 
(5ng) and LDL/VLDL (8ng). (O ) 3H -CO  HDL3, ( # )  44C-TO HDL3, ( □ )  
3H -C O /14C-TO HDL3 - SH counts measured and ( ■ )  3H -C O /14C -TO  H D L3 
- 14C counts measured.
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FIGURE 3.11 CETP ASSAY, VARIATION OF SUBSTRATE. A) A CETP assay was carried 
out with variable amounts of 3H -H D L3 (0-7.5pg) and constant LD L/V LD L 
(8pg). Assays were in triplicate and activity was calculated as the amount of 
3H counts transferred from the supernatant containing HDL3 i.e. the amount 
of counts added to an assay minus the amount remaining in the supernatant. 
B) A CETP assay was carried out with variable amounts o f LD L/V LD L 
(0-16pg) and with a constant amount of 3H -H D L3 (5pg). Percent transfer was 
calculated in the usual way. Assays were in triplicate. C) A double reciprocal 
plot is shown of the data found in Fig. 3.1 IB. Vmax = 44.4 % transfer, Km  
= 5.2pg.
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FIG U RE 3.12 CETP ASSAY - DIFFERENT ACCEPTORS. CETP assays contained 3H -H D L 3 
(5pg) and variable amounts of VLDL (O ) 0-8.4pg, LDL' ( '# )  0-16pg and 
LD L/VLDL (x ) 0-16pg. Assays were in triplicate.
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There have been reports of an assay which uses a lipoprotein bound to a solid 
support as a donor [Sparks, D.L. et al (1987)]. This type of substrate has the advantage 
that any pairs of donor and acceptor lipoproteins can be used, including using the 
same lipoproteins as donor and acceptor, and also the donor and acceptor pairs are 
easily separated by a short centrifugation. An attem pt was made to develop such a 
solid support assay using radiolabelled HDL bound to Sepharose CL-4B. However 
although linear transfer rates were observed, about ten times more CETP protein 
was required to achieve similar rates of transfer to those found in the usual CETP 
assay i.e. 5mg protein to reach 30% transfer in 2.5 hours compared to 0.35mg in the 
usual assay. Any further attempts to develop this technique were therefore abandoned.
3.3.3 Validation of the Precipitation Technique Using Ultra­
centrifugation
In order to confirm the validity of using precipitation to separate donor and 
acceptor particles, experiments were carried out directly comparing transfer rates 
measured by the precipitation technique and transfer rates measured by the u ltra­
centrifugation technique i.e. loss of radioactivity from the high density lipoprotein 
fraction and the appearance of radioactivity in the lower density lipoprotein fraction. 
A protein curve (Fig. 3.13A) showed similar transfer rates whether transfer was 
measured by precipitation or by ultracentrifugation separation. This was also the case 
for a time course of transfer activity (Fig. 3.13B). Thus using an entirely d ifferen t 
technique for separating donor and acceptor particles similar transfer rates can be 
measured. Since the precipitation technique is much less time consuming and is 
adaptable to coping with large sample numbers, this technique was routinely used.
3.3.4 A More Sensitive CETP Assay
In some instances, especially in the case of measuring CETP activity in cell 
media, the sensitivity of the above described assay was not great enough to detect 
the small amounts of activity present. In order to improve the sensitivity the assays 
were incubated for a much longer period of time. Since activity is linear to 30% 
transfer it ought to be possible to incubate the low activity samples long enough to 
reach this level of activity and the increase in activity should be linear. This was 
found to be the case. As shown in Fig. 3.14 a 1/4 dilution of a standard LPDS reached 
30% transfer in 2 to 3 hours whereas a 1/40 dilution of the same LPDS took 
approximately 10 hours to reach 30% transfer, but the progression was linear. Thus 
this long duration CETP assay could easily detect 10 times less activity than the usual 
CETP assay. The problem with this long incubation assay was that the blank rate 
increased. Obviously if  there is still any CETP associated with the substrates then 
this activity will be amplified in the more sensitive assay also. It was found that 
inclusion of a final concentration of 3% BSA in the assay improved replication 
between triplicates. It is possible that during- prolonged incubation at 42° C the 
lipoproteins begin to degenerate which may affect their precipitation by heparin
LPDS (u l 1/4 d i lu t i o n )
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FIGU RE 3.13 CETP ASSAY USING CENTRIFUGATION TO SEPARATE LIPO PR O ­
TEINS. Two identical protein curves (A) or two identical time courses (B) 
were carried out in parallel. At the end of the incubation one of the pairs of 
assays was stopped in the usual manner and the lipoproteins separated by 
precipitation (O). In the second assay a 50pl sample was placed in a one ml 
polycarbonate centrifuge tube. A d=1.182g/ml NaBr solution (25pl) was added 
to bring the density to 1.063g/ml and then the mix was overlaid w ith a 
d=1.067g/ml NaBr solution. Tubes were centrifuged for 3 hours at lOOOOOrpm 
in a Beckman TL100 Tabletop centrifuge. At the end of the centrifugation 
the top and bottom 300pl were sampled and counted. The radioactivity in the 
top fraction (•) represented the lower density lipoproteins (LD L/V LD L) and 
the bottom fraction (□) represented the high density lipoprotein fraction.
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FIGURE 3.14 . SENSITIVE CETP ASSAY - LOSS OF DPM FROM THE SUPERNATANT.
A two times volume CETP assay was carried out in an m icrofuge tube 
containing (o) blank, (•) 1/40 dilution LPDS (25/7) or (□) 1/4 dilution LPDS 
(25/7). The assays were incubated for up to 16 hours at 42°C. The assay was 
stopped with 300pl plasma and 50pl heparin manganese reagent.
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manganese. Inclusion of BSA may improve the stability of the lipoproteins. An 8 
hour assay incubation time was chosen as a convenient length for this sensitive assay. 
A protein curve is shown in Fig. 3.15. As can be seen from  the standard deviations 
this assay is much more variable than the usual CETP assay and therefore much less 
accurate. Nevertheless it can prove useful when trying to discern whether a small 
amount of activity is present or not.
3.3.5 Properties of the Measured CETP Activity
In order to ascertain whether the activity measured by the CETP assay was the 
same as that described in the literature, the properties of the measured CETP activity 
were examined. Properties that have been reported include species variation [Ha, 
Y.C. & Barter, P.J. (1982)], apoAI effects [Son, Y-S. C. & Zilversm it, D.B. (1984)] 
and heat stability [Tollefson, J.H. & Albers, J.J. (1986)].
D ifferent species have been reported to demonstrate widely varying plasma 
levels of CETP activity ranging from very low in the rat to very high in rabbits. 
CETP activity was measured in LPDP samples from seven mammalian species; rabbit, 
sheep, human, rat, pig, marmoset and mouse. As predicted the activities measured 
fell into three groups (Fig. 3.16). Pigs, rats and mice had low plasma CETP activity; 
human and marmoset LPDP had intermediate activity and rabbit LPDP had high 
activity. This activity profile reflects that reported in the literature.
ApoAI has been reported to inhibit CETP activity. ApoAI inhibition could be 
measured to extents similar to those published in the literature. It was noticed however 
that apoAI from  d ifferen t donors inhibited to greatly d ifferen t extents (Fig. 3.17). 
A fter this work was completed reports appeared in the literature of an inhibitor of 
CETP [Tollefson, J.H. et al (1988)]. This inhibitor was purified  from  HDL and had 
molecular weight 29000. It is possible that the inhibition o f CETP by apoAI may be 
due to contam ination of the apoAI preparations with some of this inhibitor. ApoAI 
is very close in molecular weight (28000) to the inhibitor protein and since apoAI is 
often purified by gel filtration it seems reasonable that apoAI preparations may be 
contaminated with this inhibitor protein. The apoAI used here was purified  by gel 
filtration.
CETP is stable to heat treatment of one hour at 56° C whereas LCAT, another 
plasma enzyme is not. LPDP samples were incubated at 56° C for one hour and then 
CETP and LCAT activities were measured in treated and control samples. CETP 
activity was unaffected by heat treatm ent (Fig. 3.18A) whereas LCAT activity  was 
totally inhibited by heat treatm ent (Fig. 3.18B).
Since CETP is relatively heat stable we sought to make use of this fact to try 
and separate CETP and CETP inhibitor activities. The measurem ent o f plasma CETP 
activity is complicated by the presence o f the CETP inhibitor protein. Any activity 
measured is the net result of CETP protein plus inhibitor protein and therefore is 
not a direct measure of how much CETP protein is there. If the two activities can
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FIGURE 3.15 SENSITIVE CETP ASSAY - PROTEIN CURVE, 8 HOURS. A CETP protein 
curve was carried out for 8 hours using the conditions described in Fig. 3.14.
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FIG U RE 3.17 APO-AI INHIBITION OF CETP - DIFFERENT APO-AI DONORS. Apo AI
from 6 human donors was received as a g ift from Philip Stewart, Glasgow 
Royal Infirmary. Apo AI (0-4pg) was tested for its inhibitory e ffec t in a 
CETP assay. (O) donor 1, (•) donor 2, (□ ) donor 3, (■) donor 4, donor 5 
and donor 6.
B 70000
60000
50000
■o 40000
*  30000
20000
10000
LPDS < ul)
35
25
LPDS <ul 1 /8  18 /8 /89 )
FIGURE 3.18 EFFECT OF HEAT TREATMENT OF LPDS ON PLASMA CETP AND LCAT 
ACTIVITY. LPDS was heated for one hour at 56° C. U ntreated LPDS was 
compared with heated LPDS in (A) a CETP assay and (B) an LCAT assay. 
(O) control, (•) 1 hour at 56° C
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be separated then interpretation becomes much easier. As CETP is heat stable, if 
inhibitor is not then inhibitor activity might be removed by heating at a tem perature 
which destroys inhibitor but does not affect CETP. If inhibitor is more heat stable 
than CETP then it may be possible to inactivate CETP and reveal inhibitory  activity. 
Samples of human LPDP were subjected to various heat treatm ents as described in 
Table. 3.7. These samples were then assayed for CETP activity. If the activ ity  measured 
is the same as the control then it is likely that neither CETP nor inh ib itor has been 
affected. If activity is increased then the inhibitor may have been inactivated, if  
activity is decreased then CETP may have inactivated. It was found that treatm ent 
up to 60° C for 30 minutes did not affect activity. Treatment at higher tem peratures 
destroyed all CETP activity.
Treated LPDP was also added to a separate sample of CETP to see if  any 
inhibitory activity could be revealed. If CETP activity is unaffected by treatm ent 
then measured CETP activity should increase - this occurred for treatm ent up to 
60° C for 30 minutes. If CETP activity is destroyed then the control CETP activity 
will stay the same if no inhibitory activity is revealed or will decrease if  inhibitory 
activity is revealed. As can be seen from Table. 3.7, no significant inhibitory  activity 
was revealed by any of the treatments. Thus we were unable to separate CETP 
inhibitor and CETP activity in this manner.
3.3.6 Storage
/
CETP is stable for at least three months at 4°C(Fig. 3.19). An activity  profile 
o f the enzyme stored at -20°C was carried out as shown in Fig. 3.19- A ctiv ity  is not 
greatly decreased over six months. It appears that there is an increase in activity at 
three months, though this has not been confirmed. The reason for this is not known 
but could possibly be an effect of the relative stabilities of CETP and inhibitor. It 
did not matter whether samples were stored as plasma and LPDP prepared after 
defrosting or were stored directly as LPDP.
TREATM ENT CETP 
ACTIVITY 
(% transfer)
INHIBITION OF 
CONTROL 
LEVEL BY 
TREATM ENT 
(%)
ACTIVITY 
WHEN 
TREATED 
LPDS IS 
ADDED TO 
CONROL 
AMOUNT OF 
CETP 
(% transfer)
REVEALED
INHIBITORY
ACTIVITY
BLANK 0 28 none
CONTROL 28 0 none
stim ulation
4 2 °C O /N 28 0 38 none
stim ulation
6 0 °C 10 min 28 0 34 none
stim ulation
60°C  30 min 27 4 39 none
stim ulation
80°C  10 min 0 100 25 11%
80°C  30 min 0 100 28 0%
100°C 10 min o 100 27 4%
lOO°C30 min 0 100 34 none
TABLE 3.7 HEAT TREATMENT OF LPDS - CETP ACTIVITY AND CETP INHIBITORY
ACTIVITY. LPDS was subjected to treatm ent by heat to various degrees. 
A fter treatm ent, the CETP activity of the sample was measured, and also its 
ability to inhibit a control amount of CETP activity.
CE
TP
 
RC
TI
UI
TY
 
<* 
tr
an
sf
er
/u
l)
- o
3 -
MONTHS IN STORAGE.
FIG U RE 3.19 CETP STORAGE - STABILITY AT 4°C AND -20°C. Human LPDS was stored 
either at 4°C (o) up to three months or at -20<>Cas plasma (•) or as LPDP ( 
□) for 9 months. Activity was measured periodically over the tim e o f storage. 
Where the activity was stored as plasma LPDS was prepared a fte r defrosting 
by centrifugation at d=1.215g/ml.
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CHAPTER IV
CETP PURIFICATION AND ANTIBODY PRODUCTION
1 Introduction
As discussed in the previous chapter, the assay of CETP activity in plasma is 
complicated. The transfer assay developed measures the sum of CETP and inhibitor 
protein activity. Thus a measured change in activity could be due to a change in CETP, 
inhibitor or both. In order to understand this situation more fully it would be beneficial 
to be able to measure the protein mass of either CETP or inhibitor.
A powerful tool for this kind of measurement would be an antibody, either 
polyclonal or monoclonal. Antibodies to both human and rabbit CETP were desirable. 
It was also intended to use rabbit antibodies to test the effect of inhibiting rabbit CETP 
in vivo. Two strategies to production of antibodies were followed:-
a) the inform ation provided from the published cDNA sequence o f CETP
[Drayna, D. et al (1987)] and predicted protein sequence was used to choose 
a peptide sequence which may be immunogenic. This peptide was used to 
raise polyclonal antibodies in sheep.
b) partially purified  human and rabbit CETP was used to immunise mice in
order to obtain monoclonal antibodies.
2 Human CETP Purification
4.2.1 Partial Purification of Human CETP
The partial purification of human CETP was carried out as described in the 
literature [Pattnaik, N.M. et al (1978), M orton, R.E. & Zilversm it, D.B. (1982), Tall,
A.R. et al (1983) and Jarnagin, A.S. et al (1987)]. Human LPDS was used as a starting 
material. This was adjusted to a high salt concentration (4M NaCl) and loaded onto 
a phenyl Sepharose column. CETP is bound to the hydrophobic column at this salt 
concentration. A low salt wash (0.15M NaCl) removes the bulk of the protein and 
then CETP activity can be eluted with water (Fig. 4.1). It has been reported that 
this chromatography step removes CETP from its inhibitor protein which remains 
bound to the column in water [Morton, R.E. & Zilversmit, D.B, (b) (1981), Son, Y-S.
C. & Zilversmit, D.B. (1984) and Tollefson, J.H. et al (1988)]. However there is one 
report that CETP inhibitor can be eluted from a phenyl Sepharose column in water 
[Nishide, T. et al (1989)]. Sometimes experimentors have seen a greater than 100%
FIGURE 4.1 PHENYL SEPHAROSE COLUMN OF HUMAN CETP - WATER ELUTION.
Human LPDS was adjusted to 4M NaCl with solid NaCl and subjected to a 
30 minute centrifugation, 35000 rpm  Beckman 45Ti rotor, to remove any 
particulate matter. The supernatant was loaded onto a 200ml phenyl Sepharose 
column which had previously been equilibrated with lOmM Tris, 2M NaCl, 
pH8.0 at 4°C. The column was washed at 30m l/hour with lOmM Tris, 0.15M 
NaCl, pH8.0. Elution was with distilled water, 0.02% sodium azide at 
30m l/hour. Fractions (7.5ml) were collected and CETP activity was assayed 
in  25pl samples of these.
FIGURE 4.2 CM52 COLUMN OF HUMAN CETP. Active fractions from the water elution 
of the phenyl Sepharose were pooled and adjusted to 50mM NaAc, pH 4.5 
by addition of 1/19 volume of 1M NaAc pH4.5. A 30 minute centrifugation 
at 35000rpm removed any particulate m atter. The supernatant was loaded onto 
a 200ml CM52 column preequilibrated with 50mM NaAc, 0.02% sodium azide, 
1 m g/m l EDTA at 4°C. Activity was eluted at 30m l/hour with a NaCl gradient 
comprising 300ml 50mM NaAc pH 4.5, 0.02% sodium azide, 1 m g/m l EDTA 
and 300ml of the same buffer but containing 0.2M NaCl. Fractions (7.5ml) 
were collected in 1ml of 1M TrisHCl pH 7.4 and 25pl samples were assayed 
for CETP activity. Pooled fractions were concentrated through an Amicon 
PM10 membrane and dialysed against Tris-saline buffer.
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recovery at this stage; this may be due to removal o f the inhibitor protein. It was 
found that in this partial purification there was a slight increase in yield after the 
phenyl Sepharose column (Table 4.1).
Active fractions from  the phenyl Sepharose column were pooled and chro­
matographed on a CM52 ion exchange column at pH 4.5. Activity was eluted with 
a 0-200mM  NaCl gradient (Fig.4.2). This column separates CETP from LCAT 
[Pattnaik, N.M. et al (1978)]. The partially purified CETP obtained from this procedure 
was purified 280 fold and obtained in a yield of 34% (Table 4.1). This preparation 
was stable for at least two months at -20° C. This fraction was referred to as ’post 
CM52 CETP’.
4.2.2 Further Purification of Human CETP
Various other chromatographic procedures were tried in an attempt to further 
purify CETP. None of these were particularly successful as the yields tended to be 
poor due to increased instability of the enzyme as it was purified  to a greater extent. 
Often the extent of purification was not great enough to make the procedure 
worthwhile. Attem pts included batch treatm ent with hydroxyl apatite [Jarnagin, A.S. 
et al (1987)] where a 6 fold purification was achieved but only 17% recovery in this 
step. A chromatofocussing column was run as described [Morton, R.E. & Zilversmit,
D.B. (1982)] and a profile similar to that published was achieved but it was found 
that the purified activity was unstable. On a Con A Sepharose column it was found 
that most activity did not bind and only a small amount of the total loaded on the 
column eluted with up to 150mM a-m ethyl-D  mannoside. Thus purification was less 
than one fold. An anti-hum an albumin column was run to try and remove the large 
amount of contam inating human serum albumin. Albumin could be removed suc­
cessfully with this column but recovery of activity was only 6% and the fold 
purification was less than one indicating that the enzyme was becoming inactivated. 
All of these purification options were discarded.
4.2.3 Emulsion Binding
During the course of these purification studies, a method was published whereby 
CETP was purified  55000 fold which included a step where CETP was bound to a 
synthetic lipid emulsion containing phosphatidyl choline, triolein and oleic acid 
[Hesler, C.B. et al (1987)]. Bound protein was separated from  unbound protein by 
passing down a gel filtration column. An attem pt was made to reproduce this 
purification exploiting the affinity of CETP for lipid particles.
A lipid emulsion o f phosphatidyl choline : triolein : oleic acid o f composition 
0.12:0.80:0.09 was made by sonicating the lipids together and then collecting the lipid 
emulsion by centrifugation. The lipid was resuspended in 50niM ammonium bicar­
bonate buffer and then passed down a Sepharose CL-4B gel filtration column. The 
peak fractions were pooled, concentrated and the lipid composition o f the pool was
68
determined. Emulsion (50mg) was incubated with post CM52 CETP (8mg) for 15 
minutes at 37°C under nitrogen and then chromatographed on a Sepharose CL-4B 
gel filtration column. The column profile is shown in Fig. 4.3B.
As can be seen from Fig. 4.3A, when CETP alone is passed down a gel filtration 
column, the unbound post CM52 CETP elutes at fraction 30 (i.e. column volume of 
80ml) slightly later than the main protein peak. When post CM52 CETP is first bound 
to the lipid emulsion and then run on a Sepharose CL-4B gel filtration column, CETP 
activity is separated into two main peaks (Fig. 4.3B). One elutes at fraction 28 
presumably as unbound CETP. The other peak elutes at fraction 18 just after the 
m ilky lipid peak at fraction 16. Thus it appears that a proportion of the CETP activity 
does bind to the lipid emulsion but a larger proportion is unbound. Therefore the 
emulsion used here was not binding optimal amounts of CETP.
In order to improve the lipid binding of CETP another type of emulsion was 
used. Intralipid 10% is a commercially available lipid emulsion of composition 
soyabean oil (10%) : fractionated egg phospholipid (1.2%) : glycerol (2.25%) (w/v). 
Post CM52 CETP (8mg) was incubated with Intralipid (50mg) for 30 minutes at 37°C 
under nitrogen. This was then passed down a Sepharose CL-4B gel filtration column. 
As can be seen from Fig. 4.3C, CETP activity elutes as one peak at fraction 15 
(40ml). No activity elutes at the position o f unbound CETP.
Fig. 4.4 shows an SDS polyacrylamide gel of the fractions across one such 
column. Serum albumin occurs across all the fractions but a band running more slowly 
at the position which might be expected for CETP appears in fractions 20 to 22. The 
average molecular weight calculated from  SDS polyacrylamide gels was 76300 + /-  
3700, n=5.
In order to check that this band was indeed CETP, a Western blot was carried 
out using a mouse anti-hum an CETP IgM monoclonal antibody (a gift from  Hans 
Dieplinger, Innsbruck). Fig. 4.5 shows the SDS polyacrylamide gel of human serum 
albumin and CETP bound to Intralipid. This was electroblotted onto nitrocellulose 
and then immunochemical detection was carried out using the monoclonal as first 
antibody and a goat anti-mouse IgM conjugated to horse radish peroxidase as second 
antibody. The monoclonal picks out the band which runs slower than the 68000 serum 
albumin band which had been tentatively described as CETP. Thus this antibody 
identified the protein that had been purified  as human CETP.
Attempts were made to remove the protein from the lipid complex. E tha- 
nokdiethyl ether delipidation resulted in complete loss of activity. The solvents may 
affect the enzyme, but this technique has previously been successful [Hesler, C.B. et 
al (1987)]. Another agent, used for delipidating plasma, C ab-O -Sil, was used to try 
and delipidate the CETP intralipid complex but it was found that Cab-O-Sil bound 
CETP as well as the lipid. Since monoclonal antibodies do not require a pure antigen 
it was decided to use the CETP still bound to Intralipid as an immunogen.
FIGU RE 4.3 SEPHAROSE CL-4B COLUMN - HUMAN CETP, FREE AND BOUND TO 
EMULSION OR INTRALIPID. (A) Human CETP (3.8mg) was loaded onto a 
100ml CL-4B column and eluted with Tris-saline buffer at 11 m l/hour. 
Fractions (2.75ml) were assayed for CETP activity. (B) Emulsion, 0.12:0.80:0.08 
PC:TO:OA (50mg) was incubated with human post CM52 hum an CETP (8mg) 
for 15 minutes at 37° C under nitrogen. This was loaded onto a 100ml Sepharose 
CL-4B column equilibrated with 50mM ammonium bicarbonate, 0.5mM 
EDTA, pH 8.5 and eluted at 20m l/hour with the same buffer. Fractions (5ml) 
were collected and assayed for CETP activity and protein content using a 
Bradford assay. (C) Intralipid (50mg) and human post CM52 CETP (8mg) 
were incubated together for 30 minutes at 37° C under nitrogen. This was 
loaded onto a 100ml Sepharose CL-4B column and eluted at 11 m l/hour in 
50mM ammonium bicarbonate buffer, 0.5mM EDTA pH 8.5. Fractions 
(2.75ml) were collected and assayed for CETP activity and protein  content 
by Bradford assay.
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FIGURE 4.4 SDS POLYACRYLAMIDE GEL ELECTROPHORESIS - SEPHAROSE 
CL-4B FRACTIONS, HUMAN CETP BOUND TO INTRALIPID. Fractions 
were loaded in sample buffer containing 5% 2-mercaptoethanol and saturated 
with urea, onto a 10% polyacrylamide gel. The gel was run overnight at 30V 
and then silver stained.
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FIGURE 45 WESTERN BLOT OF HUMAN CETP. A preparation of h“ m? “  £ £ P ^ ° u n d
to Intralipid was run on a 7.5% SDS polyacrylamide gel. Part o f the gel was 
stained with Coomassie blue (A). The rest of the gel was then blotted onto
0.2 micron nitrocellulose filter at 250mA for 3 hours. The :“i 'w f i r e d  saline 
was then stained with Ponceau red (C) or blocked with T r\s . ^ f^ f ? . snal‘?e’ 
0.02% TWEEN 20, 5% BSA (B). The first antibody was a 1/50 dilution ot a 
mouse anti-hum an CETP IgM monoclonal (gift from H D ieplinger). 1 be 
second antibody was 1/500 dilution ot g o a t  a n t i - m o u s e  IgM conjugated to 
horse radish peroxidase. The stain was developed using 4-ch Io ro -l-n ap tn o i 
and hydrogen peroxide. The reaction was stopped with sodium azide.
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3 Rabbit CETP Purification 
4.3.1 Partial Purification
A similar purification procedure to that used for human CETP was carried out 
for rabbit CETP. Again LPDS was used as a starting material. The behaviour of the 
CETP activity on the phenyl Sepharose and CM52 columns differed for the rabbit 
material. For the human enzyme, no activity was eluted from the phenyl Sepharose 
column by the low salt wash and most o f the activity eluted with water. However 
for the rabbit enzyme some activity was eluted with 0.15M NaCl - peak A (Fig. 
4.6A) and a further peak of activity was eluted with water - peak B (Fig.4.6B). These 
peaks of activity were pooled separately and loaded onto CM52 columns. When peak 
A was chromatographed on a CM52 column the activity eluted at fractions 13-14 
(Fig. 4.7A). However when peak B was chromatographed on a CM52 column the 
peak of activity eluted at fraction 66 (Fig. 4.7B). To try and ascertain whether these 
activities were different, the activity peaks from  the two CM52 columns were pooled 
and rechromatographed on a CM52 column to see if the two activities could still be 
distinguished. Two peaks were resolved on this column at fractions 18 and 57 (Fig. 
4.7C) which look like they may represent the peaks separated earlier. However this 
result is not conclusive since the peaks do not coincide exactly with the position 
where they ran before and also the first peak at fraction 18 is represented only by 
one measurement of GETP activity. There was insufficient time to study this anomaly 
further. If there are two distinct peaks o f activity on the CM52 column then this 
may indicate that CETP can exist in two forms which d iffer chrom atographically or 
that rabbit plasma expresses two CETP activities. When peak A and peak B from  the 
phenyl Sepharose column were run on an SDS polyacrylamide gel the proteins in the 
two pools were d ifferen t but the fractions were insufficiently purified  to discern 
which bands may be responsible for one or other activity (Fig. 4.8). The CETP 
activity which behaved similarly to hum an CETP was recovered in 60% yield but 
only 120 fold purification.
4.3.2 Emulsion Binding
In order to make an antigen for antibody production, the rabbit CETP activity 
which behaved in a similar manner to the human activity was bound to Intralipid 
and passed down a Sepharose CL-4B gel filtration column. The activity bound to 
the trailing edge of the lipid peak at about one half the column volume (Fig. 4.9B) 
though the activity peak was much broader than was the case for the hum an enzyme. 
Unbound rabbit CETP elutes at the column volume (Fig. 4.9A). An SDS polyacrylam ide 
gel of the column fractions showed the appearance of a slower running band in 
fractions 14-16 (Fig. 4.10). The molecular weight of this band calculated from  five 
gels was 76200 + /-  1200.
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FIGURE 4.6 RABBIT CETP PURIFICATION - PHENYL SEPHAROSE COLUMN. R abbit 
LPDS was made to 4M NaCl and loaded onto a 200ml phenyl Sepharose colum n 
equilibrated w ith 10mm Tris, 2M NaCl, pH 8.0. Elution was carried out at 
25m l/hour collecting 8ml fractions. A) Elution with lOmM Tris, 0.15M NaCl, 
pH 8.0. B) Elution with distilled water, 0.02% sodium azide. Fractions were 
assayed for CETP activity.
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RABBIT CETP PURIHCATION - CM52 COLUMN. Samples^of A) pooled 
activ ity  from the 0.15M salt wash of the phenyl Sepharose column B) pooled 
activity  from the water wash of the phenyl Sepharose column and C) pooled 
activ ity  peaks from the two CM52 columns A and B, were adjusted to 50mM 
N aA c, 0.02% sodium azide, 1 m g/m l EDTA, pH 4.5 and loaded onto a 200ml 
CM 52 column prequilibrated with 50mM NaAc, 0.02% sodium azide, lm g/m l 
ED TA  pH 4.5. Columns were eluted at 30m l/hour with a 0-200mM  NaCl 
gradient in acetate buffer. Fractions (7.5ml) were collected in 1M TrisHCl 
pH  7.4 and assayed for CETP activity.
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FIGURE 4.8 GEL ELECTROPHORESIS OF CM52 PEAKS. Pooled peaks from  the CM52 
column loaded with the low salt wash (peak A) and the water wash (peak B) 
of the phenyl Sepharose column were electrophoresed on a 7.5% SDS poly­
acrylamide gel and silver stained.
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FIGURE 4.9 CL-4B GEL FILTRATION COLUMNS OF RABBIT CETP. R abbit CETP
(A) or rabbit CETP bound to Intralipid (B) were loaded onto a 30ml (A) or 
200ml (B) Sepharose CL-4B column and eluted at 11 m l/hour (A) or 30m l/hour
(B) with 50mM ammonium bicarbonate, 0.5mM EDTA pH 8.5. Fractions, 
2.75ml (A) or 7.5ml (B)were collected and assayed fo r CETP activity.
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FIGU RE 4.10 GEL ELECTROPHORESIS OF RABBIT CETP BOUND T 0  INTRALIPID 
COLUMN FRACTIONS FROM THE CL-4B COLUMN. Fractions from  the 
Sepharose CL-4B column of rabbit CETP bound to Intralipid w ere run on a 
7.5% SDS polyacrylamide gel and silver stained.
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4 Antibody Production
4.4.1 Antibodies to CETP Peptide Raised in Sheep
One strategy to make antibodies was to choose a peptide from the CETP sequence 
which may be particularly immunogenic. This peptide can then be synthesised and 
used to raise antibodies which will hopefully react against the whole protein. Using 
the published am ino-acid sequence which was predicted from the cDNA nucleotide 
sequence [Drayna, D. et al (1987)], a hydrophilicity profile and predicted secondary 
structure was ascertained. The hydrophilicity plot was drawn by the ’Predict’ program 
(Peter M urray-R ust, Glaxo Group Research). Secondary structure was predicted by 
Chou and Fasman and Robson plots (Appendix 1). Also the consensus secondary 
structure from  eight predictions of secondary structure was plotted (Fig. 4.11) 
(program by Elios Eliopolous, Leeds). From these plots several stretches of peptide 
sequence were chosen which had a predicted |3-turn and were hydrophilic. These 
peptide properties were sought since it is likely that a part of the molecule with those 
properties would be external to the protein molecule and exposed. An exposed part 
o f the molecule is more likely to be immunogenic than one which is internal. One 
o f these peptides was finally selected by a chemist, Dr Peter Seale (Glaxo Group 
Research Ltd, G reenford) and synthesised with a cysteine residue added to the N 
term inus to aid conjugation to a protein carrier molecule. The sequence chosen was 
from  residue 351 to 360 and is shown in Fig. 4.12. The equivalent peptide from  the 
rabbit protein is also shown. There were four changes in this sequence for the rabbit. 
One of these changed an uncharged polar residue to a basic one (Gin - Arg) and 
another from  a basic residue to an acidic one (His - Glu). It was not known whether 
this would affect cross reactivity if an antibody were obtained.
To prepare the antigen the peptide was conjugated to keyhole lim pet haemo- 
cyanin (KLH). Conjugated peptide was emulsified with oil and Freund’s complete 
adjuvant and used (18pg) to inject one Black Face sheep. Immunisation was by four 
subcutaneous injections; two subscapular and two on the haunches. The animal was 
boosted a month later with the same amount of antigen but in incomplete Freunds 
adjuvant and the first sample bleed taken two weeks after the boost. Sheep serum 
showed 26% inhibition of both rabbit post CM52 CETP and human LPDS at a dilution 
of 1/10, over and above any inhibitory activity of sheep serum itself. An ELISA was 
carried out to test the binding of the antiserum to CETP peptide, KLH and human 
post CM52 CETP (Fig. 4.13). Non-immune serum showed negligible binding to any 
of these three antigens. The antiserum showed good binding activity against both the 
CETP peptide and KLH alone. However the antiserum  did not recognise hum an post 
CM52 CETP. Thus antibodies were successfully raised against the immunogens but 
these antibodies were unable to recognise the native protein in the post CM52 
preparation. This result illustrates a pitfall of using peptides to raise antibodies. The 
peptide selected does not necessarily take up the conform ation that it would in the 
native protein and therefore antibodies against the peptide conjugate do not necessarily
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FIGURE 4.12
C ys-P ro-A rg-Pro-A sp-G ln-G ln-H is-Ser-V al-A la 
351 360
Pro - A rg - Pro - Asp - Gly - Arg - Glu - Ala-V  al -  Ala
SEQUENCE OF THE PEPTIDE CHOSEN FOR PRODUCTION OF 
POLYCLONAL ANTIBODIES. The peptide chosen comprises am ino-acid  
residues 351 to 360. A cysteine residue was put on the N term inal end to 
allow conjugation to a carrier protein. A) The human sequence. B) The rabbit 
sequence.
2 2 .5  3 3 .5  4 4 .5  5 5 .5  6 6 .5
-LOG ANTIBODY DILUTION
FIGURE 4.13 ELISA OF SHEEP IMMUNE SERUM. A sheep was. im m unised w ith the 
CETP-peptide conjugated to KLH. The immune serum was tested in  an ELISA 
for its activity against the CETP peptide <$, KLH $() and hilm an post CM52 
CETP (0 . Both immune (— and non-im mune ( -  sera were tested. Plates 
were coated with antigen at lpg/m l. The second antiserum  was a donkey 
anti-sheep IgG conjugated to horse radish peroxidase at 1/1000 dilu tion.
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react against the native protein. It is possible that the antibodies raised may recognise 
the denatured protein and thus a Western blot was carried out to see whether any 
reaction could be seen with the CETP band. This type o f analysis showed that there 
was a strong specific reaction with KLH but also a non-specific staining showing 
many other bands in the human post CM52, rabbit post CM52 and the human serum 
album in tracks (Fig. 4.14). Nothing reacted at the expected molecular weight for 
CETP. This reaction could not be used to detect the amount of CETP in impure 
preparations. The work with this antiserum was suspended since it did not prove to 
be a useful tool.
4.4.2 Monoclonal Antibodies to Rabbit CETP
Two batches of mice were immunised with two d ifferen t preparations of rabbit 
CETP. The first was partially purified CETP to the post CM52 column stage. The 
second preparation used CETP bound to Intralipid. In order to use the specific CETP 
band for immunisation, the CETP bound to Intralipid was run on an SDS poly­
acrylam ide gel and then blotted onto a nitrocellulose membrane. The protein bands 
could be visualised by staining with Ponceau red. A fter cutting the appropriate band 
from  the nitrocellulose and destaining in phosphate buffered saline, the nitrocellulose 
with bound CETP could be dissolved in DMSO and used to immunise the mice (10pg). 
M ice tail bleeds were tested two months later and it was found that those immunised 
w ith the rabbit post CM52 preparation showed best inhibitory activity. These mice 
were boosted with 10pg of post CM52 CETP before spleen cells from two mice were 
fused with NS-1 cells. Two months after fusion the colonies had grown such that 
the supernatants could be tested. The cultures were cloned three times to a dilution 
o f 0.3 cells per well. A fter each cloning stage cell supernatants were tested for 
inhibition o f CE exchange in a CETP assay, using rabbit post CM52 as an enzyme 
source, and also o f TG exchange in case these activities could be inhibited separately. 
A t the last dilution stage, three positives (10.8, 10.15 and 10.16) were found to inhibit 
CETP activity by between 50 and 60%. None of the positives found in these screens 
inhibited hum an CETP. Large cultures of these were grown such that they could be 
injected into the peritoneal cavity of mice to produce larger amounts o f antibody. 
The production o f antibodies was slow in these mice so another batch of mice were 
innoculated with a greater number of cells. Ascites from  clone 10.15 showed dose 
dependent inhibition of CETP activity (Fig. 4.15) but only to 20% inhibition. A 
partially purified  preparation (by ammonium sulphate precipitation and Sephadex 
G200 column) o f this ascites showed no inhibition. A second batch of the 10.15 clone 
was grown up to try  and increase the amount o f o f antibodies. However the second 
batch of 10.15 ascites showed no activity at all. It is possible that the clone had 
become overrun with non-producer cells. Fused cells can stop production of antibodies 
fo r no apparent reason or the instability o f these cells can result in chromosones 
being lost. It was decided not to proceed with developm ent of these antibodies fu rther
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FIGURE 4.14 WESTERN BLOT OF HUMAN POST CM52 CETP USING SHEEP IMMUNE 
SERUM . Samples were run on a 7.5% SDS polyacrylamide gel and then 
electroblotted onto a 0.2 micron nitrocellulose filter. For im m unodetection, 
the filter was blocked in 5% BSA and then exposed to a 1/100 dilution of 
sheep immune serum. The second antibody used was a 1/1000 dilution of 
donkey anti-sheep IgG conjugated to horse radish peroxidase.
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FIGURE 4.15 CETP ASSAY FOR THE INHIBITORY EFFECTS OF CLONE 10.15 
A N TI-RA BBIT CETP SUPERNATANT. A mouse was inocculated with cells 
from  the 10.15 clone. Ascites were tapped after 2.5 weeks. The ascites was 
added to a CETP assay containing a control amount o f  rabbit post CM52 
CETP.
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since events in the literature had superceded the requirem ent to make antibodies to 
rabbit CETP in order to inhibit rabbit CETP activity in vivo [Whitlock, M.E. et al 
(1989), Abbey, M. & Calvert, G.D. (1989)].
4.4.3 Monoclonal Antibodies to Human CETP
As with the immunisation of mice for rabbit CETP, the mice for monoclonal 
antibodies to hum an CETP were immunised with CETP bound to nitrocellulose 
prepared from  the CETP bound to Intralipid preparation, obtained from  Western 
blotting o f a polyacrylamide gel, and dissolved in DMSO. M ice were also immunised 
with human post CM52 CETP. As well as Balb/c mice used for immunisation, a 
hybrid strain o f mice (F j hybrids of CBA and Balb/c mice) were also immunised. 
The hybrid animals are more vigorous and often show a stronger antibody response. 
The mice imm unised with post CM52 CETP showed the most inhibitory activity. 
These mice were boosted four times three weeks apart and tested each time. Tail 
bleeds were checked for activity both by inhibition of activity in a CETP assay and 
by their reaction against partially purified post CM52 CETP in an ELISA. The two 
best reactions in both the CETP assay and the ELISA were mice A x and A5 (12% 
inhibition and 50% inhibition respectively at 1/20 dilution). The animals were boosted 
again but only one survived. The spleen from  A5 was fused with NS-1 cells. Again 
the fused cell colonies were slow growing. Dilutions from  the colonies were screened 
both by the inhibition of CETP activity and by ELISA. It appeared that there were 
false positives in the CETP activity inhibition assay since positives in this assay did 
not always prove positive in the ELISA. At the last dilution three clones 24,16 and 
20 were positive. Only clone 24 produced sufficient ascites to test and this proved 
negative. Purified (by ammonium sulphate precipitation and Sephadex G200 column) 
antibody from  this ascites was also negative. It was decided to regrow clones from 
an earlier dilution stage which had proved positive in both the activity assay (60% 
inhibition) and the ELISA (0.15 OD^.gsonm). Clones D.HU.2.1E and D.HU.2.6H 
were regrown and injected into mice to produce antibodies in ascites. Both clones 
proved positive in a CETP inhibitory assay (Fig. 4.16). However in an ELISA only 
clone D.HU.2.6H reacted with human post CM52 CETP bound to the plate (Fig 4.17).
Since this ELISA used only a partially purified  CETP preparation to coat the 
plate the clone may have been reacting to something other than CETP. To investigate 
further, a Western blot was carried out to see w hether the clone would produce a 
signal at the correct molecular weight for the hum an CETP. This experim ent proved 
inconclusive since although a band at approxim ately the correct molecular weight 
reacted with the ascites, many other bands reacted too, including a strong serum 
albumin reaction which partially obscured detection o f a CETP reaction. Since ascites 
will contain mouse antibodies it is possible that the cross-reactivity may be due to 
reaction with other proteins. It is also possible that the clone was not a true clone 
and several antibodies were being produced by d ifferen t cell lines. Limitations on 
time precluded fu rther investigation of this promising clone. Further steps would be
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FIGURE 4.16 CETP ASSAY FOR THE INHIBITORY EFFECTS OF CLONES 2.1E  AND 
2.6H  ANTI-HUM AN CETP SUPERNATANT. Mice were innoculated with 
cells from either the 2.1E clone (•) or the 2.6h clone (0 . Ascites were tapped 
after three weeks. The ascites was added to a CETP assay containing a control 
amount o f human LPDS.
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FIGURE 4.17 ELISA OF MONOCLONAL ANTIBODIES TO HUMAN CETP. Supernatants 
from  the clones produced from the fusion of spleen cells from  a mouse 
immunised w ith human post CM52 CETP with NS-1 cells were tested for 
their activity against human post CM52 in an ELISA. Plates were coated with 
50pg/ml post CM52 CETP. The second antiserum was 1/1000 goat anti-m ouse 
IgG conjugated to horse radish peroxidase. £)) clone 2 .IE , (•) clone 2.6H, <p) 
non immune ascites.
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to attempt to purify the antibody from  the ascites and see whether a more specific 
reaction was obtained. If not then the clone D.HU.2.6H could be recloned and further 
ascites produced and tested.
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CHAPTER V
STUDIES OF CETP ACTIVITY IN ANIMALS
1 Introduction
Hypercholesterolaemia is one of the risk factors associated with atherosclerosis. It 
has been noted that hypercholesterolaemia in rabbits induced either by diet or by a 
genetic defect is accompanied by an increase in plasma CETP activity. It is not known 
whether this is a cause and effect relationship or whether these param eters are inde­
pendently controlled. Plasma CETP activity has been negatively correlated with HDL 
cholesterol levels in man but there is no strong correlation with total cholesterol. It is 
of interest to see whether m anipulation o f plasma total and HDL cholesterol levels affect 
CETP activity and whether CETP activity can be affected independently of plasma 
cholesterol. Various drugs can can alter plasma cholesterol levels as can feeding various 
diets. The effects of fat feeding, hereditary hyperlipidaemia, AC AT inhibitors, HMGCoA 
reductase inhibitors, probucol and other antioxidants were investigated in rabbit and 
marmoset models of hyperlipidaemia. Some studies were also carried out in humans.
2 Studies in the Rat
The rat is a species which expresses low levels of plasma CETP activity. This low 
expression of CETP is reflected in part by the lipoprotein metabolism of the rat. Most 
of the circulating cholesterol in the rat is carried by HDL and rat has a higher proportion 
of HDL than a human or a rabbit [Chapman, M.J. (1986)]. HDL in the rat has been 
demonstrated to deliver cholesterol to certain steroidogenic tissues [Gwynne, J.T. & Hess,
B. (1980), Glass, C. et al (1983)]. This predominance of HDL might be expected from  
an animal which expresses low levels o f CETP since CE will not be transferred out of 
the HDL. This raises questions as to how the rat carries out reverse cholesterol transport. 
It may be that HDL delivers cholesterol back to the liver [Quarfordt, S. et al (1980), 
Glass, C. et al (1983) and Arbeeny, C.M., R ifici, V.A. & Eder, H.A. (1987)] or possibly 
there is a transient expression of CETP activity to allow the cholesterol to be transported 
to lower density lipoproteins and taken back to the liver in that way. Rats show circadian 
rhythms [Parker, T.S. et al (1982)] in the expression of other enzymes o f cholesterol 
metabolism e.g. HMGCoA reductase, so it may be possible that CETP may display such 
a rhythm  too.
75
In order to test this hypothesis two groups of five male Wistar rats were kept in 
opposite light/dark  cycles such that when blood was sampled one group of rats was six 
hours into the light cycle and one group was six hours into the dark cycle. Blood samples 
were taken from  the tails of these ratsup to six weeks into the cycle. The CETP activities 
in the two groups of rats over the period o f the experiment are shown in Fig. 5.1. The 
am ount o f CETP measured in LPDP prepared from  the plasma sample was very low and 
hence there are very large errors on the measurements. The CETP levels o f the rats 
m easured in the m id-dark cycle was higher than that o f the rats m id-light cycle up to 
four weeks but at six weeks was lower. The difference between mid light cycle rats and 
m id dark cycle rats was only significant at six weeks (Table 5.1) but was in the opposite 
direction from  the previous two measurements. The differences detected were not 
particularly large when compared to the amount o f CETP in other species blood (up 
to 100 times greater in humans) or that can be revealed by passage of rat plasma over 
a phenyl Sepharose column to remove inhibitor [Tollefson, J.H. et al (1988)]. Before 
passage over the column rat plasma CETP activity was 1% that of human. A fter passage 
over the column rat activity was 50 to 100% that of human CETP activity, which is a 
large increase. Since no difference in CETP activity could be detected between rats in 
the m id-light cycle and those in the m id-dark  cycle except at six weeks, it appears that 
expression of CETP may be the same throughout the light/dark  cycle and no circadian 
rythm n is present. It is possible that a large amount of CETP may be expressed at time 
points other than the middle of the light cycle and the middle of the dark cycle and 
these changes would be missed by the restriction to these two time points. This would 
mean that CETP would be peaking at a time d ifferen t from  the other enzymes and also 
that the peak of activity would be very sharp.
3 Studies in the Rabbit
5.3.1 Effects of Hypercholesterolaemia on Plasma CETP 
Activity
Rabbits have proved to be a useful model of atheroma as they can be made to 
produce lesions by cholesterol feeding or casein/sucrose feeding over several months. 
The plasma cholesterol levels which are achieved do tend to be extrem ely high. 
Watanabe rabbits are a strain that are genetically deficient in LDL receptors and also 
show very high plasma cholesterol and develop lesions. Both these rabbit models of 
hyperlipidaemia have been shown to express high levels o f CETP activity [Son, Y-S.
C. & Zilversmit, D.B. (1986)]. Froxfield heritable hyperlipidaemic (HH) rabbits 
(Southampton) are a breed which show a heritable hyperlipidaemia also due to an 
LDL receptor defect. Homozygotes show extremely high plasma cholesterol levels 
>10mM, develop lesions and are a good atherosclerotic model.
TIM E AFTER 
INSTIGATION OF 
LIG H T/D A R K  CYCLE
CETP ACTIVITY 
MID LIGHT
(%t/pg)
CETP ACTIVITY 
MID D A R K
(%t/pg)
1 WEEK 0.012 + /- 0.007 0.040 + /-  0.025
4 WEEKS 0.007 + /- 0.004 0.036 + /-  0.027
6 WEEKS 0.016 + /- 0.009 0.007 + /-  0.005*
* = P<0.05
TABLE 5.1 COMPARISON OF RAT PLASMA CETP LEVELS M ID-DARK AND 
M ID-LIGHT CYCLE. Plasma CETP levels were measured at 1, 4 and 6 weeks 
for each group o f five rats after putting the rats into opposite ligh t/dark  
cycles. For the group which were sampled in the m id-dark cycle, there was 
a significant drop (P<0.05) in CETP activity between week 1 and  week 6. 
There was also a significant difference between the two groups at week 6 
(P<0.05).
0 .07
0 .06
0.06
o  0.03
0 . 0 2
0.01 •
WEEKS IM CYCLE
FIG U RE 5.1 CETP ACTIVITY IN THE RAT DURING ADAPTAIICN TO  L IG H T /D A R K  
CYCLE. Two groups of five rats were kept in a 12 hour lig h t/d a rk  cycle such 
that at sampling one group was 6 hours into tlje-|iight cycle (0  an d  one group 
was six hours into the dark cycle (<#>). Blood samples were taken fro m  the tail 
vein at 1, 4 and 6 weeks. LPDP was prepared and CETP activ ity  m easured.
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Plasma cholesterol levels and plasma CETP activities were compared in normal 
half lop rabbits (the normal strain bred with the HH rabbits) and Froxfield HH 
rabbits. Plasma cholesterol levels were significantly higher (P<0.001) in the Froxfield 
rabbits (n=6) than in the control half lops (n=10) at age 21 weeks (Table 5.2). Plasma 
CETP levels were also significantly higher (P<0.05) in these rabbits. Thus in this 
other example of genetically hyperlipidaemic rabbit, plasma CETP levels are 
dem onstrably high.
To test whether fat feeding had the expected effect on plasma CETP levels, 
D utch Belted rabbits on a high fat diet were compared to control rabbits. Plasma 
total cholesterol levels and plasma CETP levels were significantly higher in the fat 
fed  rabbits than in the controls (Table 5.3). Levels in the fat fed rabbit were 70% 
higher than the control value. Thus these data confirm  those already reported in the 
literature. Within the fat fed group plasma cholesterol was significantly correlated 
to CETP activity (r=0.73, P<0.05) but there was no correlation within the control 
group.
5.3.2 ACAT Inhibitor
Acyl CoA: cholesterol acyl transferase (ACAT) is a microsomal enzyme which 
esterifies cholesterol in cells thus allowing it to be stored as cholesteryl ester in the 
tissue. ACAT may be involved in the uptake o f cholesterol from the gut. It has been 
suggested that ACAT inhibitors would be good antiatherosclerotic drugs because they 
could inhibit cholesterol uptake by the gut and /or prevent CE deposition in peripheral 
tissues. It was tested to see whether ACAT inhibitors would affect CETP e.g. by 
increasing the amount of free cholesterol in the cell which may be transported to 
the liver.
Rabbits were fed GR69918X, an ACAT inhibitor from Cyanamid made by 
Lancaster Synthesis (CL 277082), for 12 weeks at either 30 m g/kg/day (n=10) or 100 
m g/kg /day  (n=10) for 12 weeks. Control (n=10) animals were fed vehicle only. The 
animals were 21 weeks old at the end of the experiment. Total cholesterol, HDL 
cholesterol and plasma CETP activity were m easured (Table 5.4). GR69918X had no 
effect on total plasma cholesterol but did significantly increase HDL cholesterol levels 
at 100 m g/kg/day. Animals treated with 30m g/kg/day GR69918X showed a non 
significant intermediate increase in HDL levels. CETP activity was not affected by 
treatm ent. Thus a change in HDL cholesterol was not accompanied by a change in 
CETP activity. It has been proposed that there is an inverse correlation between 
plasma HDL levels and CETP activity [Groener, J.E.M . et al (1984), Tollefson, J.H. 
et al (1988)] thus we might have expected to see a fall in CETP activity concomitant 
w ith the rise in HDL, but this was not the case. However the HDL levels measured 
here are very low and have probably been underestim ated since the technique used 
was suitable for human samples but had not been validated for hyperlipidaem ic 
rabbits. No ACAT inhibitor has yet been dem onstrated to decrease plasma cholesterol 
but this may be due to problems with bioavailability.
TOTAL
CHOLESTEROL
(mM)
CETP ACTIVITY
(%t/pg)
NORM AL RABBIT 
(HALF LOP)
2.10 + /-  1.78 0.572 + /- 0.101
HYPERLIPIDAEM IC
RABBIT
(HHL)
13.77 + /-  4.17* 0.839 + /- 0.203**
* P= 0.001 
** P= 0.05
TABLE 5.2 PLASMA TOTAL CHOLESTEROL LEVELS AND CETP ACTIVITY IN 
NORMAL AND GENETICALLY HYPERLIPIDAEMIC RABBITS. Plasma 
total cholesterol levels and CETP activities were measured in 10 control half 
lop rabbits and 6 Froxfield HH rabbits at 21 weeks o f age.
TOTAL
CHOLESTEROL
(mM)
CETP ACTIVITY
(%t/pg)
CONTROL DIET 0.87 + /- 0.34 0.185 + /-  0.022
HIGH FA T DIET 5.49 + /- 3.78* 0.316 + /-  0.077**
* = P<0.05 
** = P<0.001
TABLE 5.3 TOTAL CHOLESTEROL LEVELS AND CETP ACTIVITY IN RABBITS FED
CONTROL AND H IGH FAT DIETS. Dutch Belted rabbits were fed  either 
control (FD1) (n=4) or low cholesterol, high fat diet (n=8) fo r 11 weeks. 
Blood samples were taken from the marginal ear vein and serum  prepared. 
Total cholesterol was measured and CETP activity measured in the LPDS.
TREATM ENT TOTAL
CHOLESTEROL
(mM)
HDL
CHOLESTEROL
(mM)
CETP ACTIVITY
(%t/pg)
CONTROL
(n=10)
19.85 + /-  4.70 0.29 + /-  0.14 1.08 + /-  0.30
GR69918X
lOOmg/kg/day
(n=10)
22.58 + /-  5.19 1.03 + /-  0.50* 1.17 + /-  0.27ns
* - P<0.001
NS - not significant
TABLE 5.4 EFFECT OF AN ACAT INHIBITOR ON TOTAL CHOLESTEROL
LEVELS AND CETP ACTIVITY IN FROXFIELD RABBITS. Total choles­
terol, HDL cholesterol and CETP activity were measured in serum samples 
from  control Froxfield rabbits or Froxfield rabbits fed  either 30m g/kg/day 
or lOOmg/kg/day GR69918X, an ACAT inhibitor (Cyanamid). Each group 
contained 10 rabbits. The data for the 30m g/kg/day group is not shown.
TREATM ENT TOTAL CHOLESTEROL 
(mM)
CETP ACTIVITY
(%t/pg)
CONTROL 17.44 + /-  5.73 1.14 + /-  0.36
(n=12)
PROBUCOL 13.45 + /-  3.76ns 1.07 + /-  0.38ns
(n=12)
NS = not significant
TABLE 5.5 THE EFFECT OF PROBUCOL ON TOTAL CHOLESTEROL AND CETP 
ACTIVITY IN FROXFIELD RABBITS. One group of 12 rabbits was fed 
normal FD1 diet and one group of 12 rabbits was fed  1% probucol incor­
porated into FD1 diet for 12 weeks. Blood samples were taken from  the 
marginal ear vein. Serum total cholesterol was measured and CETP activity 
in LPDS was assayed.
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5.3.3 Salbutamol
Salbutamol is a ^  adrenergic agonist. It has been reported that cAMP stimulation 
o f  neutral cholesteryl ester hydrolase (NCEH) can lead to a decrease in cellular CE 
content in aortic smooth muscle cells [H ajjar, D.P. & Weksler, B.B. (1983)]. Since 
salbutamol works via a cAMP dependent mechanism it was tested to see whether this 
drug would have any effect on cholesterol metabolism in rabbits. If  less CE are stored 
in  the cell then more free cholesterol is available for removal from peripheral cells 
which may lead to a rise in CETP activity. A study was performed where total 
cholesterol and CETP activity was measured in 12 control HH rabbits (fed FD1 diet) 
and 12 HH rabbits fed FD1 diet containing 0.03% salbutamol for 12 weeks. At the 
end of the experiment there was no significant difference in total cholesterol and 
CETP activity between treated and control groups (data not shown).
5.3.4 Probucol
Probucol (Merrell Dow) is a drug that has been shown to have good lowering 
effects on plasma total cholesterol but is not widely used in the clinic because it also 
results in a disproportionate decrease in HDL levels [Beyen, A.C. (1986), Illingworth, 
D.R. (1987)]. However, recently it has been shown that probucol can prevent lesion 
growth in Watanabe rabbits [Kita, T. et al (1987)]. The mode of action of this drug 
remains obscure but it is known to be an antioxidant [Barnhart, R .L., Busch, S.J. & 
Jackson, R.L. (1989)]. It has been suggested that the drug may protect circulating 
LDL from  oxidative modification and so may prevent its uptake by the scavenger 
receptor into macrophages leading to foam cell development and lesion form ation 
[Naruszewicz, M. et al (1984), Parthasarathy, S. et al (1986), Carew, T.E., Schwenke,
D.C. & Steinberg, D. (1987)]. Apart from  these effects it has also been suggested 
that probucol may increase impaired plasma CETP activity [Matsuzawa, Y. et al 
(1988), Sirtori, C.R. et al (1988), Franceschini, G. et al (1989)] possibly resulting in 
increased flow of cholesterol out of peripheral tissues.
A group of twelve Froxfield HH rabbits were treated with 1% probucol 
incorporated into their diet and effects on plasma total cholesterol and CETP activity 
were measured at the end of 12 weeks and compared with a group of twelve control 
rabbits fed normal diet. Probucol did not significantly decrease plasma total cholesterol 
levels nor did it significantly decrease plasma CETP activity (Table 5.5). Since there 
was no effect on total cholesterol then it m ight not be expected that CETP would 
be affected as the rabbits were obviously not absorbing enough probucol to have a 
cholesterol lowering effect. However it is shown that probucol does not independently 
affect CETP in these rabbits. Plasma probucol levels were 145 + /- 18.2pM so probucol 
was being absorbed by these rabbits. The probucol treated rabbits showed a reduced 
am ount of lesion development compared with controls (work carried out by Jo
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M otteram, Glaxo Group Research Ltd, G reenford), thus a lesion effect o f the drug 
was apparent. This evidence does not appear to support a mechanism for CETP in 
reduction o f lesion progression.
5.3.5 Other Antioxidants
The effect o f antioxidants on plasma CETP activity was studied again using 
another novel antioxidant, GR44966X. Probucol was used in the same experiment 
as a reference. Froxfield HH rabbits were fed for five days with control diet or diet 
containing 1% probucol, 0.1% probucol or 0.1% GR44966X. GR44966X was fed in 
two forms; a) unused diet from a previous experim ent, which was four weeks old, 
for five days and b) freshly prepared diet containing GR44966X for 3 days. Plasma 
CETP activity was not significantly affected by probucol (Table 5.6). However in 
the case o f GR44966X, CETP activity was halved. This decrease was significant in 
the case of treatm ent (b), but not in the case of treatm ent (a). Group (b) showed a 
large reduction in CETP activity even though these animals were only on the diet 
for three days. Here, it seems, is an agent which can reduce CETP activity. 
U nfortunately in this particular experiment plasma cholesterol levels were not 
measured. It is not known whether GR44966X has a direct effect on CETP activity 
when added directly to an assay.
Probucol has been proposed to increase CETP activity. Therefore it is interesting 
to see that an agent which also an antioxidant appears to decrease plasma CETP 
activity. Since the numbers in the animal groups here are so small it is obviously 
desirable to repeat this experiment with larger animal groups as this may just be a 
chance observation.
4 Studies in the Marmoset
Marmosets are primates and exhibit cholesterol levels similar to those found in 
man (about 4.5mM) but it appears that they have a greater proportion o f cholesterol in 
their HDL fraction. They are therefore a useful model fo r atherosclerosis since the 
cholesterol levels are not extreme. HMGCoA reductase inhibitors inhibit the biosynthesis 
of cholesterol and have profound effects on plasma cholesterol levels. In the marmoset 
model where marmosets were treated with GR92549, an HMGCoA reductase inhibitor, 
reductions o f 37% (at lOm g/kg/day) and 47% (at 30m g/kg/day) in plasma total cholesterol 
were seen after seven days treatment. These reductions were significant (Table 5.7). 
Control animals also showed a significant but smaller decrease in plasma total cholesterol 
(20%). This may be due to stress or unspecified effects due to dosing. CETP activity 
was measured in each of the treatm ent groups at day 0 and day 7. The only significant 
change in CETP activity occurred in the control group where activity was decreased by 
37%. Cholesterol lowering by the HMGCoA reductase inhibitor- did not bring about 
lowering o f plasma CETP activity. The decrease in the activity in the control may or 
may not be related to the total cholesterol lowering in the control. If  it is due to this 
cholesterol lowering then the mechanism for this cholesterol lowering effect may d ifferent
TREATM EN T CETP ACTIVITY
(%t/pg)
NUM BER IN 
GROUP
P VALUE
SDS DIET 
(5 days X  lOOg)
1.29 + /-  0.20 3
0.1% PROBUCOL 
(5 days X  lOOg)
1.47 + /-  0.22 3 0.39
1% PROBUCOL 
(5 days X 200g)
1.17 + /-  0.47 3 0.72
0.1% GR44966X(a) 
(5 days X lOOg)
0.66 + /-  0.33 3 0.06
0.1% GR44966X(b) 
(3 days X lOOg)
0.46 + /-  0.23 2 0.05
TABLE 5.6 THE EFFECT OF AN ANTIOXIDANT, GR44966X, ON CETP ACTIVITY 
IN FROXFIELD RABBITS. Froxfield rabbits were divided into 5 groups 
and fed various diets as follows:- one group of 3 was fed normal SDS diet 
for 5 days at lOOg/day, one group o f 3 was fed diet w ith 0.1% probucol 
incorporated for 5 days at lOOg/day, one group of 3 was fed diet w ith 1% 
probucol incorporated for 5 days at 200g/day, one group of 3 was fed  diet 
with 0.1% GR44966X incorporated (diet was four weeks old) fo r 5 days at 
lOOg/day and finally one group of 2 rabbits was fed 0.1% GR44966X fo r 3 
days at lOOg/day (diet made fresh at start of experiment). Blood samples 
were taken from the marginal ear vein. CETP activity was measured in 
LPDS prepared from  the sample.
TREATM ENT TOTAL CHOLESTEROL 
(mM)
DAY 0 DAY7
CETP ACTIVITY
(%t/pg)
DAY0 DAY7
CONTROL 4.79 3.84* 0.35 0.22+
(n=6) + /-  0.36 + /- 0.20 + /-  0.09 + /-  0.05
GR92549 4.39 2.77** 0.19 0.27
10 m g/kg /day  
(n=6)
+ /-  0.09 + /- 0.13 + /- 0.08 + /-  0.11
GR92549 5.14 2.71*** 0.31 0.29
30m g/kg/day
(n=6)
+ /-  0.05 + /- 0.36 + /-  0.12 + /-  0.05
* P<0.005 ** P<0.001 *** P<0.05
+ P<0.05
TABLE 5.7 THE EFFECT OF AN HMGCoA REDUCTASE INHIBITOR, GR92549,
ON TOTAL CHOLESTEROL LEVELS AND CETP ACTIVITY IN MAR­
MOSETS. Marmosets were divided into three groups of 6. One group was a 
control group, a second group was dosed at lOm g/kg/day GR92549 for 7 
days and a third group was dosed at 30m g/kg/day GR92549 fo r 7 days. 
Blood samples were taken from the tail vein and assayed for total choles­
terol and CETP activity was measured in the LPDS.
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than that employed by HMGCoA reductase inhibitors. These marmosets demonstrated 
plasma cholesterol lowering which was not accompanied by a reduction in plasma CETP 
activity.
5 Studies in Humans
Two drug studies were carried out in humans. The first study was to investigate 
the effect of probucol on plasma CETP activities in normal volunteers. The second was 
to look at the plasma CETP activities in hypercholesterolaemic patients being treated in 
the clinic with an HMGCoA reductase inhibitor, Simvastatin.
5.5.1 Probucol
It has been reported that probucol treatm ent can lead to an increase in plasma 
CETP activity. This was not found to be the case in the rabbit study. To see if  there 
might be any effect in humans, a pilot study looking at the effect of two weeks 
treatm ent at a dose of 500mg probucol twice daily in two volunteers. In this pilot 
study a fall in total cholesterol from 5.76 + /-  0.47mM to 4.83 + /-  0.02 mM was 
seen (Table 5.8). This was accompanied by a fall in HDL cholesterol from  1.32 +/- 
0.12mM to 1.13 + /-  0.13mM. Total TG did not seem to be affected. CETP activity 
measured in the LPDS from these two patients was increased 1.8 fold in treated 
samples. Control activities were 0.094 +/- 0.002 %t/pg and after treatm ent were 0.173 
+ /-  0.001 %t/pg. An investigation was then carried out to see whether there were 
changes in the ability of the volunteers’ lipoproteins to act as donors or acceptors. 
Assays using 3H -H D L3 or LDL/VLDL from each donor in a CETP assay with a 
standard am ount o f LPDS showed that there were increased transfer rates with the 
same amount o f LPDS using lipoproteins from the post probucol samples as opposed 
to the control samples. Thus the increase in plasma CETP activity may be at least 
partly due to increased ability of the lipoproteins to act as substrates. LCAT activities 
were not greatly affected by Probucol treatment. Probucol when added to an in vitro 
assay in concentrations up to 500pM showed no significant direct effect on CETP 
activity, though there were difficulties in getting the drug dissolved in a solvent 
which would not interfere with the assay.
The results o f this pilot study were interesting but the sample size was not large 
enough to test whether the effect was statistically significant. Therefore the study 
was repeated using six healthy male volunteers. Again the schedule was taking 500mg 
probucol twice daily for two weeks. A 200ml blood sample was taken at day 0 and 
day 14.
The results o f the larger probucol study are shown in Fig. 5.9. Plasma total 
cholesterol was significantly reduced from 5.65 + /-  1-08 mM to 4.70 + /-  1-01 mM 
(P<0.005). HDL cholesterol was also significantly reduced from  1.22 +/- 0.14 mM 
to 0.86 + /-  0.14mM (PcO.001). Triglycerides were unaffected. CETP activities were 
measured in LPDS and there was found to be no significant difference between 
control 0.259 + /- 0.051 %t/pg and post Probucol samples 0.301 + /-  0.078 %t/ng.
TIME = 0 TIM E = 2 WEEKS
TOTAL CHOLESTEROL 
(mM)
5.76 + /- 0.47 4.83 + /-  0.02
HDL CHOLESTEROL 
(mM)
1.32 + /- 0.12 1.13 + /-  0.13
TRIGLYCERIDES
(mM)
0.66 + /- 0.09 0.58 + /-  0.03
CETP ACTIVITY 
using standard LP 
substrates 
(%t/pg)
0.094 + /- 0.002 0.173 + /- 0.001
CETP ACTIVITY 
using standard LPDS 
LD L/V LDL 
(%t/Mg)
0.065 + /- 0.004 0.089 + /- 0.003
CETP ACTIVITY 
using standard LPDS 
3H -H D L3
(%t/pg)
0.104 + /- 0.003 0.157 + /- 0.045
LCAT ACTIVITY 
(pm ol/hour/pg)
0.628 + /- 0.106 0.602 + /-  0.151
TABLE 5.8 MEASUREMENTS OF PLASMA LIPIDS AND ENZYME ACTIVITIES IN 
HUMANS TREATED WITH PROBUCOL. Two hum an male volunteers 
were treated with 500mg probucol twice daily fo r 2 weeks. Blood samples 
were taken at the start and finish of the experim ent. Plasma total choles­
terol, HDL cholesterol and triglycerides were measured. CETP activity and 
LCAT activity were measured in the LPDP using standard substrates. 
LD L/V LDL and HDL3 from the volunteers were also tested for their abil­
ity to act as substrates in a CETP assay using a standard amount o f LPDS.
TIM E = 0 TIM E = 2 WEEKS
TOTAL CHOLESTEROL 
(mM)
5.65 + /-  1-08 4.70 + /-  1.01*
HDL CHOLESTEROL 
(mM)
1.22 + /-  0.14 0.86 + /-  0.14**
TRIGLYCERIDE
(mM)
0.95 + /-  0.36 0.81 + /-  0 /34ns
CETP ACTIVITY 
using standard LP 
substrates
(%t/pg)
0.259 + /-  0/051 0.301 + /-  0.078ns
LCAT ACTIVITY 
(pm ol/hour/pg)
0.551 + /-  0.223 0.519 + /-  0.048ns
* = P<0.005 
** = PcO.OOl 
NS = not significant
TABLE 5.9 MEASUREMENTS OF PLASMA LIPIDS AND ENZYME ACTIVITIES IN 
HUMAN VOLUNTEERS TREATED WITH PROBUCOL - LARGE 
STUDY. Six human male volunteers were treated with 500mg probucol 
twice daily for two weeks. Blood samples were taken at the start and the 
finish of the experiment. Plasma total cholesterol, HDL cholesterol and tr i­
glycerides were measured. CETP activity and LCAT activity were 
measured in the LPDP using standard substrates.
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Using a standard LPDS and using LDL/VLDL or 3H -H D L S from  each volunteer it 
was seen that there was no difference in the ability of LD L/V LD L or HDL3 to act 
as substrates. LCAT activities were also not affected by probucol.
Thus the findings of the pilot study were not supported by the findings of the 
larger study. The effects seen were not statistically significant. The plasma CETP 
activities in the pilot study even after probucol treatm ent were at the low end of the 
range of values obtained for the six volunteers. Possibly fo r some reason CETP levels 
were depressed in the two volunteers prior to treatm ent and probucol returned them 
to a near normal value or they may have been returning to ’normal’ anyway.
In anticipation that the pilot study results where plasma CETP levels were 
increased in the post probucol samples would be repeated in the second study, samples 
of plasma from  the second study were sent to John Albers (Northwest Lipid Research 
Clinic, Seattle) who had offered to test whether there was any change in plasma 
CETP inhibitor levels after treatment. His analysis also ascertained that there was 
no significant difference in activity between control and treated samples (Fig. 5.2). 
Further analysis on these samples was carried out. Partially purified  CETP was added 
to each plasma sample and then the samples were assayed for total CETP activity. 
Significantly more activity was found in the post probucol samples and they concluded 
that the post probucol sample may contain less inhibitor than the control sample.
5.5.2 HMG CoA Reductase Inhibitor
The studies on Simvastatin were carried out in conjunction with Dr Luciano 
Comminacini at the Verona Institute. Plasma samples were sent from  patients who 
had received Simvastatin according to the dosing regime shown below: - 
TO - before starting therapy 
T45 - 45 days at lOmg per day 
T90 - 45 days at lOmg/day and 45 days at 20 m g/day 
T135 - 45 days at lOmg/day, 45 days at 20mg/day and 45 days at 30mg/day
T180 - 45 days at lOmg/day, 45 days at 20m g/day, 45 days at 30 m g/day and 45
days at 40m g/day.
A group o f eight patients was followed on this therapy. This group comprised 
four males and four females. All had Type Ha hyperlipidaemia. The plasma cholesterol 
levels and plasma CETP activities of this group are described in Fig. 5.10. At TO 
neither total cholesterol nor HDL cholesterol was significantly correlated to CETP 
activity.
Fig. 5.3 A and B follows each patient through the course of their treatm ent. 
The patients seem to fall into two groups. The first, Fig. 5.3A, contains patients 
whose measured parameters behave in a similar way to each..other throughout the 
experiment. Plasma total cholesterol levels fall, plasma HDL cholesterol levels rise 
and plasma CETP activities fall reflecting the fall in total cholesterol. The second 
group contains two patients; both show a fall in HDL cholesterol and one shows an
to
I—z
LJU
<
CL
X
</>
z
cr
QJ
LLcnz<cr
h-
LU
U
-Jo
u
D
CQ
Ocr
a
H*cno
Q.
Q
Z<
UJcr
CL
r ~
o
If>
i i i i i >i i i i i n i i i i i ! i i i i i i i m i i1warn
Bsssas
y m m m
fWmifrt
S t t
11&
J
\ S S « ^ S ^ f e S « S i
k4M0MiS iiP liiiiiiliP ^
•W t ^ ^ ^ J S ^ ^ .i P ^ l ^ ^ V l ^ liWUri,^ ^V<isPi!i<flicif0!9SSfitfiS!yVS>-!fS
n r“
o
V
T "
oro
~r~
O
CM
~i—
O
*0
If>
fO
CNJ
( 4 8 I /1 R  S Z / % )  «3 JS H V ai 33
FIGURE 5.2 CHOLESTERYL ESTER TRANSFER IN SIX VOLUNTEERS P R E - AND 
POST- PROBUCOL TREATMENT. This experiment was carried  out by Dr 
J. Albers’ laboratory, Northwest Lipid Research Clinic, Seattle. Partially 
purified CETP (25pl) was added to 2ml of each pre and post probucol sample. 
The samples were then assayed for total CETP activity.
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CHOLESTEROL
(mM)
CETP ACTIVITY
(%t/pg)
MEAN 10.4 0.273
MEDIAN 9.9 0.223
S.D. 1.9 0.116
MIN 8.6 0.189
MAX 14.1 0.508
TABLE 5.10 DESCRIPTION OF EIGH T VERONA HYPERLIPIDAEMIC PATIENTS.
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SIMVASTATIN -  SEHM INIASI
OATS
TIME COURSE OF TOTAL CHOLESTEROL, HDL CHOLESTEROL AND 
CETP ACTIVITY FOR EIGHT PATIENTS TREATED W ITH SIM VASTA­
TIN. Patients were treated with simvastatin according to the regim e described 
in the text. Total cholesterol, HDL cholesterol and CETP activ ity  were 
measured at 45 day intervals. The time course of the changes in these param eters 
is plotted. A) Six patients whose measured parameters vary in a sim ilar way 
to each other throughout the experiment. B) Two patients who showed a 
different pattern from the rest.
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increase in CETP activity. Looking over the information available for the patients 
the only thing that could be found that was remarkable about these two individuals 
was that one, Germiniasi, had the highest TG  of the group, and the other, M agnanini, 
had the lowest TG of the group and a very high plasma cholesterol level (14mM).
Plasma total cholesterol, HDL cholesterol and CETP activity were compared at 
T=0 and T=180 days (Table 5.11). There was a significant (P<0.001) 32% decrease 
in total plasma cholesterol. This would be expected as simvastatin is a hypocholes- 
terolaemic agent. HDL cholesterol was increased by 11% but this was not significant. 
HDL may play a protective role and so a fall in total cholesterol with a concomitant 
rise in HDL cholesterol will lead to a favourable LDLrHDL ratio. Plasma CETP 
activity was significantly reduced (P<0.01) by 41 %. A significant fall in CETP activity 
was seen to accompany the fall in plasma total cholesterol levels in this experiment 
with humans whereas a similar experim ent with marmosets, although showing an 
effect on total cholesterol demonstrated no effect on plasma CETP levels. There are 
two main differences between the studies. Firstly the time scale is quite different. 
The marmoset experiment was only over seven days whereas the hum an experiment 
was over 180 days. It is possible that there is a lag in any appearance of effect on 
CETP levels and so a change was not picked up in marmoset experiments. Secondly 
the group of humans which were being treated were very hypercholesterolaemic 
(mean total cholesterol level = 10.4mM) whereas the marmoset mean cholesterol was 
4.7mM. Thus a decreasing effect on plasma CETP activity may only be apparent if 
activity is raised in the first place as in hypercholesterolaemia. Neither total cholesterol 
nor HDL cholesterol were significantly correlated to CETP in this population.
TIME = 0 TIM E = 180 % CHANGE
TOTAL
CHOLESTEROL
(mM)
10.4 + /- 1.9 7.1 + /-  1.9 -32%*
HDL
CHOLESTEROL
(mM)
1.6 + /- 0.6 1.8 + /-  0.9 +1 1%ns
CETP ACTIVITY
(%t/pg)
0.273 + /- 0.116 0.160 + /-  0.065 -41%**
* '=  P<0.001 
** = P<0.05 
NS = not significant
TABLE 5.11 THE EFFECT OF SIMVASTATIN ON TOTAL CHOLESTEROL, HDL
CHOLESTEROL AND CETP ACTIVITY IN EIGHT HYPERLIPIDAEM IC 
PATIENTS. Patients were treated with simvastatin according to the regime 
described in the text for up to 180 days. Total cholesterol, HDL cholesterol 
and CETP activity were measured in the first and last samples.
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CHAPTER VI
REGULATION OF CETP SECRETION IN CELLS
1 Introduction
Cells have been demonstrated to secrete CETP in culture. Cell types studied include 
J774, a mouse m acrophage-like cell line [Tollefson, J.H. et al (1985)], HepG2, a human 
hepatoma [Faust, R.A. & Albers, J J .  (1987)], CaCo-2, an enterocyte cell line [Faust, 
R.A. & Albers, J J .  (1988)] and human monocyte derived macrophages [Tollefson, J.H. 
et al (1985)]. It is possible that these cells represent the cells responsible for CETP 
production in vivo. Obviously the mass of CETP protein is a contributing factor to the 
overall expression of CETP activity. Being able to understand what controls the secretion 
of this protein may help provide insight into the significance of CETP. The variety of 
cell types which express CETP secretion is in itself confusing. Which are the most 
relevant cell types to study? Liver cells, intestinal cells and macrophage cells all secrete 
the protein. Intestinal cells may be important if  CETP serves some post prandial function: 
plasma CETP activity is increased during alimentary lipaemia [Tall, A. et al (1986)] and 
free fatty  acids have been shown to increase CETP secretion by CaCo-2 cells. The liver 
is central to cholesterol metabolism and HepG2 cells have been shown to secrete CETP. 
Also CETP has been detected in liver perfusates, possibly due either to hepatocytes or 
K upffer cells. The liver may be able to secrete CETP in response to either hormones 
or in response to changes in plasma cholesterol levels. I f  CETP is involved in reverse 
cholesterol transport it would be im portant to regulate the am ount o f enzyme expressed 
so that cholesterol balance between the liver and the periphery  can be m aintained. Upsets 
in the balance may lead to atherosclerosis. Macrophages have been shown to be involved 
in lesion development and can form  lipid laden foam cells w ithin the lesion. CETP may 
be secreted by these cells in order to improve the flow o f cholesterol into or out o f cells. 
In this way CETP may be having localised effects.
There are a variety of hypothetical roles for CETP w ith the protein having either 
systemic or local actions. Studying the response of the cells to various effectors may 
highlight the importance of a particular mechanism. Culture systems can be very artificial 
and it is im portant to corroborate any findings by looking at the effect of any relevant 
effectors in vivo.
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FIGURE 6.1 TIME COURSE OF CETP SECRETION IN HUMAN MONOCYTE DERIVED 
MACROPHAGES, J774 CELLS AND HEPG2 CELLS. H um an m onocyte 
derived macrophages were isolated as described in the m ethods and plated 
into 6 well plates. They were cultured for 7 days and then washed in  serum -free  
medium and then incubated in serum -free medium for 8, 24 and 48 hours at 
37° C. HepG2 cells were plated into 6 well plates and cultured as described in 
the methods. When they had reached 90% confluence they were washed with 
serum -free medium. J774 cells were washed with serum -free m edium  and 
then plated into 6 well plates at a density of lxlO6 cells/m l/well. The HepG2 
cells and J774 cells were incubated in serum -free medium for 0, 18, 25, 42 
and 66 hours. At each time point conditioned medium was collected and frozen 
at -70° C until they were assayed fo r CETP activity. M acrophages (O), J774 ( •  
), HepG2 0 ). - -
TREATM ENT TRANSFER SECRETED 
INTO MEDIUM 
(%t/40pl)
CONTROL 9.7 + /- 3.8
CON A (lOpg/ml) 7
TP A (lOpg/ml) 16
EtOH (10pl) 9
LPS (lOpg/ml) 3
TGF(3 (lOng/m l) 7
LDL (200pg/ml) 11
PROBUCOL LDL (200pg/ml) 3
HDL (200pg/ml) 11
PROBUCOL HDL (200pg/ml) 6
AcLDL (200pg/ml) 4
pVLDL (200pg/ml) 3
TABLE 6.1 CETP SECRETION BY MACROPHAGES IN TH E PRESENCE OF VARIOUS 
EFFECTORS. Human monocyte derived macrophages were isolated and 
cultured for 8 days. The medium was then removed, the cells washed with 
serum free medium and the medium replaced with 1ml serum -free medium 
containing various agents as listed in the table. Cells were incubated in this 
medium for 24 hours at 37°C. The medium was then collected, frozen at -20° C 
and assayed for CETP activity.
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which were more likely to have specific effects. PMA (Fig. 6.2A) at a lower dose, 
had no significant effect on CETP secretion. LPS (Fig 6.2B) also at a more physiological 
dose of 500ng/ml had little effect on CETP secretion though in these cells very little 
CETP was secreted anyway. The effect of IL -1 , an im m unoregulator and local 
hormone, on CETP secretion by macrophages was also studied. F irstly IL-1 was tested 
at one concentration; lOng/ml over 48 hours. It appeared that IL-1 may have had 
some stim ulatory effect at 48 hours though again secretion in the control cells was 
low. When a 10 fold higher concentration o f IL-1 was tested over 24 hours no 
difference in CETP secretion was found between the control and either 10 or lOOng/ml 
IL-1 (Fig. 6.3).
Problems were encountered in the work with macrophages in that cells prepared 
from  differen t donors would behave very differently  from each other. Macrophages 
were obtained by harvesting blood circulating monocytes and differentiating them 
into macrophages by allowing them to adhere to a plastic culture plate coated with 
poly-D -lysine. Yields of cells found sticking to the plate varied largely between 
preparations. Also the amount of CETP secreted by cells from  d ifferen t donors varied 
a great deal. Since cells required autologous serum it was not feasible to pool blood 
from  differen t donors to try and even out discrepancies. Thus the macrophages were 
not a very useful line with which to continue the work since their properties were 
so inconsistent.
J774 cells are a mouse macrophage-like cell line. They secrete CETP and the 
effects of PMA and various agents which interfere with cholesterol metabolism were 
studied in this cell line. PMA had a slight stim ulatory effect on CETP secretion at 
48 hours (Fig 6.4) but again in this experiment cell secretion was barely measurable. 
A collection of, effectors which might affect the cholesterol balance of the cell were 
tested to see whether they had any effect on CETP secretion. These effectors were 
LDL, AcLDL and. two drugs; an HMGCoA reductase inhibitor, mevinolin (sodium 
salt), and an ACAT inhibitor, 58-035 (Sandoz). J774 cells can accumulate cholesterol 
in response to exposure to AcLDL. They take up this m odified LDL in an uncontrolled 
manner and store the cholesterol as CE in lipid droplets thus form ing foam cells. 
LDL is taken up by a receptor which is tightly controlled resulting in dow n-regulation 
o f the receptor and o f HMGCoA reductase, and up-regulation o f the esterifying 
enzyme ACAT. Fig. 6.5 shows the effects o f these treatm ents on CETP secretion by 
J774 cells. There was no significant effect w ith any of these agents at 40 hours. 
However it appeared that at 15 hours there was an increase in CETP secretion showing 
a peak with AcLDL, mevinolin and 58-035. It is d ifficult to explain how these 
treatm ents had the same effect. AcLDL should increase the CE content o f the cell, 
mevinolin should decrease the total cholesterol content of the cell and 58-035 should 
decrease the CE content but increase the FC content of the cell. Again the secretion 
in some of these studies was very low.
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FIGU RE 6.2 CETP SECRETION BY MACROPHAGES - EFFECT OF PH ORBOL 
MYRISTATE ACETATE (PMA) AND LIPOPOLYSACCHARIDE (LPS). 
Human monocyte derived macrophages were isolated and cultured in  80cm2 
culture flasks for 8 days (PMA) or 12 days (LPS). Tlie cells were washed with 
serum -free medium and then incubated with 20ml medium containing 40ng/m l 
PMA (A) or 500ng/ml LPS (B). M edium  was sampled at 0, 19, 24, 43 and 48 
hours (A) or 0, 16, 24, 39 and 49 hours (B). Sampled medium was frozen  at 
-70°Cand assayed for CETP activity using a sensitive CETP assay. £)) control 
cells, (•) treated cells.
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FIGURE 6.3 EFFECT OF INTERLEUKIN-1 (IL -1 ) ON CETP SECRETION BY HUMAN 
MONOCYTE DERIVED MACROPHAGES. Hum an monocyte derived 
macrophages were isolated and plated into 6 well plates. A fter 11 days in 
culture cells were washed with serum -free medium and then incubated in 
serum -free medium containing Ong/ml (O), lOng/ml (•) and lOOng/ml (□ ) 
IL-1. Conditioned medium was sampled at 0, 5, 17 and 24 hours and stored 
at -70° C. Medium was concentrated 4 fold using a M inicon concentrator and 
assayed for CETP activity.
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FIGU RE 6.4 THE EFFECT OF PMA ON CETP SECRETION BY J774 CELLS. J774 cells
were washed with serum -free m edium  and then cultured in  175cm2 tissue 
culture flasks containing 40ml m edium  and cells at a density o f lx l0 6 cell/m l. 
One flask contained control medium ®  and one flask contained m edium  with 
40ng/m l PMA (•). A t 0, 19, 24, 43 and 48 hours 1ml was sampled from  each 
flask, the cells removed by centrifugation and the medium frozen a t -70° C. 
CETP activity in the medium was assayed using a sensitive assay.
FIG U RE 6.5 THE EFFECT OF INCUBATION W ITH ACETYL LDL, LDL, M EVINOLIN
OR 58-035 ON CETP SECRETION BY J774 CELLS. Five m edium  culture 
flasks were set up with J774 cells in  serum-free medium at a density of 
0.5x106 cells/ml. Flasks were; control (O), AcLDL 50pg/ml (• ), m evinolin 
lOOnM 58-035 20pM (H) and LDL 50pg/ml ($ . Samples (1ml) from  each 
flask were taken at 0, 16, 24, 39 and 47 hours. Solution 4 (2ml) was added 
to each sample to bring the background density to 1.215g/ml and centrifuged 
fo r 3 hours in the Beckman TL100 centrifuge to remove the lipoproteins. 
Infranatant (2ml) was dialysed against Tris-saline buffer and then concentrated 
to 0.25ml using a Minicon concentrator and assayed fo r CETP activity.
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Similar studies were carried out in the HepG2 cells and the CaCo-2 cells. HepG2 
cells showed no response to PMA (Fig. 6.6). Of the treatm ents with AcLDL, LDL, 
mevinolin and 58-035, only LDL seemed to have a stimulatory effect at 24 hours 
(Fig.6.7). It was tested to see whether CaCo-2 cells could be stimulated to secrete 
more CETP with free fatty  acid. With the cells used here, this effect was not seen 
(Fig. 6.8). It is possible that the CaCo-2 cells used here were not d ifferentiated  enough 
to have form ed tight junctions and assembled their vectorial organisation.
In summary, although some effects were seen with IL-1 in hum an monocyte 
derived macrophages and with AcLDL, mevinolin and 58-035 in J774 cells the 
significance of these effects was d ifficult to determine since in general the amount 
o f CETP activity secreted was very low and the errors in the CETP assay m easurement 
were very large when the lim it for sensitivity of the assay (about 5% transfer) was 
reached. Thus measurement of CETP activity in cell media was not a satisfactory 
way of investigating the control o f CETP secretion. Had an antibody been available 
at the outset of this study then it could have been used to detect CETP in the medium 
by ELISA, dot-blotting or immunoelectrophoesis (if it was polyclonal).
3 Detection of CETP Messenger RNA levels in Cells
An alternative and more sensitive way of trying to ascertain the amounts o f CETP 
secretion is to measure the amount o f mRNA produced by these cells. The level of 
m RNA is not necessarily a direct measure of the amount of CETP secreted since all the 
mRNA may not be translated and all the protein may not be secreted. It will however 
give a good indication of whether gene transcription is being switched on due to regulation 
by certain effectors.
6.3.1 Probes
In order to detect mRNA from  cells a probe which will hybridise to the CETP 
mRNA sequence is required. A 75 base pair oligonucleotide was selected from  the 
hum an CETP cDNA sequence [Drayna, D. et al (1987)]. The oligonucleotide represents 
amino acid 126 to 150 of the CETP protein. The sequence was checked fo r homology 
to other known sequences by searching a computer database of structures, the ’Oligo’ 
datafile (Genetics Departm ent, Glaxo Group Reasearch Ltd, G reenford). The probe, 
GR91788X, was synthesised by Dr B. Coomber (Glaxo Group Research Ltd, 
Greenford) on a Biosearch oligonucleotide synthesiser. The properties o f this probe 
and that of the 1581 base pair full length cDNA probe (gift from  D. Drayna, 
Genentech, San Francisco) are shown in Table 6.2. A 25 base pair complementary 
prim er, GR91789X, was also synthesised for use in radiolabelling the probe.
Probes could be labelled using the random priming method [Feinberg, A.P. & 
Vogelstein, B. (1984)] though in the case of GR91788X its specific prim er GR91789X 
was used rather than random primers. Table 6.3 show the percentage incorporation 
and specific activities of all the probes used in these studies. They were all labelled 
to similar extents and to similar specific activities, The actin probe was used as a
TinC (hour*)
FIG U RE 6.6
FIG U RE 6.7
TH E EFFECT OF PMA ON CETP SECRETION BY HEPG2 CELLS. Two 
175cm2 flasks o f HepG2 cells were allowed to reach 90% confluence. The 
cells were washed with serum-free medium and then incubated in se rum -free  
medium at 37° C (O) or serum -free medium containing 40ng/m l PM A (•). 
Samples (1ml) were taken at 0, 19, 24, 43 and 48 hours, centrifuged b riefly  
to remove cell debris and frozen at -70°C. Samples were assayed fo r CETP 
activity using a sensitive assay.
TH E EFFECT OF INCUBATION W ITH ACETYL LDL, LDL, M EVINOLIN 
OR 58-035 ON CETP SECRETION BY HEPG2 CELLS. HepG2 cells were 
plated onto 6 well plates. When they were 90% confluent the cells were washed 
with serum -free medium and then incubated with serum -free m edium , control 
(O) or serum -free medium containing AcLDL 50pg/ml (•), m evinolin lOOnM 
(R), 58-035 20pM M  and LDL 50pg/ml Medium (1ml) was sam pled a t 0, 
4 and 24 hours. Solution 4 (2ml) was added and the samples centrifuged fo r 
3 hours in a Beckman TL100 tabletop centrifuge to remove the lipoproteins. 
Infranatants were dialysed against Tris-saline buffer, concentrated to 0.25ml 
and assayed fo r CETP activity.
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FIGU RE 6.8 TH E EFFECT OF FREE FATTY ACIDS ON THE SECRETION OF CETP 
BY CACO-2 CELLS. CaCo-2 cells were cultured to 2 weeks post confluence 
in  Trans wells. Each well was tested fo r its resistance and only cells with 
resistance >3000 measured with a voltm eter were used. Cells were washed 
w ith serum -free medium and then incubated in serum -free m edium  (O) or 
serum -free medium containing 0.5mM sodium oleate (•), made as described 
in  the methods section. Samples were taken at 0 ,5 ,1 6  and 24 hours, centrifuged 
to remove cell debris and frozen at -70° C. Medium was concentrated four 
fold using a Minicon concentrator and assayed for CETP activity.
GR91788X CETP cDNA
SOURCE B. Coomber 
Glaxo
D. Drayna 
Genentech
CODING
SEQUENCES
a.a. 126-150 a.a. 8-476 
+178 untranslated
SIZE 75 bp 1581 bp
% C or G 54 54
SENSITIVITY OF 
DETECTION - 
THEMSELVES
0.5 pg
i
at least 0.5pg
SENSITIVITY OF 
DETECTION - 
EACH OTHER
lOpg O.lpg
TABLE 6.2 PROBES FOR THE CETP GENE. GR91788X was an oligonucleotide probe 
synthesised by B. Coomber (Glaxo Group Research Ltd, G reenford) and the 
CETP cDNA was a g ift from D.Drayna (Genentech, San Francisco).
PROBE n INCORPORATION
(%)
SPECIFIC ACTIVITY 
(dpm/pg)
GR91788X 7 62.7 + /- 16.2 2.2xl09 + /-  0 .6xl09
CETP cDNA 6 63.5 + /- 15.4 2 .3xl09 + /-  0 .4xl09
ACTIN 2 54.5 + /- 6.4 1.4xl09 + /-  O.lxlO9
TABLE 6.3 INCORPORATION OF LABEL INTO AND SPECIFIC ACTIVITY OF 
PROBES USED FOR HYBRIDISATION.
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control as the mRNA for actin should be expressed in all cells, although when cells 
undergo division then actin message will increase as new protein is being synthesised, 
and confluent cells may not produce very much.
Once probes were available, suitable hybridisation conditions had to be found 
which would produce a specific signal for each probe. This was done by starting at 
the calculated (38.6°C, see Appendix 2) for GR91788X and decreasing the 
tem perature in small stages to find the best hybridisation conditions. The actin probe 
was provided commercially (Oncor) and Terry Baker (Glaxo Group Research Ltd, 
G reenford) advised o f hybridisation conditions. The cDNA probe was provided by 
Dr D Drayna (Genentech) and I was advised of hybridisation conditions by Dr D 
G affney (Royal infirm ary, Glasgow). The hybridisation conditions chosen are shown 
in Table 6.4.
6.3.2 Slot Blots
Initially slot blots of DNA and RNA were carried out to see whether 
hybridisation to the probe could be detected and to see how quantitative it was. The 
cDNA probe can be detected to 50pg and GR91788X to 0.5pg by hybridisation to 
GR91788X. Using the technique of slot blotting it was possible to detect 20 to 50 
Mg RNA from  cells (Fig. 6.9) DNA from J774 and HepG2 cells and macrophages had 
strong signals upon hybridisation to GR91788X. The J774 total RNA signal could 
be seen clearly at 50pg loading and a signal with macrophage RNA at lOOpg loading. 
There was only a faint hybridisation with HepG2 and macrophage total RNA at 50pg. 
There was no strong cross reactivity with yeast or calf liver rRNA which meant that 
message need not be purified as hybridisation can be carried out on total RNA 
without the rRNA interfering. However what was becoming clear from  this blot was 
that hybridisation did not appear to be quantitative using this system e.g. 50pg 
macrophage RNA shows much less than 50% of the signal from  the hybridisation to 
lOOpg macrophage RNA. This may have been due either to unequal loading onto the 
slot blot or to the fact that the probe sometimes finds one area o f the filter more 
accessible than another. This point was reemphasised in another blot (Fig 6.10) where 
hybridisation to untreated cell RNA was compared to RNA from  cells treated with 
PMA. The signal was not proportional to the am ount o f RNA loaded so it was 
impossible to tell whether PMA had increased or decreased mRNA production. For 
J774 and HepG2 cells it did appear that the hybridisation signal was stronger for the 
RNA from treated cells. In this blot yeast rRNA did hybridise at lOOpg.
6.3.3 RNA Gels
A more sensitive and quantitative way of detecting mRNA levels is a nuclease 
protection assay. In this assay probe is hybridised to mRNA in solution. The mix is 
then treated with Sx nuclease which digests any single stranded DNA, so that the 
probe protects the region of interest. The product can be run on a gel and the product 
detected by autoradiography.
+ /-  FORM AM IDE HYBRIDISATION
TEMPERATURE
(°C)
WASHING
TEM PERA TU RE
(°C)
GR91788X + 35 35
CETP cDNA - 65 65
ACTIN + 42 60
TABLE 6.4 HYBRIDISATION CONDITIONS FOR PROBES USED.
SAMPLE GR91788X
GR91788X +
CETP cDNA +
CALF LIVER rRNA -
YEAST rRNA +
TOTAL RNA CaCo2 -
J774 -
macrophage -
HepG2 -
mRNA CaCo2 -
J774 -
macrophage -
HepG2
TOTAL RNA -
RABBIT LIVER
mRNA -
RABBIT LIVER
TABLE 6.5 SUMMARY OF HYBRIDISATION RESULTS, Samples were prepared,
electrophoresed on formaldehyde gels and Northern blotted onto H ybond-N  
as described in the methods. Membranes were probed with GR91788X and 
autoradiographed to detect any hybridising bands. + denotes hybridisation,
- denotes no hybridisation.
FIGURE 6.9 SLOT BLOT OF J774, HEPG2 AND MACROPHAGE RNA AND DNA. Sample
preparation, blotting onto Hybond-N  and hybridisation to GR91788X were 
carried out as described in the methods section. Rows 1 to 3: 10, 1 and 0.1 pg 
GR91788X; Row 4: 5, 10 and 20pg J774 DNA; Row 5: 5, 10 and 20pg HepG2 
DNA; Row 6: 5, 10 and 20pg macrophage DNA; Row 7: 20 and 50pg J774 
RNA; Row 8: 20 and 50pg HepG2 RNA; Row 9: 20, 50 and lOOpg macrophage 
RNA; Row 10: 5, 10 and 20pg calf liver ribosomal RNA; Row 11: 5, 10 and 
20pg yeast rRNA.
FIGURE 6.10 SLOT BLOT OF RNA FROM CONTROL AND PMA TREATED J774 CELLS, 
HEPG2 CELLS AND MACROPHAGES. RNA and DNA was prepared from  
cells cultured in the presence or absence of 40ng/ml PMA for 48 hours as 
described in the methods section. Samples were prepared, loaded onto a slot 
blot and hybridised to GR91788X. Row 1 to 3: 50, 5 and 0.5pg GR91788X; 
Row 4 and 5: 10pg DNA from control J774 cells, HepG2 cells and macrophages 
in duplicate; Row 6: control RNA J774 (50pg), HepG2 (30pg) and m acrophage 
(90pg); Rows 7 to 12: the first two slots of each row a re '20 and 50pg RNA, 
row 7 J774 control, row 8 J774 PM A -treated, row 9 HepG2 control, row 10 
HepG2 PM A-treated, row 11 macrophage control, row 12 macrophage 
PM A-treated; Rows 13 to 17: 5, 10 and 20pg DNA, row 13 J774 control, row 
14 J774 PM A-treated, row 15 HepG2 control, row 16 HepG2 PM A -treated , 
row 17 macrophage PM A-treated; Row 18 and 19: yeast and calf liver rRNA 
at 20 and 100pg
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Prior to attempting this assay it is necessary to check that the mRNA from  
cells can be detected on a denaturing gel and that the probe will recognise the mRNA 
band of the correct length for CETP 1900 + /-  50 base pairs [Drayna, D. et al (1987)]. 
When total RNA is run on a formaldehyde gel the two ribosomal 28s and 21s bands 
can be seen after staining by ethidium  bromide with the mRNA running as a smear 
in  between. If  the RNA is degraded then a lot o f low molecular weight m aterial can 
be seen.
When total RNA or mRNA from  J774, HepG2 and CaCo-2 cells and from  calf 
liver were run on formaldehyde gels, no hybridising band could be detected although 
the probe could detect itself and the cDNA (Table 6.5). Others have detected CETP 
message in human liver and other tissues but not in HepG2 or U937 cells [Drayna, 
D. et al (1987)]. There are two possible reasons why this might be the case. E ither 
the RNA is being degraded or the CETP message is present at very low concentration. 
The extent of RNA degradation can usually be seen on the formaldehyde gels. Usually 
some smearing o f degraded RNA can be seen below the lower ribosomal band but 
most of the RNA appears intact. However if  the CETP RNA is particularly susceptible 
to degradation then it is possible that most o f the CETP message is lost during the 
RNA preparation. If it is just that the CETP message is present in a very low amount 
then another gene message which should be present in high concentration (e.g. actin) 
should be easily detectable. For detecting CETP message from  different animal tissues, 
Drayna et al [Drayna, D. et al (1987)] used 15pg of mRNA. The gels run here had 
only 20pg total RNA or 2pg mRNA. As the m RNA band is likely to be more diffuse 
after electrophoresis on an agarose gel then it may be more difficult to detect than 
on a slot blot. When a large amount o f RNA (200pg) from  HepG2, J774 and CaCo-2 
cells was run on a formaldehyde gel and probed with an actin probe then for each 
lane two bands could be seen; one occurring between the 28s and 21s ribosomal RNA 
bands which corresponds to the actin message and a low molecular weight smear 
which probably represents fragments of degraded actin message. Thus it appears that 
both problems are occurring. Degradation of the RN A preparation is obviously taking 
place but despite this actin hybridisation can still be seen. It can be assumed that 
CETP message in the preparations will be being degraded. Since Drayna et al used 
large quantities of RNA check to detect message from  tissues then the CETP message 
is probably present in low amounts. To improve detection on these N orthern blots 
the RNA purification and electrophoresis conditions need to be improved so that 
degradation does not occur. One way of trying to improve detection of the signal is 
to am plify the message that is there using the polymerase chain reaction (PCR).
6.3.4 Polymerase Chain Reaction of CETP
Work was started to try and use PCR to am plify the CETP message. This would 
indicate whether the message was present and w hether the failure to detect it was 
due to limits in sensitivity of detection. Suitable prim ers were selected such that a 
region o f the CETP message that could be detected by GR91788X would be am plified.
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Primers were chosen according to several criteria; they were 20 base pairs long, ended 
with a G  or C, contained approximately GC:AT content and contained no runs or 
simple repeats. Two sense and two antisense primers were chosen with approximately 
200 to 300 base pairs separating the sense prim er from  the antisense prim er (Fig. 
6.11). This 200 to 300 nucleotide stretch was complementary to the GR91788X probe. 
These prim ers were found to work successfully as prim ers using the CETP cDNA 
as a template (Fig. 6.12). Preliminary attempts to am plify this CETP sequence using 
RNA from  J774, U937, HepG2 and CaCo-2 cells met with lim ited success. Only the 
J774 m RNA gave a weak band corresponding to the appropriate length for the 
message which would be expected with the primers used. Limitations on time precluded 
fu rther investigations here. It will require a lot more work to find  the optimal 
conditions for detecting the CETP message using this system.
SENSE PRIM ERS 1 5’ GAAGTATGGCTACACCACTG 3’
2 5’ GTCCATTGACTTCGAGATCG 3’
ANTISENSE PRIMERS 3 5’ CGGCCATGATGTTAGAGATG 3’
4 5’ CTCCATCTGAAAGGATGCTG 3’
FIGURE 6.11 PRIMERS FOR AMPLIFICATION OF CETP CODING SEQUENCE BY 
THE POLYMERASE CHAIN REACTION.
-I r \ n  A
FIGU RE 6.12 POLYMERASE CHAIN REACTION USING CETP cDNA AS A TEM PLATE.
The polymerase chain reaction was carried out as described in the methods 
using lng cDNA as a template and primers 1 and 3, lane 1; prim ers 1 and 4, 
lane 2; primers 2 and 3, lane 3; primers 2 and 4, lane 4.
89
CHAPTER VII
RESTRICTION FRAGMENT LENGTH POLYMORPHISMS OF THE CETP GENE.
1 Introduction
Genetic factors may play a role in the development of atherosclerosis. Restriction 
fragm ent length polymorphisms (RFLPs) have been used to study the variability in the 
genes of proteins associated with cholesterol metabolism. M utations of genes can be 
detected when they alter the recognition sites for restriction enzymes. Digestion o f DNA 
with these enzymes will result in d ifferen t sizes o f genomic DNA depending on the 
frequency of the restriction sites. The fragm ents can be separated by gel electrophoresis 
and fragments from  the gene of interest can be detected by their hybridisation to a gene 
probe. If  variation can be detected in candidate genes then it is possible to investigate 
w hether this genetic variation is related to an individual’s phenotype. RFLPs may be at 
the site of the m utation, or more likely, may be linked to the site of the mutation.
There appears to be a negative correlation between plasma HDL cholesterol levels 
and plasma CETP activity [Tollefson, J.H. et al (1988)] and animals which have low 
HDL levels have high CETP activities and vice versa [Ha, Y.C. & Barter, P.J. (1982), 
Chapm an, M.J. (1986)]. Within the human species, individuals with extremely high HDL 
cholesterol, hyperalphalipoproteinaemics, have low or absent CETP activity [Koizumi, 
J. et al (1985), Kurasawa, T. et al (1985)]. Since HDL levels seem to be related to CETP 
activity  it was decided to investigate whether variation in the CETP gene (as detected 
by RFLPs), was related to plasma levels of the enzyme and whether this also might be 
reflected in plasma HDL levels. The cDNA of the hum an CETP gene has been cloned 
[Drayna, D. et al (1987)] and was made available by D r D Drayna, Genentech. Two 
RFLPs of the CETP gene had already been detected using the restriction enzyme TaqI 
[Drayna, D. & Lawn, R. (1987)]. The TaqlA polymorphism can be detected as fragm ents 
o f two lengths; A x 7.5kb and A2 9.0kb, occurring with frequencies o f 0.88 and 0.12 
respectively. The TaqlB polymorphism can be detected as fragm ents of Bj 4.4kb and B2 
5.3kb o f frequencies 0.52 and 0.48 respectively. The frequencies for both these poly­
m orphisms were measured in a population o f 32 subjects.
2 Polymorphisms of the CETP Gene
A battery o f restriction enzymes were tested to see whether any further RFLPs o f 
the CETP gene could be detected. A group o f 10 individuals were chosen from  a 
population of 65 individuals selected from an opportunistic screening programme. These
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individuals were those with the five highest and the five lowest HDL levels. If any 
polymorphism were to occur at a reasonable frequency, i.e. greater than 0.1, then it 
would probably be detected within this small group.
The 1581 bp cDNA CETP clone was initially used to hybridise to the fragments 
produced by the enzyme. The CETP gene was not polymorphic for the restriction enzymes 
A lul, A pal, BamHI, Banll, Bgll, Bglll, BstEII, Clal, D ral, EcoRI, EcoRV, H aelll, HincII, 
H ind lll, H infl, Hhal, Hpal, K pnl, PstI, PvuII, Rsal, Sail, Smal, Sstll, X bal and Xhol. 
The CETP gene was however polymorphic for the restriction enzyme StuI [Freeman, D. 
et al (1989)]. This was detected as a pattern of three invariant bands; 5.8kb, 4.8kb and 
3.4kb, and the presence (Si) or absence (S2) of a 4.0kb band. Detection o f this 4.0kb 
band was difficult. To try and improve detection a shorter, 732bp, fragm ent of the 
CETP cDNA probe was used (work carried out by Dr Dairena Gaffney, Royal Infirm ary, 
Glasgow). This was obtained by digesting the 1581 bp probe with PstI and PvuII restriction 
enzymes and corresponds to bp 677 to 1409 of the published sequence [Drayna, D. et 
al (1987)]. The StuI blots from the 10 individuals were reprobed with this smaller probe 
and it was found that two allelic fragments at 4.0 and 4.3kb could be detected (Fig. 1), 
in addition to the invariant 3.4kb band. It thus appears that the Sx allele at 4.0kb was 
being detected previously but that the hybridisation signal of the larger probe to the 
4.3kb band was not strong enough to be seen. This may be because the three invariant 
bands at 5.8, 4.8, and 3.4kb, obtained when probing with the large 1581 bp probe, 
hybridised strongly to the labelled probe while the 4.0 and 4.3kb bands hybridised only 
weakly. The small probe did not hybridise to the larger invariant bands and therefore 
the 4.0 and 4.3kb bands could hybridise more probe and a stronger signal was discerned. 
Once the polymorphism was detected the whole population of 65 individuals was screened. 
From  the 42 results obtained (the other results were ambiguous) the frequency o f the 
Sx (4.0kb) allele was calculated to be 0.92 and the frequency of the S2 (4.3kb) allele was 
0.08. Only individuals with the Sj band alone and both bands together were detected. 
These were classified as homozygotes and SiS2 heterozygotes respectively.
Mendelian codominant inheritance was dem onstrated in one family (Fig. 1). The 
first six tracks were probed with the 1581 bp probe. As can be seen it is d ifficu lt to 
determ ine which individuals express the 4.0kb band. The mother (A in Fig. 1) is SiS2 
and the father (B) is SjSj . The son (C) has inherited the S1S1 genotype and the daughter 
(D) has inherited the genotype.
The TaqlA and B polymorphisms were also detected in this population. It was 
found that using a 362 bp probe which corresponded to amino acids 8 to 128 in the 
m ature protein, obtained by EcoRI and PvuII double digestion of the 1581 bp CETP 
cDNA, that the detection of the TaqlB polymorphism was much clearer. Dr Dairena 
G affney, Royal Infirm ary, Glasgow, produced the 362bp probe and carried out any 
reprobing of ambiguous blots.
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3 A Study to Investigate the Relationship of RFLPs of the 
CETP Gene to Plasma Lipid Parameters 
7.3.1 Strategy
The aim of this study was to examine the possibility that variation in the CETP 
gene may be associated with alterations in the activity of plasma CETP and plasma 
HDL cholesterol levels. Plasma LCAT activity was also measured since the CETP 
and LCAT genes are in close proximity on chromosone 16; 16q21 and 16q22 
respectively. It is possible the variation detected in the CETP gene may be marking 
a linked m utation in the LCAT gene. Besides these two enzyme activities, plasma 
total and HDL cholesterol were measured.
F ifty -six  individuals were selected from  an opportunistic screening programme 
in Glasgow on the basis of their HDL levels. Normotryglyceridaemic (<3.0mM) 
individuals with low HDL levels (<lm M ) or high HDL levels (>2.5mM for females 
and >2.0mM for males) were selected. Plasma total cholesterol, HDL cholesterol, 
CETP activity and LCAT activity were measured. The individuals were also typed 
for the TaqI and StuI polymorphisms of the CETP gene and the MspI and PstI 
polymorphisms of the apoAI gene [Coleman, R.T. et al (1986)]. RFLPs of the apoAI 
gene were studied since apoAI is a component of HDL and a cofactor of LCAT and 
it was necessary to see whether any trends in the lipid parameters were associated 
with variation in this gene. It would also give an indication of gross disturbances of 
lipid param eters or genes in this population. No polymorphisms of the LCAT gene 
have yet been detected. The lengths of the polymorphic fragments detected by 
hybridisation to CETP or apoAI gene probes are shown in Table 7.1. The genotype 
frequencies are also shown. The allele frequencies for the TaqlB polymorphism d iffer 
from  those obtained by others [Drayna, D. & Lawn, R, (1987)]. This may be due to 
differences in the selected populations as both sample sizes are rather small. All 
statistical analyses were carried out by Marion Chatfield, Glaxo Group Research Ltd, 
Ware.
7.3.2 Cholesterol Levels
Total cholesterol levels were measured in 48 individuals from the population 
and were found to be normally distibuted. For each polymorphism, the num ber, 
mean, standard deviation and range of the cholesterol measurements is given for each 
genotype within the polymorphism (Table 7.2). T -tes t and analysis o f variance were 
then used to test whether total cholesterol levels d iffered between the genotypes. 
There was no significant difference between the total cholesterol levels o f each 
genotype group for any of the polymorphisms.
POLYMORPHISM FRAGM ENT
LENGTHS
(kb)
GENOTYPE
FREQUENCY
ALLELE
FREQUENCY
TaqlA A i A2 A iA i A iA 2 A2A2 A i a 2
7.5 9.0 43 6 0 0.94 0.06
TaqlB Bi b 2 BjB, Bi B2 b 2b 2 Bi b 2
4.4 5.3 26 19 11 0.63 0.37
StuI SiSx SiS2 SiSi SjS2 Si S2
4.3 4.0 34 8 0.90 0.10
PstI Pi P2 PiP i PiP2 P2P2 Pi P2
2.2 3.3 43 6 0 0.94 0.06
MspI M j m 2 M iM i M XM2 m 2m 2 M x m 2
0.67,1.08 1.75 42 11 0 0.90 0.10
TABLE 7.1 POLYMORPHISMS OF THE CETP AND APO Al GENES. The TaqlA,
TaqlB and StuI polymorphisms are linked to the CETP gene. PstI and MspI 
polymorphisms are linked to the apo Al gene. For TaqlA and TaqlB 
number of individuals n=56, PstI n=49, MspI n=53 and for StuI n=42. In 
some instances technical difficulties precluded satisfactory assignment of 
genotype.
POLYMORPHISM STATISTIC TOTAL CHOLESTEROL (mM) PROBABILITY
OF
SIMILARITY
TaqlA GENOTYPE 
No. 
MEAN 
STD. DEV. 
RANGE
A iA i A i A2
42 6
6.18 5.48
1.10 0.88
4.25,8.70 3.85,6.45
BiB, BiB2 B2B;
25 15 8
6.39 5.64 6.01
1.01 1.20 0.93
0.15
TaqlB GENOTYPE 
No. 
MEAN 
STD. DEV. 
RANGE 4.80,8.70 3.85,8.40 5.00,8.00
0.11
StuI GENOTYPE 
No. 
MEAN 
STD. DEV. 
RANGE
SiSx
34
6.15
1.23
3.85,8.70
SiS2
7
5.96
0.74
5.05,7.15
0.70
PstI GENOTYPE 
No. 
MEAN 
STD. DEV. 
RANGE
PiPl
42
6.08
1.07
4.25,8.70
P 1 P 2
6
6.19
1.34
3.85,7.50
0.81
MspI GENOTYPE 
No. 
MEAN 
STD, DEV. 
RANGE
MiMx
37
6.07
1.14
3.85,8.70
M jM 2
9
6.22
1.06
4.80,8.00
0.72
TABLE 7.2 TOTAL CHOLESTEROL LEVELS AND POLYMORPHISMS. For each 
polymorphism the number, mean, standard deviation and range of total 
cholesterol (mM) is given. T-tests and analysis o f variance were used to 
test whether total cholesterol differed between genotypes.
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7.3.3 HDL Cholesterol
HDL levels were measured before and after recall and the average used for 
analysis. There were 39 individuals in the low HDL group (28 males and 11 females) 
and 17 individuals (7 male and 10 female) in the high HDL group. Table 7.3 shows 
for each polymorphism the num ber of individuals of a particular genotype in the 
high or low HDL group. A Fisher’s Exact test was carried out ot test whether the 
distribution of genotypes in the high and low HDL groups d iffered  between the two 
groups. For the TaqlB polymorphism the difference in distribution o f individuals 
between genotypes B ^ ,  BXB2 and B2B2 in the high and low HDL groups was 
significant (P=0.0014). Class BjBj has 62% of the individuals in the low HDL group 
but only 12% of the patients in the high HDL group. There was no significant 
difference (P>0.05) between the proportion of individuals of each genotype between 
the two HDL groups for the other polymorphisms.
HDL levels are affected by sex; females tend to have higher HDL levels than 
males; thus it is im portant to look at the sexes separately. Table 7.4 divides the TaqlB 
data into males and females. The number of individuals in each class of the poly­
morphism (and the percentage of the total for the group) are given fo r high and low 
HDL groups and shown for males and females separately. The difference between 
high and low HDL groups in the percentage of individuals occuring in each poly­
morphism class is calculated for males and' for females. It can be seen that the 
differences between high and low HDL groups are similar for both males and females. 
The numbers in each group are too small for this to be tested statistically. Since the 
observation that a large percentage of low HDL individuals are BjBx and a low 
percentage of high HDL individuals are BjBj is seen both for males and for females 
the data can be combined.
There was no difference in cholesterol level (P=0.12) or LCAT activity (P=0.48), 
using t-tests, between the high and low HDL groups. CETP activity did significantly 
d iffer (P=0.006), using a Wilcoxon signed rank test, between the two groups; median 
CETP activity in the low group was 0.15 %t/pgLPDS/2.5 hours and m edian CETP 
activity in the high HDL group was 0.11 %t/pgLPDS/2.5 hours.
7.3.4 Plasma CETP Activity and LCAT Activity
CETP activity did not appear to be normally distributed in this population. 
CETP activity is summarised for each genotype for each polymorphism in Table 7.5. 
The Wilcoxon signed rank test or Kruskal Wallis test were used to examine whether 
CETP activity d iffered between genotypes for each polymorphism. There was a 
significant difference between the classes of the TaqlB (P=0.01) polymorphism and 
a nearly significant (P=0.057) difference between the classes of the StuI polymorphism.
POLYMORPHISM LOW HDL GROUP 
No(%)
HIGH HDL GROUP 
No(%)
PROBABILITY 
OF SIMILARITY 
IN PERCENTAGES
TaqI AjAj 35(91) 8(80) 0.59
A iA 2 4(9) 2(20)
BiBx 24(62) 2(12)
BiB2 10(26) 9(53) 0.0014
b 2b 2 5(12) 6(35)
StuI SjSj 27(79) 7(88) 1.0
SiS2 7(21) 1(12)
PstI PiPi 33(85) 10(100) 0.32
PiP2 6(15) 0(0)
MspI MiMj 30(81) 12(75) 0.72
MXM2 7(19) 4(25)'
TABLE 7.3 DISTRIBUTION OF INDIVIDUALS BETWEEN H IG H  AND LOW HDL 
GROUPS. For each polymorphism the number of individuals of a particu­
lar genotype is given for high (HDL cholesterol >2.0mM for men, >0.25mM 
for women) or low HDL (HDL cholesterol <1.0mM) groups. This is also 
expressed as a percentage of the total number of individuals in that group. 
A Fisher’s Exact test was used to test whether the distibution of genotypes 
in high and low HDL groups differed between the groups.
POLYMORPHISM MALES 
LOW HDL
MALES 
HIGH HDL
DIFF
%
FEMALES 
LOW HDL
FEMALES 
HIGH HDL
DIFF
%
NO. (%) NO. (%) NO. (%) NO. (%)
BiB, 17 (61) 0 (0) -61 7(64) 2 (20) -44
BiB2 7 (25) 4(57) 32 3 (27) 5 (50) 23
b 2b 2 4 (1 4 ) 3(43) 29 1 (9) 3 (30) 21
TABLE 7.4 DISTRIBUTION OF INDIVIDUALS BETWEEN H IG H  AND LOW HDL
GROUPS FOR MALES AND FEMALES. The data from  Table 7.3 is shown 
for the TaqlB polymorphism. The data for males and females are displayed 
separately. The difference in the percentage of individuals in the high and 
low HDL groups is given for each class of the polymorphism.
POLYMORPHISM STATISTIC CETP ACTIVITY 
(%t/pg LPDP protein)
PROBABILITY
OF
SIMILARITY
TaqlA GENOTYPE
No.
MEDIAN
QUARTILES
RANGE
A jA i A jA2
43 6 
0.157 0.133 
0.114,0.204 0.127,0.141 
0.069,0.590 0.124,0.235
0.63
TaqlB GENOTYPE
No.
MEDIAN
QUARTILES
RANGE
BiBi BjB2 B2B2 
26 19 11 
0.181 0.124 0.139 
0.140,0.209 0.110,0.157 0.070,0.162 
0.075,0.590 0.078,0.235 0.056,0.227
0.010
StuI GENOTYPE
No.
MEDIAN
QUARTILES
RANGE
SiSi SjS2 
34 8 
0.145 0.210 
0.123,0.199 0.160,0.231 
0.069,0.445 0.070,0.590
0.057
PstI GENOTYPE
No.
MEDIAN
QUARTILES
RANGE
PiP i P1P2 
43 6 
0.150 0.148 
0.122,0.204 0.140,0.164 
0.069,0.590 0.085,0.180
0.65
MspI GENOTYPE
No.
MEDIAN
QUARTILE
RANGE
M jM j M jM2
42 11 
0.143 0.139 
0.110,0.200 0.088,0.162 
0.056,0.590 0.069,0.180
0.28
TABLE 7.5 PLASMA CETP ACTIVITY AND POLYMORPHISMS. For each poly­
morphism the num ber, median, quartiles and range of CETP activity (% 
transfer/pg LPDP protein) are given. The Wilcoxon signed rank test and 
Kruskal Wallis test were used to test whether CETP activity differed 
between genotypes. Quartiles are defined such that the % of observations 
below them is 25 and 75 respectively.
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Plasma LCAT activity was log normally distributed in this population. A 
summary o f LCAT activity for each genotype for each polymorphism is shown in 
Table 7.6. Using t-tests and analysis of variance it was observed that only in the case 
of the MspI polymorphism of the apoAI gene did LCAT activity significantly d iffer 
between genotypes M XM! and M XM2 (P=0.003).
7.3.5 Summary
This study set out to examine whether genetic variation at the CETP gene may 
have an influence on plasma HDL cholesterol levels. The relationship between 
polymorphisms in the CETP gene, apoAI gene and HDL levels was investigated in 
56 unrelated individuals with high or low HDL levels. RFLPs o f the apoAI gene 
were included to check for disturbance in the apoAI gene [Ordovas, J.M. et al (1986), 
Kessling, A.M., Horsthemke, B. & Humphries, S.E. (1985)] which may affect HDL 
levels. The apoAI polymorphisms were not related to HDL cholesterol or plasma 
CETP activity in this population but there was a significant relationship between the 
MspI polymorphism and plasma LCAT activity. MjMx individuals had lower plasma 
LCAT activities than M XM2 individuals. Since the d>1.215g/ml fraction of plasma 
used to assay the enzyme will contain some apoAI stripped from  the individuals’ 
HDL during ultracentrifugation, this relationship may be merely reflecting the ability 
of the individuals’ apoAI to act as a cofactor for LCAT. However a large excess of 
exogenous apoAI is added to the LCAT assay and should overcome any of this 
variability. This observation needs to be confirmed in a larger sample population.
CETP may have a strong influence on HDL levels. It was found that the low 
HDL group of individuals had a 40% higher median CETP activity than the high 
HDL group. While the TaqlA polymorphism of the CETP gene showed no relationship 
to HDL cholesterol or CETP activity, the TaqlB polymorphism was significantly 
related to both these parameters. Individuals with the B2 allele were more likely to 
have high HDL levels and low CETP activity. The StuI polymorphism showed a near 
significant link with CETP activity but not with HDL cholesterol. Since the TaqlB 
polymorphism can be detected by the 362bp probe (amino acids 8 to 128) then this 
indicates that the polymorphism is towards the 5 prime end of the gene. Since it 
appears from  the genomic sequence that the CETP gene is made up of many short 
exons interrupted by large introns [Agellon, L.B. et al (1989)] it is possible thet the 
variable site occurs within an intron. It is not known whether this effect on CETP 
activity is an effect on protein mass or CETP inhibitor. The whereabouts of the 
CETP inhibitor gene is unknown. Since none of the polymorphisms in the CETP 
gene were associated with LCAT activity it is unlikely that the results can be attributed 
to a change in the LCAT gene which is in linkage disequilibrium  with a CETP 
polymorphism. There has been a report [Borresen, A -L . et al (L987)] where an effect 
of haptoglobin subtypes on serum HDL levels was demonstrated. They suggested that 
this result may be due to linkage to LCAT. From the data presented here, it is possible 
that the result is due to linkage to the CETP gene.
POLYMORPHISM STATISTIC LCAT ACTIVITY 
(pm ol/hr/pgLPDP protein)
PROBABILITY
OF
SIMILARITY
TaqlA GENOTYPE
No.
GEOMETRIC MEAN 
RANGE 
LOG MEAN 
LOG STD. DEV.
A 1A 1
43
0.366
0.186-0.962
-1.01
-5.53
A i A2
6
0.326
0.207-0.697
-1.12
-5.66
0.54 .
TaqlB GENOTYPE
No.
GEOMETRIC MEAN 
RANGE
LOG MEAN 
LOG STD. DEV.
B]Bi BjB2
26 19 
0.367 0.352 
0.186- 0.207 
0.686 0.697 
-1.00 -1.04 
-5.58 -5.3C
b 2b 2
11
0.427
0.191-
0.962
-0.85
-5.39
0.43
StuI GENOTYPE
No.
GEOMETRIC MEAN 
RANGE 
LOG MEAN 
LOG STD. DEV.
SiSi SjS2 
34 8 
0.376 0.302 
0.204-0.697 0.186-0.737 
-0.98 -1.20 
-5.93 -5.50
0.15
PstI GENOTYPE
No.
GEOMETRIC MEAN 
RANGE 
LOG MEAN 
LOG STD. DEV.
P1P1
43
0.358
0.191-0.737
-1.03
-5.54
P iP2
6
0.368
0.186-0.962
-1.00
-5.39
0.89
MspI GENOTYPE
No.
GEOMETRIC MEAN 
RANGE 
LOG MEAN 
LOG STD. DEV.
M jM i
42
0.337
0.186-0.686
-1.09
-5.57
M xM 2
11
0.490
0.286-0.962
-0.71
-5.58
0.0033
TABLE 7.6 PLASMA LCAT ACTIVITY AND POLYMORPHISMS. For each poly­
morphism the number, mean and standard deviation of the logged data is 
given. The geometric mean and range are also shown. T-tests and analysis 
of variance were used to test whether LCAT activity logged differed 
between genotypes.
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A report linking the TaqlB allele with high HDL levels and high apoAI levels 
was published [Kondo, I. et al (1989)]. The study carried out here confirm s some of 
their observations and implicates the involvement of CETP by direct measurement 
of plasma CETP activity.
There are lim itations on interpreting data of this type. The population size, 
n=56, is small and when rare genotypes are studied then the num ber o f individuals 
in a particular genotype class is low. Since the HDL distribution was deliberately 
biased in order to try  and see an effect, this also made statistical analysis difficult. 
Ideally this study should be extended to cover a larger sample population with a 
normal HDL distribution and an equal representation of males and females.
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CHAPTER VIII
DISCUSSION
1 CETP Assay
Assaying CETP can be a complicated process. Activity can be m easured in two 
ways either by exchange or as net mass transfer. It is also possible to measure the protein 
mass of the enzyme. There are factors other than mass e.g. substrate lipoproteins, LCAT, 
lipoprotein lipase and CETP inhibitor, all of which can influence observed CETP activity 
to a greater or lesser extent. Thus it is im portant to decide what measurement is actually 
required. For studies on the control of the secretion of CETP protein or synthesis of 
CETP it is relevant to look at protein mass. However for experiments on changes in 
plasma levels of CETP activity the situation is more complicated. Is it more relevant to 
measure CETP activity per se or CETP activity in the presence of inhibitor? Is it 
comparable to measure CETP activity in d ifferen t individuals using their endogenous 
lipoproteins or is it better to use exogenous lipoproteins standardised for a set of 
measurements and compare activities without the influencing effect of variation in 
lipoprotein concentration? The answers to these questions will depend greatly on what 
thie experiment is designed to determine. If for example a drug treatm ent is known to 
alter lipoprotein composition but is being studied for its effect on CETP activity rather 
than on protein concentration then the influence o f the change in lipoprotein composition 
may also be taken into account by using endogenous lipoproteins in the assay. If  however 
a measurement of the expression of CETP activity is required i.e. net o f CETP plus 
inhibitor protein, then it may be more reasonable to use exogenous lipoproteins. Changes 
in plasma CETP activity may be due to changes in protein mass, inhibitor protein or 
activation of the enzyme. Ideally, to dissect the situation out, measurement o f protein 
mass, inhibitor mass and exchange or net transfer activity should be carried out. This 
is especially important when looking at control mechanisms involved in regulating plasma 
CETP activity as so many things can affect CETP activity. U nfortunately the tools to 
carry out these assays have not been available.
In this thesis CETP exchange activity was determined using exogenous lipoproteins 
which measured activity in the presence of inhibitor. The activity measured demonstrated 
the properties reported for CETP in the literature. It was decided that this activity was 
probably the most relevant and most practical given the tools available fo r looking at 
changes in plasma CETP activity but would allow no conclusions to be drawn as to 
whether any change in measured activity resulted from  changes in enzyme mass or an
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alteration of its activity. It is possible to remove inhibitor using a phenyl Sepharose 
column but this was not feasible for a large num ber of samples and was only attempted 
w ith the cell secretion studies when little CETP activity could be measured and it was 
suspected that CETP inhibitor was being secreted too. This exchange assay was able to 
allow processing of large numbers of samples relatively easily and any change in plasma 
CETP activity was readily detectable. The problem  was that there were limitations on 
the interpretation of changes in activity.
Another problem arose from using LPDS as an enzyme source because of the 
distribution of CETP and inhibitor in plasma. CETP binds to lipoproteins, especially 
HDL, but the association may be disrupted by ultracentrifugation. Inhibitor has been 
purified  from HDL and this implies that it too may be associated with lipoproteins. It 
is not known to what extent inhibitor is removed from  lipoproteins during centrifugation, 
neither is it known whether there is a difference in activity between bound and free 
forms. Studies have shown that the m ajority o f CETP (80%) [Groener, J.E.M. et al 
(1984)] is removed from HDL during ultracentrifugation; however it is not known 
whether the proportion removed by ultracentrifugation is affected by the concentration 
of HDL in the plasma. Attempts to determine this were not successful (data not shown). 
A way of circumventing this problem would have been to use dilute plasma to measure 
CETP activity. However a fivefold range of CETP activities was found in the individuals 
studied here and dilutions of LPDP in the assay ranged from 1 to 1/5. Thus those 
plasmas which would be diluted a little would have their CETP activities affected by 
their endogenous lipoproteins far more than those diluted to a greater extent. Therefore 
it would be necessary to correct for HDL concentrations anyway.
A net transfer assay was also attempted (data not shown) and although transfer 
activities similar to those reported in the literature were obtained [Ogawa, Y. & Fielding, 
C.J. (1985)], the assay lacked sufficient sensitivity to detect changes in activity. This 
was mainly because the actual mass of lipid transferred was very low.
Antibody detection methods were the methods of choice for mass determinations. 
A t the outset of the project there were insufficient data on the inhibitor protein to 
consider trying to raise antibodies to it. However an attem pt was made to raise antibodies 
to CETP. Antibodies would allow the measurement of protein mass and could be used 
to determine whether changes in CETP activity were due to changes in the amount of 
CETP or changes in its activity. Antibodies which inhibit the enzyme as well as bind 
to it are useful to examine the effects of inhibiting the action of CETP in vitro and in 
vivo. It had been planned to study the effect of inhibiting plasma CETP activity in the 
rabbit if  antibodies which inhibit the rabbit enzyme could be obtained. However since 
similar studies were carried out by two other groups during the course o f the thesis it 
was decided not to pursue this objective.
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Two approaches were attempted for making antibodies in the absence of having 
a completely pure antigen. One approach was to synthesise a peptide corresponding to 
a part of the CETP molecule which may be immunogenic. This peptide was used to 
raise polyclonal antibodies in sheep. Antibodies were successfully raised to this antigen 
and to the carrier molecule, KLH. Unfortunately the antibodies produced did not 
recognise native or SDS denatured CETP.
The second approach was to make monoclonal antibodies using partially purified 
CETP to immunise mice. Mouse spleen cells were fused with NS-1 cells in order to 
produce clones making antibody to CETP. This approach was not completed but a ’clone’ 
which produced antibodies which cross reacted with other proteins was obtained showing 
reasonable inhibition of CETP activity and good binding to post CM52 CETP in an 
ELISA. Immunodetection methods using either monoclonal or polyclonal antibodies would 
include ELISA, RIA and immunoelectrophoresis. Using any of these detection methods 
it may have been possible to try and work out the relationship between CETP mass and 
CETP activity in plasma. This may help give some idea as to which value may be the 
best to measure in particular circumstances. Detection o f CETP mass would also have 
been useful to try and work out the distribution of CETP between bound and free forms 
and whether this is affected by HDL concentration. In summary, knowledge of CETP 
mass in conjunction with CETP activity would have made interpretation of results, 
especially in the drug and population studies, very much easier.
The monoclonal approach to making antibodies was found to be much more 
successful than using the peptide approach. Making antibodies using a synthetic peptide 
can work but unfortunately it is unpredictable as to whether one peptide is better than 
another for raising antibodies. This problem arises since there are no definite criteria 
on which one can base a decision to select a peptide that will be immunogenic. Our lack 
of knowledge on what secondary and tertiary structure a protein will take in solution 
leaves us entirely unable to predict with confidence which parts of the molecule may 
be immunogenic. The results obtained here, i.e. that antibodies were raised to the peptide 
but that these antibodies failed to recognise native CETP illustrate the shortcomings of 
the approach. Antibodies can be raised to the desired antigen but the antigen is obviously 
not expressed in the same way in solution as when it is incorporated in the CETP 
molecule.
With the monoclonal approach the difficulty was screening the clones for activity. 
Two methods were used, inhibition of CETP activity and ELISA. The ELISA was limited 
in that pure antigen was not available and instead partially purified CETP was used. 
Any positives in the ELISA were antibodies which did bind to the post CM52 preparation 
but could be binding to any one of a number of proteins in that preparation, not 
necessarily CETP. The inhibition of CETP activity should have been more straightforw ard 
since an antibody which inhibits CETP should be picked up. This method would not 
detect any non-neutralising activities. However it was found that false positives occurred 
in this assay. Supernatants from  clones would cause inhibition of CETP activity but 
would not bind to post CM52 in an ELISA. It is possible that the cells were producing
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something which interfered with the CETP assay e.g. affecting the precipitation of the 
lipoproteins by heparin manganese. Possibly polysaccharides, especially sulphated ones, 
or proteins which bind sulphated polysaccharides or even metal ions may have been 
causing the spurious effects. At the final stages only clones which produced an activity 
which was positive in both the CETP inhibitory assay and the ELISA were progressed. 
Other problems encountered with the monoclonal approach were the instability of clones 
and the length of time that some clones took to grow. Some clones were very slow-growing 
and increased the time it took to establish a clone and grow up enough cells for inocculation 
for ascites production.
Antibody production would have been much easier had a pure antigen been 
available. The CETP protein was not purified to homogeneity here. It was found that 
after a certain stage the enzyme was unstable and lost activity. The enzyme was greatly 
stabilised by binding to lipid and the protein could be purified almost to homogeneity 
by binding to lipid emulsions. Unfortunately it was not possible to remove the protein 
from the lipid and retain activity. This may have been due to the harshness of the 
delipidation affecting the activity of the enzyme or due to the fact that lipid may be 
required to remain bound to the CETP in order for it to function. CETP complexed to 
Intralipid was electrophoresed on an SDS polyacrylamide gel such that the CETP band 
could be clearly seen. The gel was then blotted onto nitrocellulose and the CETP bound 
to the nitrocellulose was cut from the membrane. CETP bound to nitrocellulose was then 
used as an antigen for immunising mice. However in the final event it was found that 
immunisation with the less pure post CM52 preparation produced a much better antibody 
response in mice as measured by inhibition of CETP activity. This suggests that as in 
the case of the peptide denatured CETP may not be a suitable antigen for raising 
antibodies capable of inhibiting CETP activity. Had pure antigen been available in 
quantity screening o f clones by ELISA would have been appropriate and it may have 
been possible to purify antibodies on a CETP column. Also polyclonal antibodies could 
have been raised by immunisation of sheep with pure antigen.
Rabbit CETP behaved differently from human CETP during purification. Two 
CETP activities were separated on the phenyl Sepharose column, one eluting with low 
salt and one eluting with water. These activities appeared to chrom atograph differently 
on the CM52 column when run separately. When the activity peaks from  the CM52 
peaks were pooled and rerun on a CM52 column then two activities were separated. The 
result was however inconclusive since one of the peaks only included one measurement 
of CETP activity. It does appear that rabbit CETP activity differs from  hum an CETP. 
It is possible that the two peaks of activity seen for the rabbit on the phenyl Sepharose 
column were an artefact due to overloading of the phenyl Sepharose column. However 
the activities were still d ifferen t on a CM52 column. Possibly the rabbit has two plasma 
CETP activities or plasma CETP can exist in different forms in plasma e.g. free monomeric 
CETP and aggregated CETP.
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Further avenues of study related to CETP purification and antibody production 
would involve firstly trying to progress the promising clone which demonstrated an 
anti-hum an CETP activity. If one were found then this could be used a) to determine 
the distribution of CETP in plasma to decide whether it is a correct representation to 
measure CETP activity in the LPDP fraction and b) to investigate the relationship 
between CETP mass and CETP activity in the plasma. It may also be worthwhile to use 
the monoclonal antibody to try and purify CETP to homogeneity by im m unoaffinity 
chromatography. Pure CETP would be useful for a standard in measurements of mass 
and activity and also may be used to raise further antibodies which may allow improvement 
o f the detection techniques. For example a sandwich ELISA using two CETP antibodies 
may be better than using a one antibody ELISA. Radio immunoassay of CETP may also 
be a possibility. If polyclonal antibodies are raised then alternative techniques are possible 
e.g. immunoelectrophoresis.
It would also be interesting to follow up the observation that there may be two 
rabbit CETP activities. It is necessary to confirm  the observation first and then if 
confirm ed, to progress to attem pting to purify both activities to homogeneity and sequence 
them.
2 Studies in Animals
Using the exchange assay a num ber of studies were carried out to investigate CETP 
activity in various animal species; rat, rabbit, and man; and the influence of various 
drugs on this activity. The animal species have been used as models of hum an lipoprotein 
metabolism. The rat is often used because of its convenient size, however this species 
has a different lipoprotein profile from  the human with most cholesterol being distributed 
in the HDL fraction rather than in the LDL fraction as in man. The rabbit is a useful 
species, however in order to observe hypercholesterolaemia so that lipid lowering effects 
can be demonstrated, these animals have to be fed a high fat or cholesterol diet or else 
have to be genetically hypercholesterolaemic. The marmoset is a prim ate and shows 
plasma cholesterol levels similar to that found in man without special feeding. Their 
lipoprotein distribution is not quite so similar to man since a higher proportion of 
cholesterol is carried in the HDL fraction. Lipid lowering effects have been demonstrated 
in this animal.
Rats have very low plasma CETP activity and this may in part be responsible for 
the lipoprotein distribution in this species. High HDL cholesterol levels and low LDL 
cholesterol levels would result from  negligible CETP. This would suggest that reverse 
cholesterol transport is carried out by the HDL particles in this species since cholesterol 
cannot be transferred to lower density particles to allow the cholesterol to be taken up 
by LDL receptors. There is some evidence for the role of HDL in delivering cholesterol 
to the liver in the rat. However there is m ounting evidence that cholesterol esterification 
can take place in LDL and it is possible that this process occurs in the rat. An alternative 
hypothesis is that CETP activity could be expressed at certain times and may in fact 
show a circadian rhythm as do some other enzymes of cholesterol metabolism in the rat.
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In fact it has been demonstrated that rat plasma does contain CETP activity but that 
this activity is normally suppressed by the presence of CETP inhibitor protein. In order 
to test for the presence of a circadian rhythm  for CETP, plasma CETP activity was 
measured in two groups of rats, one group in the m id-light cycle and the other was in 
the m id-dark  cycle, a time at which another enzyme HMGCoA reductase is at the peak 
of its circadian rhythm. All the plasma CETP activities measured were very low and 
although a significant difference between the activity of the enzyme m id-light cycle 
and m id-dark  cycle was noted at six weeks after adaptation to the ligh t/dark  cycle, the 
difference was only a very small fraction of what one might expect to see if  inhibitor 
was removed. Thus it was concluded that there was no circadian rhythm  of CETP activity 
in these rats or if so, the peak of activity was so sharp that it could not be detected at 
twelve hour intervals.
The studies in the rabbit first of all confirmed that fat feeding normal Dutch 
Belted rabbits resulted in hypercholesterolaemia accompanied by an increase in plasma 
CETP levels. It was also found that in a breed of rabbits (Froxfield) which shows a 
heritable hyperlipidaemia due to an LDL receptor defect demonstrated an increase in 
plasma CETP levels similar to that seen in the Watanabe rabbit.
It is not known whether this rise in plasma CETP activity is an independent response 
or whether it is secondary to a rise in plasma total cholesterol or a rise in cholesterol in 
a particular lipoprotein subfraction. Drug studies are a means to test whether it is possible 
to alter cholesterol levels without altering CETP activity or vice versa.
Three classes of drug were looked at in the Froxfield rabbit model o f hypercho­
lesterolaemia; an ACAT inhibitor, a fa agonist and two antioxidants. The fa agonist, 
thought to be able to reduce the amount of cholesterol stored in a cell by stimulating 
neutral cholesteryl ester hydrolase (NCEH), had no effect on either plasma total cholesterol 
or plasma CETP activity. The ACAT inhibitor did not significantly change plasma total 
cholesterol but did significantly increase plasma HDL levels. This increase in HDL levels 
was not accompanied by a change in CETP activity. Since a negative correlation between 
plasma HDL levels and CETP activity has been demonstrated one might expect changes 
in the HDL fraction to be accompanied by changes in CETP activity, more so than to 
changes in total cholesterol which shows no such correlation. This was not found to be 
the case in this experiment where HDL levels changed but total cholesterol did not. 
However this study was inconclusive in that the measurement of plasma HDL levels was 
not entirely satisfactory.
Probucol is an interesting drug in that despite causing a decrease in HDL cholesterol, 
FH patients treated with the drug show xanthoma regression. The regression is correlated 
with the decrease in HDL. Watanabe rabbits treated with probucol show reduced arterial 
lesion formation. In this study where rabbits were fed probucol for 12 weeks no change 
in either plasma total cholesterol or CETP activity was found. It was expected that a 
fall in total cholesterol would be seen and plasma measurements of probucol demonstrated 
that the drug was being absorbed. There was evidence that arterial lesion progression
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was reduced in the treated animals. Thus in the absence of any effect on CETP activity 
an effect on the lesions was seen. This tends to negate the idea that a mechanism involving 
CETP is responsible for the reduction in lesion form ation.
Cases have been observed in humans where plasma CETP activity has been affected 
by treatm ent with probucol. Two familial hyperalphalipoproteinaemic (FHALP) patients, 
one with impaired CETP activity and both showing an abnormal direction of CE net 
transfer from  LDL/VLDL to HDL, had normal CETP activity and direction of net 
transfer after treatm ent and a decreased HDL2 cholesterol. Type II hyperlipidaemic 
patients treated with probucol had an increased CETP activity and decreased HDL2 
while HDL3 was unchanged. In the larger study o f normal humans on probucol investigated 
here, despite a pilot result where two volunteers showed an increase in CETP activity, 
there was no significant effect on CETP activity although both total cholesterol and 
HDL cholesterol were significantly decreased. It is possible that an effect on CETP 
activity would only be seen if  CETP activity was im paired to start with i.e. probucol 
’normalises’ CETP activity. A possible mechanism for this could be via the CETP inhibitor 
protein. If impaired CETP activity were due to increased inhibitor protein, then decreasing 
the amount of inhibitor would normalise the activity. It is interesting that the post 
probucol samples appeared to contain less inhibitor than the control samples. Thus in 
these normal samples perhaps inhibitor is being affected but this is not apparent as 
would be in diseased samples where CETP activity was compromised.
Probucol is an antioxidant but it is not known whether its effects on slowing the 
progress of atherosclerotic lesions is due to this property. The effect o f another unrelated 
antioxidant was tested for its effect on CETP activity in rabbits. It was found that 
GR44966X decreased plasma CETP activity, the opposite of what might be expected 
for probucol. It is not known how this drug affected plasma cholesterol levels. Before 
this result can be followed up it should be confirm ed in a larger group of animals and 
its effect on plasma cholesterol monitored.
HMGCoA reductase inhibitors were used to treat both marmosets and a group of 
human hyperlipidaemic patients in the clinic. Significant decreases in plasma cholesterol 
were seen in both species but differing effects on plasma CETP were seen. In the 
marmosets there was no effect of treatm ent on CETP activity. However in the humans, 
CETP activity was reduced over the same time period as the total cholesterol. Again it 
is possible that changes in CETP are seen only when the plasma levels are abnormal to 
start o ff with. The marmosets used here were normal but the human patients had high 
plasma cholesterol and high CETP activities which were decreased towards more normal 
levels by drug treatment. A second difference here is the time scale over which the 
experiments took place. The marmosets were treated for only one week whereas the 
humans were treated for up to six months. However changes in plasma cholesterol were 
seen in the 7 day experiment in marmosets. It is possible that CETP activity changes 
over a longer period of time. These differences may also be just reflecting species 
differences. -
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No clear pattern of behaviour for CETP emerges from  these experiments. They 
do point to conditions which may have importance when looking at changes in CETP 
activity. Species may respond differently depending on the importance of CETP inhibitor 
in affecting overall CETP activity. It seems that in the rat there is a greater expression 
of inhibitor than there is in the rabbit. These experiments and others also seem to indicate 
that drugs may have more of an effect on CETP levels when activity is impaired or 
raised since it is on these occasions that changes in CETP activity are demonstrated. The 
length of time over which dosage takes place may also be an im portant factor. Although 
long term  experiments seem to show that changes in CETP activity m irror changes in 
total cholesterol e.g. in cholesterol fed rabbits [Quig, D.W. & Zilversmit, .D.B. (b) (1988)] 
or as in the case here of treating hyperlipidaemics w ith Simvastatin, an effect was not 
seen in the short term experiment using marmosets.
It is not possible from these experiments to sort out a cause and effect relationship 
between CETP and total cholesterol. It is not known whether the level of these parameters 
are controlled independently or whether one follows a change in the other. If a drug 
treatm ent may be found which affects each param eter separately then it may be possible 
to get some insight into this question. Inhibition of CETP activity may not be directly 
due to inhibition of the enzyme. It may result from changes in inhibitor concentration 
or changes in CETP distribution between HDL particles and the plasma.
The question arises as to whether it would be therapeutically beneficial to inhibit 
CETP. Certainly plasma levels are raised in hyperlipidaemics; and in FHALP (a condition 
predisposing to high HDL levels and longevity) plasma CETP levels are low or reduced. 
However in experiments where CETP has been inhibited in vivo by antibodies [Whitlock, 
M.E. et al (1989)], HDL CE rose in the absence of an increase in LCAT activity and 
the clearance of 3H-cholesteryl ether from both the HDL and the plasma compartments 
was decreased. Thus although HDL cholesterol rose it appeared that HDL CE catabolism 
was decreased. Therefore the usefulness of a CETP inhibitor is still unclear.
3 Secretion of CETP by Cells
J774 cells, macrophages, HepG2 cells and CaCo2 cells were Studied for control of 
CETP secretion. These cells have been reported to secrete CETP activity. It was confirmed 
in the study carried out here that these cells do secrete CETP. However the amount of 
CETP secreted was very low and it appeared that the assay system used here was not 
sensitive enough to detect accurately the amount of activity found in the supernatants. 
Measures to increase the sensitivity of the assay; incubation for a longer time and 
concentration of cell media did improve detection, but transfer measured was still not 
much more than 5% transfer over the course of the assay, a level of detection which 
was near the lim it of sensitivity for the assay. Thus it was found that measurements of 
CETP secretion by cells and its regulation by effectors was not reproducible and changes 
in amount of CETP activity were not large compared to the error on the CETP 
measurement itself.
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This inability to detect changes in CETP activity may be the reason why it was 
d ifficu lt to reproduce results quoted in the literature e.g. stimulation of CETP secretion 
in CaCo2 cells by free fatty  acids. The level of CETP secretion detected here appears 
to be lower than that quoted in the literature but not grossly so. It is possible that the 
cells used here were suffering from  an undetected infection (e.g. mycoplasma) or were 
not at an appropriate passage num ber, being either too high or too low. It is possible 
that at a high passage num ber the cell line loses characteristics of the original parent 
cell. Cell viability in serum -free medium becomes a problem after 24 hours and it is 
also possible that some cells may be producing CETP inhibitor protein as well as CETP 
thus making it appear that no CETP is secreted. Media from  some experim ents were 
passed over a phenyl Sepharose column but this did not reveal any latent CETP activity 
so this possibility may be unlikely. The macrophages on occasion did show quite large 
amounts of secretion (>10% transfer/60pl medium) but this varied greatly from  donor 
to donor and is not reproducible for the same donor either. Macrophages are a cell type 
known to demonstrate great variabilty between donors. There were even great differences 
in cell yield between d ifferent donors. Since the results from the cell secretion studies 
were not reliable it is impossible to draw any conclusions as to the effects of various 
treatm ents on the cells.
Thus alternative ways were considered for measuring the effect of various treatments 
on CETP levels. It is possible to look at the level of mRNA which indicates at least the 
rate of transcription if not the rate of translation of CETP. It was found that CETP 
mRNA could be detected by slot blotting and hybridisation to an oligonucleotide probe. 
Using 50pg of total RNA, CETP message could be detected in macrophages, J774 and 
HepG2 cells. Unfortunately the hybridisation of probe to the membrane did not appear 
to be quantitative. This may have been due to unequal loading of RNA onto the membrane 
or due to the fact that the hybridising probe found RNA on the top of a loaded area 
more accessible than that underneath or may find some parts of the m em brane more 
accessible than others due to positioning of the filter in the hybridising bag. It was clear 
from  an experiment where control and PMA treated cells were compared for hybridisation 
o f their RNA to a CETP probe that it was difficult to determine quantitative differences 
between them.
Another technique which was started was a nuclease protection assay where 
hybridisation occurs in solution avoiding the problems of accessibility o f RNA on a 
filter. It was first necessary to validate the hybridisation techniques to test that CETP 
mRNA could be detected on a Northern blot at the correct position, to test that the 
probe hybridised correctly to the CETP mRNA. Running both total and purified  mRNA 
from  various cell types on a formaldehyde gel and blotting onto nitrocellulose, it was 
found that CETP probes did not give a signal when hybridising to the m em brane blots. 
Using an actin probe as a control it was discovered that this was due to two factors. 
Firstly, the CETP message may be present in smaller amounts than the actin  message 
and so is more difficult to detect. Secondly, degradation of RNA, which was not detectable 
by eye with ethidium  bromide staining was occuring since the actin probe bound to a
104
smear of low molecular weight material. It is possible that RNA is being degraded by 
RNAases introduced either at the purification stage or at the sample preparation and 
gel running stage.
To improve upon these results the procedures for handling RNA would have to 
be stringently assessed and altered so that as little contamination of the RNA samples 
with degrading enzymes as possible took place. It is possible that the partial alkaline 
hydrolysis of the RNA gels before blotting was too harsh and may have been degrading 
the RNA at that stage. This would account for a more diffuse arrangement of a particular 
mRNA but would probably not be responsible for the low molecular weight RNA because 
in order for the RNA to reach this position on the gel it would have had to have been 
degraded before electrophoresis.
To test whether little signal was being obtained due to low concentration of CETP 
message, it would be possible to am plify the message using polymerase chain reaction. 
Preliminary experiments showed that a sequence within the CETP gene could be am plified 
using combinations of 4 chosen prim ers, two sense and two antisense. The PCR should 
be able to amplify sequences from  both genomic DNA and mRNA after reverse tran ­
scription to cDNA. Thus this technique may be employed to detect whether any CETP 
message is present. It is not easy to use this technique in a quantitative manner at present.
Once the problems with RNA degradation have been sorted out and one is satisfied 
that CETP mRNA is present, one can return to testing whether a CETP probe can 
hybridise to CETP mRNA on a N orthern blot. The nuclease protection assay may be 
used to measure the amount of mRNA in a particular sample though it is possible that 
a slightly longer probe (100 to 200 base pairs) would be required for best effects. A 
nuclease protection assay when set up would be very sensitive and could be used to look 
for changes in CETP secretion brought about by various effectors. Effectors o f interest 
would include cytokines e.g. IL-1 and TGF(3 and also agents which could alter the 
cholesterol balance of the cell. It would be interesting to see whether a cell would respond 
to changes in its cholesterol levels by altering output of an enzyme which may be involved 
in flux of cholesterol in and out of the cell.
4 CETP RFLP Analysis in a Population
The RFLP analysis in the population of high and low HDL individuals produced 
some interesting results. Firstly a significant relationship between an MspI polymorphism 
of the apoAI gene and plasma LCAT activity was revealed. Individuals with the M jM 2 
genotype had significantly higher LCAT activities (P<0.004) than those with genotype 
M jM i. It is not clear how variation in the apoAI gene would affect plasma LCAT activity. 
It may be a result of the method of preparation of LCAT for the analysis. Since LPDP 
is used as the enzyme source then it is possible that endogenous apoAI which has come 
free of the HDL during ultracentrifugation may be playing a part in activating the 
enzyme and variation is being expressed via this mechanism. However it does seem
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unlikely that this effect would be seen in the presence of a large amount of exogenous 
apoAI. It is possible that the apoAI polymorphism may be marking for another area on 
the chromosone which may somehow affec t LCAT activity.
The main aim of the study was to investigate whether variation at the CETP gene 
influenced plasma CETP activity and HDL levels. It was found that individuals with 
the TaqlB rare allele, B2, had significantly lower CETP activity (P<0.01). This result is 
not surprising since it might be expected that variation in the structure of the CETP 
gene detected directly, or more likely indirectly by linkage, by the TaqlB polymorphism 
can affect plasma enzyme levels. What is more interesting is that this same polymorphism 
is seen to be associated with HDL levels. There is a significantly (P<0.002) d ifferent 
distribution o f individuals between the genotypes B ^ ,  B ^  and B2B2 in the high and 
low HDL groups.
It has previously been suggested that there is a negative correlation between HDL 
levels and CETP activity both from measurements of both parameters within a population 
and from  the example of FHALP people who have no or negligible CETP activity. It 
is impossible to sort out from this evidence alone a cause and effect relationship. The 
evidence from  the RFLP study implies that CETP may have an effect on HDL levels 
which supports the idea that CETP may have an antiatherosclerotic role. It has recently 
been reported [Brown, M.L. et al (1989)] that one FHALP family displays a splicing 
defect in CETP pre mRNA resulting in an inherited deficiency of CETP. This dem ­
onstrates that a prim ary defect in CETP results in a phenotype demonstrating high plasma 
HDL levels.
One must be careful not to draw too many conclusions from RFLP analysis. For 
a start what is being measured is not necessarily the mutation in the gene which is 
responsible for the variability itself but more likely a site which cosegregates with the 
m utation of interest. Since there is a distance between these two points there is a possibility 
of recom bination between them so that there is not a 100% correlation between the 
presence of the RFLP site and the site responsible for the variation in CETP activity. 
It is not even necessarily true that the site responsible for differences in activity is in 
the CETP gene itself. It may be in a nearby related gene. For example it is feasible that 
if  the gene for CETP inhibitor protein were on chromosone 16 the RFLP in the CETP 
gene could mark for a mutation in the CETP inhibitor gene which could also influence 
plasma CETP activity. If measurement o f CETP mass could be carried out then this 
could sort out whether the differences in CETP activity associated with the RFLP alleles 
were due to changes in CETP mass or were due to changes in factors which influence 
plasma CETP activity.
M ajor reservations with the RFLP study carried out here were small population 
size, the unequal distribution between males and females especially since they were 
d ifficu lt to analyse separately due to small numbers, and the number of tests carried 
out. Since a large number of significance tests were carried out here testing five RFLPs 
against four plasma parameters (20 tests) then it is* possible that by chance alone some
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of these tests will prove significant. A crude way of accounting for this is to multiply 
the significance level obtained by the number of tests carried out. If this is done then 
the significance of the association between the TaqlB RFLP and plasma CETP activity 
is lost but that with the plasma HDL levels remains. It is also very important to determ ine 
w hether the proportion of plasma CETP activity found in the LPDP is affected by the 
levels of plasma HDL as discussed earlier. If this were the case then this may account 
partly for the results seen in the RFLP analysis.
This work confirms the findings of Kondo et al [Kondo, I. et al (1989)]. They 
found an association between the TaqlB polymorphism and apoAI levels and this effect 
was not seen in smokers when the population was divided into smokers and nonsmokers. 
The work here demonstrates a similar effect in a d ifferen t population and and suggests 
a mechanistic link between a CETP RFLP, low CETP activity and high HDL levels. 
There was no inform ation on our population to allow us to look at the effect of smoking.
It is obviously important to try and repeat this result with an improved study 
design. Improvements would include increasing the population size to at least 200 with 
50% male and 50% female individuals. If  possible CETP mass as well as CETP activity 
should be measured.
5 Summary
The aims laid out at the beginning of this project were:-
1) To assess the relationship between plasma CETP activity and CETP mass.
2) To inhibit CETP activity in vivo.
3) To examine the effects of drugs affecting cholesterol metabolism on CETP
activity.
4) To identify factors controlling CETP secretion by cells in culture.
5) To test for any relationship between RFLPs o f the CETP gene and plasma CETP
activity and HDL levels.
An assay was set up which could measure CETP activity in plasma, but an antibody 
to CETP which may have been used to assay for CETP mass was not produced. Thus 
the relationship between these two parameters could not be assessed. A good monoclonal 
antibody has been produced by another group [Yen, F.T. et al (1989)] and inform ation 
on this relationship may soon be forthcoming. It would be interesting to find out why 
some animals have such an excess of CETP activity. When CETP activity was inhibited 
by antibodies in the rabbit, the plasma CETP levels only needed to return to 20-30% 
of the level normally found in plasma for any effects on the lipoprotein caused by 
antibody inhibition to be normalised. Also when inhibitor is removed from pig plasma 
using a phenyl Sepharose column, much more inhibitory activity 'could be eluted than 
was required to inhibit the pig transfer activity separated. It might be expected that if  
CETP activity and CETP inhibitor protein are present in such large excesses then control 
of activity by altering the amounts of these proteins might be difficult. However some
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animals obviously do exhibit a tight control on CETP activity and their plasma levels 
are completely inhibited. Possibly there are further areas of control in the plasma 
compartm ent e.g. binding and dissociation of CETP to its substrate lipoproteins. It has 
been demonstrated that binding of CETP to HDL is increased by conditions which 
increase CETP activity e.g. in the fatty acid stimulation of CETP activity. It may be 
more appropriate to examine what is happening at the local level in the lipid transfer 
complex. Local control systems of binding of CETP or inhibitor to lipoproteins may be 
obscured by measurements of excesses of free CETP and inhibitor. Now that more 
inform ation on the CETP inhibitor is available direct mass measurements of inhibitor 
may also be possible in future.
Since studies on the inhibition of CETP in vivo in the rabbit by both polyclonal 
and monoclonal antibodies were published in 1989 the search for a rabbit monoclonal 
antibody was discontinued. The results from these published studies were interesting. 
HDL CE levels were increased as would be expected but there was no increase in LCAT 
activity. Thus this increase in CE was probably due to decreased catabolism. Supporting 
this it was found that the clearance of labelled cholesteryl ether from  the HDL and 
plasma compartments was delayed and there was decreased uptake of label into the liver. 
Conversely when CETP was injected into rats labelled apoAI containing HDL particles 
were cleared from the blood more quickly and there was an increase in accumulation 
of CE in the liver. These experiments indicate that CETP is necessary for RCT and CE 
may be being delivered to the liver for excretion by the lower density lipoproteins, LDL 
and VLDL, after transfer from  HDL. Since LCAT activity is not affected by CETP 
antibodies it seems that CETP is not involved in cholesterol removal from the cell unless 
it interacts with the cell directly. It is difficult to accommodate the evidence of increased 
CETP activity in hyperlipidaemia and low or zero CETP activity in FHALP people with 
a role for CETP in RCT when hyperlipidaemia is associated with increased risk of 
atherosclerosis and FHALP is associated with longevity especially as in the latter case 
the lack of CETP is a prim ary defect. These two conditions have led to proposals that 
CETP interferes with the RCT pathway by diverting cholesterol away from  HDL which 
is returning CE to the liver. Several groups have discovered a negative correlation between 
CETP activity and HDL levels. Perhaps the paradox here can be explained by the time 
scale over which the in vivo antibody inhibition studies took place. CETP was inhibited 
for only at most 48 hours. It may take longer than that for a new steady state RCT 
pathway to be reached, and what has been measured in these studies may only be a 
transitional state. It is certainly true that in the FHALP family, which has a genetic 
error leading to im proper splicing of the CETP gene, affected individuals are not dying 
of prem ature heart disease. Another interesting result that arose from  the inhibition of 
CETP by antibodies is that C E ' still appears in LDL in the absence of any measurable 
CETP activity. It appears then that LDL can act as a substrate for LCAT. Perhaps animals 
lacking CETP activty employ this mechanism for getting CE into LDL and to the liver 
via the LDL pathway.
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The effect of several drugs on CETP activity in several species was studied. No 
consistent effects were observed. Certainly hyperlipidaemia due to a genetic fault and 
to fat feeding led to increased CETP levels as has been reported previously. Treatments 
which decreased CETP activity were GR44966X, an antioxidant, in Froxfield rabbits 
and Simvastatin in hyperlipidaemic humans. The effect of an HM GCoA reductase 
inhibitor in another species, the marmoset, did not agree with the finding in humans. 
There may be two reasons for this. One is that the time scales of the experim ent were 
d ifferen t and the other is that the marmosets had normal cholesterol levels whereas the 
humans had abnormally high cholesterol levels. It seems to be a recurring theme that 
CETP levels can revert to normal levels once the individual is treated. Increased CETP 
is lowered by Simvastatin or om ega-3-fatty acids and impaired CETP activity is increased 
by probucol in some cases. It is possible that control of CETP activity only becomes 
critical once the lipoprotein metabolism has gone awry. Changes in CETP activity may 
only be reflecting abnorm al cholesterol levels or lipoprotein compositions rather than 
causing them. Treatm ent with drugs may be affecting CETP activity because they are 
normalising cholesterol and lipoprotein metabolism in other ways e.g. HM GCoA reductase 
inhibitors will decrease cholesterol biosynthesis and reduce plasma cholesterol. Certainly 
when one can see decreases in CETP activity mirroring decreases in plasma cholesterol 
in the Simvastatin treated patients (where CETP is abnormally high), when changes in 
CETP activity in the marmoset are not seen although plasma cholesterol levels are reduced, 
it does imply that the changes in CETP activity are secondary to the fall in plasma 
cholesterol rather than the other way around.
Studies into the control of CETP secretion were frustrated by technical difficulties. 
It would be interesting to know whether increases in plasma CETP activity are due solely 
to changes in enzyme activation or whether there is increased mass. Obviously if there 
is increased mass then this makes control of the synthesis of CETP very im portant. The 
experiments where vectorial secretion of CETP by CaCo2 cells can be increased by free 
fatty  acids imply that at least in some cases, as in the post-prandial state, CETP synthesis 
is upregulated. The main source of CETP in the body is not known. It has been calculated 
from the rate o f secretion in HepG2 cells that the liver could account for the entire 
body synthesis of CETP. Liver does secrete CETP but this may be contributed to by 
the K upffer cells as well as the hepatocytes and in fact little CETP m RNA synthesis 
has been detected in HepG2 cells. Certainly the effect of free fatty  acids on CaCo2 cells 
cannot be ignored. Possibly this control may be of local importance involved mainly 
with the processing o f lipids after a meal.
The study of the relationship between RFLPs of the CETP gene, plasma CETP 
levels and plasma HDL levels is interesting because it suggests that CETP may have a 
direct effect on HDL levels and that CETP is not passively reflecting plasma cholesterol 
levels. This evidence must be treated cautiously however as it is not directly measuring 
the genetic mutation responsible for the effect but is just following a m arker for it and 
so relies upon statistical interpretation. Because this is so, the study ought to be repeated
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in a larger population so that the statistical power of analysis can be strengthened. It is 
also im portant to follow up the genetic study with a study that can investigate the 
metabolic mechanism that results.
What roles does CETP play in cholesterol metabolism? The answer is still unknown 
but it does seem increasingly likely that the role is an important one as more mechanisms 
for the regulation of CETP activity are discovered. It also seems likely that the role is 
a varied one as evidence is strong for its involvement in a number of areas especially 
reverse cholesterol transport and post-prandial processing of lipids.
110
APPENDIX I
HUMAN CETP PREDICTED SECONDARY STRUCTURE FROM THE DEDUCED
AMINO-ACID SEQUENCE
Using the published cDNA sequence and predicted protein sequence [Drayna, D. et al (1987)] 
the ’Predict’ computer programme (Peter M urray-R ust, Glaxo Group Research Ltd, 
G reenford) was used to carry out Chou & Fasman and Robson predictions for secondary 
structure. A hydrophilicity/hydrophobicity plot is also shown. Hydrophilic residues are 
plotted above the line and hydrophobic residues below the line.
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APPENDIX 2
CALCULATION OF THEORETICAL MELTING TEMPERATURE OF DNA
Tm = 16.6 log[M] + 0.41 [PGC] + 81.5 - PM - B /L  - 0.65 Pf
M = m olarity of Na (.0.75M)
PGC = % G or C in single strand (between 30-60%)
PM = % mismatched base (should be 0)
B = 675
L = probe length in bases (75) 
f  = percentage formamide (50%)
Stringency is taken as being 12°C below the melting tem perature
Tm = 16.6 log 0.75 + 0.41 x 31 + 81.5 - 0 - (675/75) - 0.65 x 50 
Tm = -2.07 + 12.71 +81.5 - 9 - 32.5 
Tm = 50.6° C
Stringency = 38.6° C
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APPENDIX 3 - ABBREVIATIONS
AC AT acyl Co A cholesterol acyl transferase
apo apolipoprotein
BSA bovine serum albumin
CE cholesteryl ester
CETA cholesteryl ester transfer activity
CETP cholesteryl ester transfer protein
CM chylomicron
CO cholesteryl oleate
dCTP deoxycytidine triphosphate
DEPC diethyl pyrocarbonate
DNA deoxyribonucleic acid
dNTP deoxyribonucleotide triphosphate
DMSO dimethyl sulphoxide
EDTA ethylenediaminetetraacetic acid
ELISA enzyme linked immunosorbent assay
FCS foetal calf serum
FFA  free fatty acid
FH familial hypercholesterolaemia
FH ALP familial hyperalphalipoproteinaemia
HDL high density lipoprotein
HSA human serum albumin
IL-1 in terleuk in-1
K L H  keyhole limpet haemocyanin
LCAT lecithin cholesterol acyl transferase
LDL low density lipoprotein
113
LP lipoprotein
LPDP lipoprotein depleted plasma
LPDS lipoprotein depleted serum
LPS lipopolysaccharide
LTP lipid transfer protein
MOPS morpholinopropanesulphonic acid
mRNA messenger RNA
NCEH neutral cholesteryl ester hydrolase
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PC phosphatidyl choline
PCR polymerase chain reaction
pCMPS parachloromercuriphenylsulphonate
PL phospholipid
PMA phorbol myristate acetate
RCT reverse cholesterol transport
RFLP restriction fragm ent length polymorphism
RNA ribonucleic acid
SDS sodium dodecyl sulphate
SSC sodium chloride, sodium citrate buffer
TBS Tris buffered saline
TEM ED N ,N ,N \N ’,-tetramethylethylenediam ine
TG triglyceride
TMB tetram ethyl benzidine
TO triolein
Tween 20 polyoxyethylenesorbitan monolaurate
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VLDL very low density lipoprotein
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APPENDIX 4 - SUPPLIERS OF REAGENTS
Alpha Laboratories 
40 Parham Drive 
Eastleigh 
Hampshire 
U.K.
Amersham International pic
White Lion Road
Amersham
Bucks
U.K.
Amicon Ltd 
U pper Mill 
Stonehouse 
Glos 
U.K.
Baker Instruments
Shirloy Avenue
Windsor
Bucks
U.K .
BDH Ltd 
Broom Road 
Poole 
Dorset 
U.K.
Wako kits for FFA determ inations
Radiochemicals
DNA M ultiprime labelling kit
Hybond N
Apparatus and membranes for u ltra fil­
tration
Triglyceride assay kit
General chemicals
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Beckm an-RIIC Ltd
Progress Road
Sands Industrial Estate
High Wycombe
Bucks
U .K .
B io-rad Laboratories
3rd & Regatta Boulevard
Richmond
CA 94806
USA
Boehringer M annheim Gm bh
Bell Lane
Lewes
East Sussex
U.K.
British Biotechnology Ltd
Watlington Road
Cowley
Oxford
U .K.
Cambio
34 M illington Road
Cambridge
U.K.
Costar Corporation
205 Broadway
Cambridge
MA
USA
Centrifuges, rotors and tubes
Protein assay 
Gel matrices
Kits for cholesteryl ester and triglyc­
eride
Reagents for fluorescent CE assay 
Primers for PCR
Taq polymerase
Transwells
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CRB
Button End 
Harsten 
Cambridge 
U .K .
Denley Instruments Ltd
Natts Lane
Billinghurst
Sussex
U.K .
Difco Laboratories
D etroit
M ichigan
USA
Dynatech Laboratories
Daux Road
Billingshurst
West Sussex
U .K .
Evans Medical 
Horsham 
Surrey 
U .K .
Gibco 
PO Box 35 
T rident House 
R enfrew  Road 
Paisley 
U .K .
KLH
Spiralmix
Freunds adjuvant
M icrotitre plates
Streptomycin
Tissue culture medium including Bio­
cult
Foetal calf serum 
Non essential aminoacids 
Molecular biology reagents 
Restriction enzymes
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Jones Chromatography
T ir-Y  Bgrta Industrial Estate
New Road
Hengoed
Mid Glamorgan
U.K.
K abivitrum  Ltd 
Riverside Way 
Uxbridge 
M iddx 
U .K .
Kodak Laboratory and Research Prod 
ucts
Acornfield Road
Knowsley Industrial Park North
Liverpool
U.K.
Labmedic Ltd
M axron NSE
Green Lane
Romiley
Stockport
Cheshire
U.K.
Lancaster Synthesis Ltd
Eastgate White Lane
Morecambe
Lancs
U.K.
Spherisorb
Intralipid
Film developing solutions 
Cab-O-Sil
Sebia lipofilm kits
Probucol
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MSE
Manor Royal 
Crawley 
Sussex 
U .K .
National Diagnostics 
U nit 3
Cham berlain Road
Aylesbury
Bucks
U .K .
A/S NUNC 
Kam strupvej 90 
Kam strup DK-4000 
Roskilde 
Denmark
Oncor Inc 
Box 870 
G aithersburg 
MD 20877 
USA
Packard Instruments Co. Ltd
2200 Warrenville Road
Downers Grove
Illinois
USA
Peptide and Protein Research 
U niversity of Reading 
Reading 
U.K .
Sonicator
Ecoscint
Tissue culture plastics 
ELISA plates
Actin probe 
Hybridisation fluid
Scintillation fluid
Synthetic peptide
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Perkin Elmer Ltd
Post Office Lane
Beaconsfield
Bucks
U.K .
Pharmacia LKB Biotechnology 
M idsummer Boulevard 
Central M ilton Keynes 
Bucks 
U.K.
Sigma Chemical Co. Ltd
Fancy Road
Poole
Dorset
U .K .
Special Diet Services Ltd (SDS)
PO Box 705
Witham
Essex
U.K.
Vestric Ltd 
Northolt 
M iddx 
U.K.
Whatman Ltd 
Springfield Mill
Luminescence spectrometer
Gel matrices
Molecular biology reagents 
Polybuffer 94 
Ficoll Paque 
dNTP
mRNA purification kit 
Nitrocellulose
General chemicals
Antibodies
Hydroxylapatite
Con A Sepharose
Human serum albumin
Pristane
Poly-D-lysine
Animal diets
Penicillin
Gel matrices
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M aidstone
K ent
U .K .
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